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Abstract 
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Title of thesis: The failing diabetic patient in primary care 
Higher degree for which submitted: Doctor of Philosophy (PhD) 
Year of submission: 2005 
Diabetes is a progressive disorder. The majority of people with Type 2 
diabetes are likely to require more intensive treatment regimes over 
time and a substantial proportion have sub-optimal glycaemic control 
as measured by glycated haemoglobin (HbA 1 c). For these people a 
change to insulin is a possible option. However, this requires a major 
step for most people and their clinicians. The aim of this research was 
to ascertain the size of the problem, to obtain the views and 
perceptions about diabetes management of people with Type 2 
diabetes and their carers' (including diabetic nurses and general 
practitioners), to establish a consensus based management regime, 
and to ascertain the possible impact on diabetes specific quality of life 
of the commencement of insulin. 
This thesis used four methodologies. An existing primary care 
database was analysed to assess the scale of the problem of the 
poorly controlled Type 2 diabetic population in primary care. 
Qualitative research using focus groups was used to explore the 
beliefs of patients and clinicians towards diabetes and in particular the 
commencement of insulin in those failing on oral treatment. A mixed 
consensus group was used to describe a care pathway for these 
patients. Finally, in a cohort of people with Type 2 diabetes failing on 
oral therapy, a disease specific questionnaire was used to ascertain 
quality of life issues around the initiation of insulin. 
Mann findings: 
1) Over half of people with Type 2 diabetes were in poor 
glycaemic control, defined as an HbA 1 c >8%. 
2) People with Type 2 diabetes viewed diabetes as a "mild 
disease", using their experience and the social effects of living 
with their diabetes to monitor progress. They saw insulin as a 
last resort to be delayed as long as possible. 
3) Clinicians felt the majority of diabetes care could and should be 
provided in the community with an active management 
approach. Non-compliance with treatment was seen as an 
issue. Insulin was viewed positively while, at the same time, 
seen as being actively resisted by patients. The increase in 
resource and workload around insulin initiation was a major 
concern. 
4) Much uncertainty remained regarding the management of the 
failing diabetic patient. The value of early insulin treatment was 
questioned for the asymptomatic patient. Shared decision-
making was advocated but problems around risk/benefit 
information and lack of resources in both primary and 
secondary care wer13 highlighted. 
5) Insulin treatment in a cohort of people with Type 2 diabetes in 
poor glycaemic control on oral hypoglycaemic agents resulted 
in a modest but significant improvement in glycaemic control in 
routine care. Insulin initiation did not result in a change in 
quality of life. Patients' satisfaction with their tablet treatment 
was high but increased significantly on starting insulin therapy. 
However, these conclusions were limited by low study numbers 
from poor study recruitment. 
Conclusions 
Improving the care of people with poorly controlled Type 2 diabetes 
who are on maximal oral treatment is not straightforward and 
represents large resource and workload issues. Patient and clinician 
beliefs affect management and are not always currently sought and 
addressed. The benefits of early, more aggressive treatment with 
insulin need to be better quantified and information better presented 
to allow patient participation in decision making: glycaemic control is 
not the only factor that needs to be considered. A large gap in 
resources to achieve this was identified. The effect of insulin 
treatment on quality of life unfortunately has not been adequately 
answered in this research due to low participant numbers. 
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Chapter 1 
1. Introduction 
Globally, diabetes is one of the commonest chronic diseases affecting 5% of the 
world's population[1] and doubling every generation[2]. Type 2 diabetes 
accounts for up to 95% of this total. In the UK it affects 1.8 million people with 
an estimated 1 million currently undiagnosed[3]. 
The costs to the NHS are high, with diabetes accounting for 5% of total costs 
and 10% of hospital inpatient costs. The indirect costs are less well documented 
but probably equally high. The cost to the individual in terms of loss of earnings 
and decreased quality of life are also considerable and often forgotten. Life 
expectancy is decreased on average by up to 1 Oyrs. 
Type 2 diabetes gives rise to metabolic disturbance by two main factors: a 
reduced capacity for the pancreatic islet cells to produce sufficient insulin and a 
reduced ability of the body's tissues to utilise insulin effectively, so called 'insulin 
resistance.' This results in poor diabetic control with hyperglycaemia leading to 
diabetic complications. The increasing trends towards reduced physical activity, 
convenience foods, and obesity are major factors in fuelling the diabetes 
epidemic. 
Treatment of Type 2 diabetes has so far yielded only partial success. Over time 
diet and oral hypoglycaemic drugs fail to adequately control blood glucose 
levels at which point insulin treatment is usually required. In the primary care 
setting the use of insulin has always been regarded as problematic. This has 
been in part because of the perceived logistical difficulties in initiating insulin 
0 . 1 
therapy in primary care, but also because of the attitudes of both clinicians and 
patients towards the use of insulin, especially concerns around the areas of 
needles, injections, and the risk of hypoglycaemia. 
As a practicing clinician I am well aware of patients who have had poor diabetic 
control despite oral therapy but in whom a switch to insulin represented a step 
too far. Understanding the attitudes of both care providers as well as patients is 
key towards helping facilitate the decision to use insulin therapy. In addition it is 
important to have an estimate of the improvement that can be expected from 
such a switch and the impact on quality of life and diabetic control produced. 
This thesis is thus rooted in pragmatic care. From a general practitioner's 
viewpoint the use of routine insulin would need to be justified and in many 
cases it may be necessary to alter the mind set of carers so that they have a 
lower threshold for the use of insulin in people with Type 2 diabetes. In this 
thesis I have explored the following: 
o The extent of the problem of diabetes 
o The attitudes of patients towards diabetes and insulin treatment 
o The attitudes and perceptions of primary care clinicians towards diabetes 
and insulin treatment 
o Can a consensus be reached on the management of the person with 
poorly controlled diabetes? 
o What is the impact of the introduction of insulin therapy on quality of life 
- _.,._ .:. _,. 
and diabetic control? 
2 
As a result of this research it was possible to better understand the dynamics 
surrounding the management of poor diabetic control in primary care and 
assess the true impact of introducing insulin therapy for the person with poorly 
controlled Type 2 diabetes. These factors need to be taken into account in 
planning local community based diabetes services. 
The thesis has represented a journey in terms of my own awareness of the 
topic, the methodologies used and also in understanding the difficulties in 




2. Literature Review 
Diabetes is a condition characterised by chronically raised blood glucose levels. 
It is caused by a reduced effect of the pancreatic hormone insulin, due to an 
absolute or relative lack of insulin production and/or reduced insulin action 
(insulin resistance). 
Early clinical descriptions of diabetes are to be found in ancient Egyptian 
writings (e.g., Ebers Papyrus, 1500 BC). Polyuria and wasting were recognised 
as cardinal symptoms and it was initially thought to be due to a disease of the 
kidney. The word 'diabetes' was coined in the 2"d century AD by Aretaeus of 
Cappadocia, deriving from the Greek for 'a passer through, a syphon'. John 
Rollo (d.1809) applied the adjective 'mellitus' to diabetes (Greek and Latin for 
'honey'). The causes of diabetes have been explored particularly over the last 
three centuries, from the discovery of sweetness of the urine by Thomas Willis 
in the 1 ih Century, through to the discovery of insulin by Banting and Best in 
1921, and subsequently the unravelling of its structure by Sanger in 1955 and 
Hodgkin in 1969. 
There are two main types of diabetes. Type 1 (previously termed Insulin 
Dependent Diabetes Mellitus) presents in childhood or early adulthood, and 
accounts for approximately 15% of all diabetes in Europe. It is caused by an 
autoimmune destruction of the pancreatic beta cells responsible for insulin 
production. Insulin treatment is required to maintain life. Type 2 (previously 
termed Non-Insulin Dependent Diabetes Mellitus) accounts for around 85% of 
diabetes in Western countries, typically presenting ove~r the age of 40yrs. It is 
caused by a relative lack of insulin production in association with a variable 
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degree of 'insulin resistance': available insulin having a reduced effect on target 
tissues. 
Diabetes is diagnosed in one of three ways[4]: a random plasma glucose of 
>11.1 mmol/1 accompanied by symptoms of diabetes; by a fasting plasma 
glucose =/> 7.0mmol/l; or by a random plasma glucose =/>11.1 mmol/1, 2hrs 
after an oral 75g glucose load (the oral glucose tolerance test). 
This thesis is concerned with Type 2 diabetes and further discussion will 
concentrate on this. 
2.1. Aetiology 
Type 2 diabetes is caused by a combination of reduced insulin secretion from 
pancreatic beta cell dysfunction and decreased insulin action (insulin 
resistance) at a cellular level[4, 5]. Genetic and environmental factors are 
involved. A genetic component is suggested by a reported lifetime concordance 
of between 33-90% for identical twins. Having a single parent with diabetes 
imparts a 15% lifetime risk of diabetes, rising to 75% if both parents are 
affected[3]. Despite family aggregations, inheritance is not straightforward and 
appears to be multigenic and is as yet, incompletely understood. Environmental 
factors implicated include particularly, obesity and a sedentary lifestyle[6, 7]. 
Insulin resistance is present in 90% of people with Type 2 diabetes[B] and 
present in most people in the pre-diabetic state[5, 9]. It occurs when the body 
has a reduced response to circulating insulin in its target tissues: skeletal 
muscle, adipose tissue and liver[1 0]. Decreased insulin sensitivity leads to a 
compensatory hyperinsulinaemia[9]. This cannot be sustained due to 
6 
pancreatic beta cell dysfunction, resulting in increasing hyperglycaemia and the 
development of impaired glucose tolerance and diabetes[11, 12]. Insulin 
resistance is associated with a cluster of atherogenic risk factors in the insulin 
resistance (or metabolic) syndrome, first described by Reaven[13]. Features 
include insulin resistance, hyperinsulinaemia, glucose intolerance or diabetes, 
dyslipidaemia (high triglycerides, low hdl cholesterol), and hypertension. 
Visceral obesity and a pro-coagulant state were other associations noted later 
and now included in the syndrome. 
2.2. Epidemiology 
Type 2 diabetes is one of the most common chronic diseases in the UK(14] 
affecting 1.8 million people with an estimated further 1 million undiagnosed[3]. 
The number of adults with diabetes has been estimated worldwide to be 135 
million in 1995, rising to 300 million by 2025[15]. Most of this increase is 
expected to occur in developing countries where a 170% increase is expected, 
from 84 to 228 million. Developed countries, however, do not escape this trend 
with an expected 42% increase, from 51 to 72 million. 
Prevalence has increased dramatically, predominantly because of changes 
towards a more sedentary lifestyle, increasing obesity and ageing (16]. Large 
geographical variations are seen with a ten-fold variation in prevalence 
between the highest and lowest risk populations. Rates are highest in the Pima 
Indians of Arizona, USA (50%), and on the South Pacific island of Nauru (40%). 
These communities have experienced radical change from a traditional to 
Westernised lifestyle. Low rates are seen- in undeveloped rural areas such as 
parts of Africa and China. 
7 
Diabetes is a major cause of mortality and morbidity - the most common cause 
of blindness in people of working age[17], a major cause of kidney failure and 
of lower limb amputations[14]. Mortality for patients with Type 2 diabetes is 
twice that of the non-diabetic population even after adjusting for age, blood 
pressure, cholesterol, body mass index and smoking[18]. In the UK, 
cardiovascular disease accounted for around 75% of deaths in people with 
diabetes[14]. 
2.3. Economic costs 
The overall economic burden is great. The NHS spends 5% of its budget (£3.5 
billion) on diabetes care and this is expected to rise to 10% by 2011 [19]. In 
Europe, the cost of treating diabetes and its complications has been estimated 
to be 5.8% of the total healthcare budget[20]. Diabetic patients used up to 9.4% 
of all inpatient bed days[21] and have 4 times the probability of being admitted 
to hospital compared to non-diabetic populations (x12 the rate of admission for 
heart disease and stroke) [21]. Up to 10% of the UK hospital budget is spent on 
treating diabetes and its complications[22]. 
The indirect costs of diabetes may amount to as much as one and a half times 
those of the direct costs[23]. Indirect costs may be categorised, in rank order, 
as lost productivity due to short-term illness, permanent disability and 
premature death. It is estimated that people with diabetes spend £500 million of 
their own money coping with their diabetes and social services costs amount to 
£230 million[24].Type 2 diabetes has a negative effect on employment status 
and work productivity, even when there are no major complications. In an 
international randomised controlled trial[25] 26% less people with Type 2 
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diabetes were employed when compared to the general population, after 
allowing for age, gender and nationality. It is estimated that people with Type 2 
diabetes lose twice as much time from work as the general population[14, 26]. 
2.4. Management of Type 2 diabetes 
Type 2 diabetes is initially managed by dietary change, limiting the 
consumption of saturated fats and replacing them with monounsaturated or 
polyunsaturated fats. Complex carbohydrates are substituted for simple 
carbohydrates and a high fibre intake encouraged. Dietary advice has been 
significantly modified in recent years with greater flexibility in the proportions of 
energy derived from carbohydrate and monounsaturated fats[27]. It is 
suggested that fats are limited to <35% of total energy intake: saturated fats 
<1 0%, n6 polyunsaturates <1 0%, n3 polyunsaturates at least two portions per 
week of oily fish, and monounsaturates increased to 10-20% of energy intake. 
Carbohydrates should be limited to 45-60% but sucrose can be taken up to 
1 0% of energy intake, provided it is taken in the context of a healthy diet. 
Weight reduction and an increase in exercise are advocated but in practice are 
difficult to achieve for the majority of patients. Only 10-20% achieve good 
glycaemic control on diet alone. The majority require the addition of oral 
hypoglycaemic drugs or insulin. Insulin will be required by almost 50% of 
patients within 6yrs of diagnosis[28]. 
2.4.1. Oral Hypoglycaemic Agents (OHA) 
There are four main groups of oral agents used to control hyperglycaemia: the 





Metformin is the only biguanide used in the UK. It increases insulin action, 
although the exact mechanism is not fully understood. It decreases hepatic 
gluconeogenesis thus reducing glucose production. It does not cause weight 
gain or hypoglycaemia and in the obese is associated with a significant 
reduction in diabetes related events, all cause mortality, and stroke[29]. 
2.4.1.2. Insulin secretagogues 
Two drug groups increase pancreatic insulin secretion: the sulphonylureas 
(SUA) and the meglitinide analogues. SUA stimulate insulin secretion by 
binding to sulphonylurea receptors (SUR) on the pancreatic beta-cell plasma 
membrane, causing membrane depolarisation and exocytosis of insulin 
granules. They are associated with weight gain. The meglitinides, repaglinide 
and nateglinide, bind to the SUR by a different mechanism to the SUA resulting 
in a shorter duration of action, and are therefore used to control postprandial 
hyperglycaemia. Insulin secretagogues can be used alone or in conjunction 
with metformin. 
2.4.1.3. Thiazolidinediones 
Otherwise known as the 'glitazones', this group of drugs are insulin sensitizers. 
They enter the cell and bind to the peroxidase proliferator-activated receptor 
(PPARy). This is a nuclear receptor found mainly in adipocytes, and to a lesser 
extent in muscle and the liver. The glitazone forms a complex in the cell that 
stimulates expression of insulin-sensitive genes. These increase glucose 
uptake, increase adipocyte lipogenesis and decrease circulating fatty acid 
levels. Glitazones are associated with weight gain and fluid retention. They can 
be used as monotherapy or added to metformin or SUA. 
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2.4.1.4. Alpha-glucosidase inhibitors 
Alpha-glucosidase inhibitors delay carbohydrate absorption thereby lowering 
postprandial blood glucose levels. They inhibit disaccharidase enzymes and 
this gives a high incidence of gastrointestinal side effects. They are only 
effective in patients with adequate beta-cell function. 
2.4.2. Oral Hypoglycaemic Agent (OHA) Failure 
The natural history of Type 2 diabetes whether initially controlled with diet 
alone, diet and oral drug treatment, or diet and insulin, in the absence of any 
precipitating event, is towards loss of glycaemic control [28, 30, 31]. Poor 
glycaemic control is defined as an HbA1c level >7.5% [24]. In the UKPDS 
study[28] oral treatment failure was more likely to occur in patients with younger 
age at onset of diabetes (<54yrs mean), in the lean, and in those with high 
fasting plasma glucose (FPG) at onset. The failure rate was proportional to the 
FPG at randomisation (61% for FPG >1 0 mmol/1, 23% for those with initial FPG 
<7.8 mmol/1). The annual failure rate was 7% and linear, 44% over six years. 
Pontiroli found a similar rate of 6.2% pa for oral treatment failure in the lean and 
1.2% pa and 2.5% pain the obese and overweight respectively[32]. 
2.4.2.1. Immunogenic factors 
The presence of autoimmune antibodies in a small number of late onset 
diabetes suggests a slowly evolving autoimmune insulitis of the insulin 
dependant type. It suggests that these patients are in fact a discrete subgroup 
of type 1 diabetes. Antibodies to Glutamic Acid Decarboxylase (GAD) were 
found in 76% of insulin deficient Type 2 diabetic patients, but in only 12% of 
non-insulin deficient patients[33l A minority, 10-15%, of cpeople·with Type 2 ·· 
diabetes have Islet Cell Antibodies (ICA's)[34]. Marked impairment of beta-cell 
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function was seen when ICA's were associated with phenotype HLA-
DR3/DR4[35]. The presence of these antibodies was associated with impaired 
beta cell function, lower body weight, and with a higher frequency of other 
organ-specific antibodies and autoimmune disease[33, 34]. This group can be 
differentiated from Type 2 diabetes by defining the period of good glycaemic 
control prior to oral treatment failure. A prolonged period of 3-5 years would 
avoid misclassification[36]. 
2.4.2.2. Insensitivity to OHA 
Patients failing on one oral agent do no better with substitution of another[37, 
38]. Withdrawal of chronic sulphonylurea or metformin therapy has generally 
shown deterioration in glycaemic control[39, 40]. These findings suggest that 
oral treatment failure is not a drug related problem but rather a patient-related 
or disease-related problem. 
2.4.2.3. Insulin release and Insulin resistance 
Reduced insulin secretion and increased insulin resistance are the hallmarks of 
Type 2 diabetes[41]. In two studies of non-obese patients with oral treatment 
failure an increased insulin resistance and decreased beta cell function was 
noted compared to those patients still responsive [42, 43]. Insulin resistance is 
related to obesity in Type 2 diabetes [44, 45]. Weight loss can reduce insulin 
resistance but does not appear to influence insulin secretion [46, 47]. 
2.4.3. Treatment options for OHA failure 
Treatment options advocated have included very low calorie diet, temporary 
intensive insulin therapy, combined therapy with insulin and oral hypoglycaemic 
agehls,'arfd stand'artfor intefisive-insUiiritherapy. 
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2.4.3.1. Very low calorie diets (VLCD) 
VLCD supplying 400-600 calories per day (protein, with vitamin, potassium and 
magnesium supplements) over 3-4 weeks has shown better initial improvement 
in blood glucose control than conventional diets [48, 49]. Weight loss is 
commonly regained off the diet but improvement in blood glucose levels may 
persist for up to 1 year. VLCD therapy has also been used on an outpatient 
basis with success[50]. This type of dietary treatment may be helpful in patients 
with severe obesity and poor dietary compliance but long-term results are not 
sustained. The American Diabetic Association suggests that they should be 
considered only in conjunction with a structured weight management 
programme [49] while the European Association for the Study of Diabetes 
(EASD) suggest their use should be restricted to patients with a BMI of 35 
kg/m or over, who are supervised in experimental medical centres[16]. 
2.4.3.2. Temporary intensive insulin therapy 
Intensive insulin therapy requires the patient's admission to hospital for 
treatment. Normoglycaemia is obtained using continuous subcutaneous insulin 
infusion and maintained over 2-3 weeks [51, 52]. This can improve insulin 
resistance and endogenous insulin secretion, allowing control to be maintained 
by oral hypoglycaemic agents and diet. The authors of the cited studies 
restricted treatment to those patients with relatively unimpaired endogenous 
insulin secretion (as implied by C-peptide levels) and achieved good control 
over periods of over 2 years in 50% of cases. 
2.4.3.3. Combination therapy 
Secondary failure occurs over time with all forms of monotherapy. This wa~ 
demonstrated to diet by Hadden et al.[30] and to diet, sulphonylurea, metformin 
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and insulin in the UKPDS study[28]. Combination therapy was initially studied 
as an adjunct to failed insulin therapy. Meta-analyses had shown typically a 
reduction in glycated haemoglobin of 1% [53-55]. This was regarded as a 
disappointing result and many advised against its use[53, 56, 57]. Adding 
insulin to sulphonylurea treatment at the time of sulphonylurea failure has been 
shown to be effective provided some residual endogenous insulin secretion 
remains, as is usually the case. Evening intermediate or long-acting insulin 
suppresses overnight hepatic glucose production (HGP) improving fasting 
plasma glucose (FPG). This effect on HGP may be due to insulin's suppressant 
effect on free fatty acid concentrations[58]. The daytime sulphonylurea deals 
with post-prandial glucose peaks by stimulating remaining endogenous insulin 
secretion. Medium or long acting insulin preparations at bedtime have been 
shown to control FPG with little risk of nocturnal hypoglycaemia[58-60] and to 
be less likely than a morning insulin dose to cause daytime hypoglycaemia[60]. 
This is particularly relevant to the elderly diabetic. Controlled studies have 
shown the effectiveness of a combination of bed-time insulin with day-time 
sulphonylurea (BIDS) in patients with recent OHA failure [61-63]. Combination 
therapy gave better FPG and glycated haemoglobin levels than a single insulin 
injection alone. Yki-Jarvinen et al. compared bedtime insulin combined with 
sulphonylurea, metformin, or a second insulin injection [64]. Weight remained 
unchanged in the insulin with metformin group, compared to significant weight 
gain (3.6-4.6kg) with the other combinations. This was achieved with slightly 
better glycaemic control and less hypoglycaemia. Combination therapy gives 
levels of control similar to multiple injection insulin regimes with less 
inconvenience, less weight gain and reduced hyperinsulinaemia. Compared to 
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single injection insulin therapy it gives better control. Superficially, combination 
treatment is some 30-50% more costly. However, if factors such as extra 
supplies of syringes I pens, needles, greater use of SMBG readings, more 
frequent out-patient attendance, and possibly more emergency treatment are 
considered, it may well be cost-effective. Moreover, multiple injections, 
particularly in the elderly, may require greater supervision from relatives or 
district nurses. 
2.4.3.4. Insulin therapy 
Indications for insulin treatment include ketosis, significant weight loss 
regardless of initial weight and severe symptoms of hyperglycaemia[56]. Insulin 
treatment is associated with improvement in general well being[65, 66]. Use in 
the obese patient, particularly if gaining weight, is problematical. Often all that is 
achieved is excess weight gain with no improvement in glycaemia. Intensive 
insulin regimes can achieve near normoglycaemia in experimental conditions at 
the expense of significant weight gain[67]. More rigid outpatient regimes have 
given similar results to standard regimes[65, 68]. However, in an attempt to 
improve community care in Michigan, USA, insulin use increased but without 
improvement in glycaemic control[69]. 
Long acting insulins have been used alone or in combination with oral agents 
as the initial treatment for oral treatment failure. The advent of genetically 
engineered long acting insulins (insulin glargine and detemir) has refined 
treatment, providing a more stable baseline insulin level over a 24hr period. 
Some patients will require a full insulin regime, usually with twice daily 
premixed insulin. 
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2.4.4. Behavioural Aspects 
Diabetes is one of the most psychologically and behaviourally demanding of the 
chronic medical illnesses and psychological factors are relevant to nearly every 
aspect of diabetes and its treatment[70]. Patients are required to take over the 
management of processes that the body normally self regulates. This involves 
life-long behavioural change. Diet, exercise and blood glucose levels need to 
be monitored on a daily basis. Advances in treatment require the patient to 
undertake ongoing education and display adaptability to cope with changes in 
management that these advances bring about. A longitudinal study by Davis 
showed psychological impact was one of the top five predictors of mortality in 
diabetes[71]. 
2.4.4.1. Adherence 
Diabetes is a complex, demanding, chronic illness that requires high levels of 
responsibility from the patient. It is therefore not surprising that adherence can 
be low in diabetes. Haynes defined it as 
"The extent to which a patient's behaviour coincides with medical 
advice. "[72] 
Adherence is less value laden than compliance and better conveys the self-
regulatory nature of the diabetic regime[73, 74]. The term concordance is also 
currently used, being thought to indicate a more active role played by the 
patient in agreeing a course of action. To comply, patients must have been 
given explicit instruction on exactly what is expected of them. Vague 
generalisations such as 'lose weight' or 'increase your exercise' are not 
sufficient. It must be specific and based on the individual patient's situation. The 
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patient must have understood what is being asked of them. Very little is 
remembered from face to face consultations. Key points need reinforcing with 
written literature. 
The medical model typically sees the doctor as the 'expert' who 'knows best' 
and the ideal patient as the passive, obedient recipient of instructions. Patients 
not conforming are characterised as 'deviant' and attempts have been made to 
identify the characteristics of the 'non-compliant patient'. This is not the model 
that the patient necessarily uses[75]. The patient approaches the consultation 
with ideas and views on illness and the use of medicines and has expectations 
both of the doctor and of advice or treatment offered. Advice will be discussed 
with family and friends before being evaluated. Various theories have been put 
forward to explain patient behaviour and these will be expanded further. 
In a study of behavioural influences on patient self-care Hunt found the key 
factors influencing treatment choices were 1) belief in the power of modern 
medicine; 2) the desire to act and feel "normal"; 3) the desire to avoid physical 
symptoms; and 4) limited economic resources[76]. All patients were trying to 
control their diabetes but none of them followed all recommendations all of the 
time. Advice was modified in light of everyday circumstances. Self-care 
behaviour is reasoned behaviour[??, 78]. Similarly, in patients attending a 
Rheumatology clinic, Donovan found patients were active in their non-
compliance. They drew on their lay beliefs and experiences, together with 
information gleaned from other sources such as friends, the media and 
pharmacy staff[79]. 
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Adherence is not a one-dimensional construct. Adherence to one aspect is not 
necessarily related to adherence to other aspects of self-management[80]. It 
may be high for one aspect such as tablet taking, but be low for other aspects 
such as exercise or diet. It also varies between individuals and within individual 
patients over time[80]. It has been suggested that different health beliefs 
influence specific self-care tasks[81]. 
Adherence is a difficult concept to measure. Health status measurements, such 
as glycosylated haemoglobin (HbA 1 c), have often been used as surrogate 
measures, despite the literature finding no direct relationship between 
adherence and diabetes control[80, 82, 83]. The adequacy of the prescribed 
regime and the progressive nature of the disease process itself affect 
glycaemic control. Provider ratings have proved similarly inaccurate and open 
to bias[84]. Behavioural assessment is highly specific and useful for detecting 
technical skills deficits, such as insulin administration or blood glucose testing, 
but is labour intensive and requires observer training[85]. Counting permanent 
products, such as pill counts, can at times be helpful, but is little used outside of 
research studies. Home blood glucose monitoring can now be better assessed 
when using meters with large memories that can be downloaded. Self reporting 
has been successfully used to assess concordance with multiple behavioural 
components, using diaries[80], and 24hr recall interviews[86]. These have 
proved reliable, may be conducted by telephone, but do require trained 
interviewers. 
Non-adherence varies across the different components of the diabetes regime. 
It is dynamic, varying during the course of the disease and at different times in 
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a person's life. It is not surprising therefore that global measures of 
concordance are unreliable[84]. Instruments that measure specific components 
are more useful, but more work needs to be done to assess validity and 
reliability over differing populations (children, adolescents, adults, and the 
elderly). 
As Cox states[87], the initial question may have been "what affects 
compliance?" The final question however needs phrasing as "what individual, 
social and environmental factors affect specific self-care behaviours?" 
2.4.4.2. Patient Characteristics 
Poor coping skills, both for diabetes specific problem solving skills and 
management of general stress, have been shown to influence self-care and 
treatment outcomes[88]. 
Diabetic patients are twice as likely to be depressed as non-diabetic 
patients[89]. people with diabetes with complications have five times the 
frequency of depression compared to the non-diabetic population[90]. 
2.4.4.3. Health Beliefs 
Behavioural adherence to the complicated diabetic regime is understandably 
difficult to constantly achieve. Health beliefs have been associated with regime 
adherence and metabolic control. Here again there is no straightforward 
relationship. Improved control relates to beliefs on specific regime tasks. 
Health beliefs have been suggested as a promising alternative to traditional 
personality variables in predicting adherence[91]. Becker developed the Health 
Belief, Model for predicting medical,regime compliance· from-the originalwork of 
Rosenstock[92, 93]. Support for this model has been found in a variety of 
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medical conditions[94]. This model postulates that the likelihood of a patient 
adhering to a medical regime is determined by five psychological readiness 
variables: a) the perceived susceptibility to the disease process; b) the 
perceived severity of the condition; c) the perceived benefits of taking action, d) 
the perceived costs of taking action and e) the degree to which internal or 
external cues to action are present to activate the other factors. 
Partial associations of specific variables of the model have been shown. In 
diabetic populations, perceived illness severity was associated with adherence 
to diet and weight loss[95]. Global response to the health belief model has been 
found[95]. Harris[96] examined the health beliefs of 93 male diabetic patients. 
Belief in severity of the illness was associated with compliance, but overall, 
health beliefs were better predictors of metabolic control than of compliance 
itself. Brownlee-Duffeck et al.[73], looking at the health beliefs of 193 type 1 
diabetic patients, found older patients' belief in the perceived benefit of regime 
adherence was associated with both adherence and metabolic control. In 
younger patients, perceived costs figured most prominently in relation to 
adherence, but perceived severity and susceptibility were the most important 
beliefs associated with metabolic control. 
Ajzen's theory of reasoned action suggests that behaviour is strongly correlated 
with intention to perform that behaviour[??]. This in turn is modified by a 
person's attitude toward the behaviour and the subjective norm (the influence of 
family, friends and experts). Wolfenbuttel, using Ajzen's attitude-behaviour 
model to study insulin injecting in elderly people with Type 2 diabetes, found a 
high correlation between intention to and actually starting insulin treatment. The 
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main factor influencing intention was the subjective norm, especially health care 
professionals[97]. 
Explanatory or commonsense models of illness seek to link disease and 
symptom labelling with patient perspectives on the aetiology, course and 
treatment of illness[98]. The common sense model posits that individuals' 
understanding of illness is based upon somatic symptoms and life experiences 
and thus may differ significantly from the biomedical view of illness[99, 1 00]. 
Cowen suggests that variation in patient-practitioner perspectives in Type 2 
diabetes affects patients' disease orientation[1 01]. Hunt, in an ethnographic 
study of Mexican American people with Type 2 diabetes, found patients 
attempted to connect biomedical causes and treatment success or failure 
through personal histories[1 02]. A further ethnographic interview study of older 
women with Type 2 diabetes showed lay aetiological perspectives were 
associated with dietary adherence more so than socio-demographic factors 
including ethnicity, education and income[1 03]. Those who implicated 
previously poor dietary practices, currently being overweight, or having 
'improper bodily functions' were all more likely to follow dietary advice. Glasgow 
related personal belief models and socio-environmental barriers to self reported 
diabetes self-management[1 04]. Regime specific measures were found to be 
stronger predictors than were more general measures. Looking at the 
construction of illness beliefs Hunt et al. described an iterative process of initial 
beliefs modified by ongoing experiences and social circumstances. They 
concluded that illness explanations are dynamic entities determined by their 
usefulness in the individual person's social environment[105]. "Consideration of 
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the causal reasoning of patients opens up a window onto the understanding 
and interpretations of their illness"[1 02]. 
A patient's Health Locus of Control (HLOC) has been suggested as having an 
influence on health behaviour and outcome. HLOC has been described as the 
degree to which individuals feel able to influence their own health 
behaviour[1 06]. People with an internal HLOC believe they have control over 
health behaviours and hence can influence outcomes. Those with an external 
HLOC feel powerless to control their health and therefore feel unable to affect 
their health outcomes[1 07]. Peyrot examined diabetes-specific locus of control 
(DLC)[1 08]. They found that the internal DLC could be further subdivided into 
autonomy and self-blame components. Autonomy was generally associated 
with positive outcomes whereas self-blame was associated with negative 
outcomes. This is consistent with other work[1 09]. Externality associated with 
chance had negative outcomes. The other dimension of external DLC, powerful 
others, could also be usefully split into two components. Negative outcomes 
were associated with strong health professional influence whereas positive 
outcomes were found with non-medical significant others. 
2.4.4.4. Coping strategies 
Kelleher[11 0] sees the patient's attempt to incorporate diabetes into their lives 
as one more role to fulfil. People have multiple different life roles or 
identities[111] (parent, mother, husband) that have to be balanced. The diabetic 
role is but one more to be accommodated. Issues and problems have to be 
faced in developing all these identities. In his qualitative study of 30 diabetic 
patients he found three main themes. The themec cWbeiii'~f'rfa"rnial';the" theme·· 
of control (whether feeling in control, or daily life being dominated by the 
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diabetes), and loss of spontaneity (how much life had to be altered to fit around 
diabetes). Tying in with these themes, he found three overall coping strategies. 
Being in control - 'copers' were willing to alter treatment regime rather than 
reduce their social roles and saw themselves as healthy. Adapting to diabetes-
'normalisers' accept they have diabetes but alter social relationships to fit 
around it. They still regarded themselves as healthy. 'Worriers and agonisers,' 
in whom diabetes maintains dominant, find diabetes interferes with other life 
roles, causing anxiety and a perception of ilhealth. 
Maclean[112] examined the meaning patients attach to self-care actions in 
relation to diet. Many individuals sought a balance between health and well-
being. When health did not compromise well-being adherence to diet was not a 
problem but if there was a conflict patients took liberties with their diet. Murphy 
and Kinmonth[113] found, in people with Type 2 diabetes, two broad groups. 
Firstly, those who avoided short term symptoms by adjusting diet etc, or 
adjusted their lives around avoiding symptoms. They tended to feel diabetes 
was serious but not for them. The second group were avoiding long-term 
complications and felt they had a controlling role over their diabetes, and were 
more likely to feel diabetes was serious for them. 
2.4.4.5. Psychosocial Factors 
Davis, looking at correlates of survival in a longitudinal study of Type 2 diabetic 
patients, found that social impact of diabetes (measured by the Diabetic 
Educational Profile) was in the top five correlates of mortality (age, social 
impact, renal function, complexity of dietary regime, and history of smoking) 
above diabetic control· as measured by glycated haemoglobin and·· other 
physiological parameters[71]. 
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Family support has been shown to have both positive and negative effects. 
Regime-specific measures of family support differentiated high or low 
adherence better than global family support measures[114]. Non-family support 
has not been extensively researched. 
2.4.4.6. Physician attitudes 
It has been assumed that doctors' management of diabetes is based firmly on 
their knowledge of medical science and variation in performance is due to 
ignorance, forgetfulness or conscious disregard[115, 116]. Increasing 
knowledge alone is not sufficient to improve doctor performance[117, 118]. 
However, doctors' beliefs have been shown to be equally or more important. 
Kinmonth and Marteau, in a questionnaire study, showed GP teachers to have 
a more pessimistic outlook on type 1 diabetes, to perceiving the disease to 
have more risks, and to have a lower belief in the efficacy of treatment 
compared to a previous sample of secondary care doctors[119]. Marteau 
showed differences in beliefs when comparing paediatricians and general 
physicians. Paediatricians attributed less risk of diabetes complications, 
believed less in the efficacy of tight blood glucose control and tolerated a wider 
variation in blood glucose levels in their patients[120]. Weinberger found doctor 
beliefs, rather than their knowledge of effective diabetes management, to 
predict good blood glucose control[121]. He compared two groups of medical 
internists (12 in each group), dividing them into successful (those whose 
patients' blood glucose levels were below the clinic mean) and those who were 
unsuccessful (above the mean). The successful group was distinguished by 
their belief in strict blood sugar control, the early use of oral hypoglycaemic 
. . 
agents, and their perception that they were doing less well compared to their 
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peers. Pendleton found physicians rated the difficulty in complying with aspects 
of diabetic regime higher than did their patients[122]. This was felt to be due to 
either the physicians overestimating the difficulty or patients underestimation 
(or underreporting) of the difficulty. Discrepancies have been shown between 
patient and physician perceptions of treatment goals. In a study of obese Type 
2 patients there was a 53% discrepancy in overall goals, a 57% discrepancy in 
specific weight loss goals and a 43% discrepancy in blood glucose goals[123]. 
Clinicians tend to frame their explanatory models of diabetes in patho-
physiological terms, whereas patients emphasised the social domain and the 
impact diabetes had on their lives[101]. 
Doctors need to be aware of their patients' perceptions of compliance and of 
their readiness to change lifestyle behaviour. Verheijden, in a study of Dutch 
primary care physicians, found relatively low agreement between perceptions of 
physicians and those of patients regarding patients' readiness to change 
behaviour, adding another potential barrier[124]. Cowen highlighted the 
differences in patient and doctor perspectives that can have significant effects 
on how standard biomedical advice is received[1 01]. Hulka suggested that 
compliance is a function of the doctor-patient relationship[125]. A study of 93 
diabetic men showed belief in severity of illness to be related to compliance. 
Health beliefs were stronger predictors of metabolic control than of compliance 
itself[96]. Educating health care professionals on the specific problems of 
compliance may be more effective than educating patients[126]. In a study of 
nurse I patient communication Street et al found improved glycaemic control 
was associated with nurses being less controlling and directive[127]. 
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2.4.4.7. Barriers to adherence 
Barriers to adherence may involve factors such as costs, time involved, 
availability of resources locally, and competing demands. Patient beliefs and 
health care provider attitudes, as well as social norms and pressures, can at 
times act as barriers to improved glycaemic control. 
Intensive treatment is associated with an increase in hypoglycaemic episodes 
and weight gain[128]. Lorenz has argued that use of the word 'intensive' in 
regard to insulin therapy is, in itself, a barrier to patients receiving best 
treatment, both from the physicians' and the patients' perspective[129]. 
Larme and Pugh, using in-depth interviews and rating scales, found primary 
care providers in Texas perceived diabetes as difficult to treat and were wary of 
hypoglycaemia when considering insulin. They felt inadequate in their ability to 
control the disease and lacked time to deal with the patient education and 
instruction necessary to instruct patients in insulin use. Korytkowski[130], 
similarly identified physicians' perception of their inadequacy in controlling the 
disease with treatments other than insulin, and concerns over hypoglycaemia 
and weight gain as key barriers to insulin therapy. 
Polonsky and Jackson coined the term 'psychological insulin resistance'[131] to 
describe patients' resistance to starting insulin. They identified perceived loss of 
control over one's life (insulin restricting life), poor self-efficacy (doubts about 
ability to cope with an insulin regime}, personal failure (guilt at not controlling 
diabetes with earlier strategies), perceived disease severity (insulin indicating 
their disease is entering a more ~erious phase), injection-related anxiety, and-a 
perceived lack of positive gain from insulin (will not improve glycaemic control) 
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as key factors inhibiting patients from initiating insulin. In a study of insulin 
na"ive Type 2 diabetic patients 57% expressed insulin related anxiety[132]. 
Monitoring of blood glucose levels with frequent finger prick testing may be 
perceived by the patient as painful, time consuming, and often producing poor 
results: in effect a punishment. Because adherence does not guarantee good 
glycaemic control again it may be viewed negatively. Behaviourally, improved 
self-care leading to failure to improve control, inevitably leads to reduced further 
efforts. 
Social stigma has been identified as a barrier to effective diabetes self-
management[133]. Patients avoid injecting themselves in public and may 
therefore inject at inappropriate times or places. They fear discrimination in the 
workplace, many trying to keep their diabetes a secret. 
Thus, Type 2 diabetes is a complex chronic progressive illness requiring a high 
level of self-care behaviours from patients. Diet and oral treatments eventually 
fail to control blood glucose levels and insulin therapy is often then required. 
However, there are many influences affecting whether patients start insulin 
therapy, from both patient and clinician perspectives. These will be further 
explored in this thesis. 
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3. Type 2 diabetes: the size of the problem 
3.1. Introduction 
With the increase in obesity and a sedentary lifestyle, Type 2 diabetes is 
increasing at an alarming rate. It is estimated to affect 110 million people 
worldwide and this figure is likely to double by the year 2010[134]. In the UK it 
affects 1.8 million people with an estimated 1 million currently undiagnosed[3]. The 
costs of diabetes care come mainly from dealing with the complications of 
diabetes, particularly by secondary care. It is estimated that 15% of the United 
States total healthcare budget is taken up with diabetic care[135]. In the UK 
diabetes care consumes up to 10% of the NHS acute sector budget[136]. This 
accounts for direct costs only; the indirect costs (lost productivity, permanent 
disability and premature death) may be even greater[23]. 
To investigate the scale of the problem in more detail, particularly in relation to 
people with poor glycaemic control, a representative single district with a 
comprehensive diabetic register was chosen as the basis of a demographic and 
clinical database. This project, the first in this thesis, was undertaken in 1999 and 
was based on the latest available complete year's data, 1998. 
3.2. The Nortlh Tees diabetoc register 
A comprehensive, community based register of people with diabetes was started 
in the North Tees district of Northern England in 1992 and has been previously 
described and found similar to other published UK data[137]. All general practices 
in the area participated in the register together with the North Tees district hospital. 
The Cleveland Multidisciplinary Audit Advisory Group supported the register 
project and a working group consisting of the local diabetologist, two general 
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practitioners, three nurses and audit support staff oversaw the running of the 
project. Data were collected directly from general practice records by a single 
diabetes facilitator visiting individual practices on an annual basis. The 100% 
participation of practices and the one person responsible for data collection 
ensured a high level of data completeness. Data were fed back to practices on an 
annual basis comparing individual practice data to the anonymised district data. 
Consent was obtained from the individual general practices for access to their data 
held on the register. 
The register served the population of Stockton local authority district of the Tees 
Health Authority, with an estimated population of 178,920 in 1999[138]. 
In 1998 there were 3549 people with diabetes on the register giving prevalence for 
diabetes of 1.98%. Fourteen percent had Type 1 diabetes and 86% had Type 21 
diabetes. 
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North Tees diabetic population 
age at 31 .12.99 
Figure 2 Total North Tees diabetic population 1999 
Std. Dev = 15.90 
Mean = 61 
N = 3549.00 
Type 2 diabetes had been defined here, arbitrarily, as age at onset of diabetes 35 
years or older. It is unusual for Type 1 diabetes to present above this age but there 
are signs of Type 2 diabetes presenting at an earlier age particu larly in people of 
Asian extraction . However, Type 2 diabetes remained , in the main, a disease of 










North Tees type II diabetic population 
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Figure 3 North Tees type II diabetic population 
Looking at the Type 2 diabetic population, the average patient has had their 
diabetes for five years and to be in relatively poor glycaemic control with a 
glycosylated haemoglobin (HbA 1 c) of 8.2%. It is of note that general practice 
provided total care for over 80% of the population. 
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Table 1 Characteristics of the North Tees Type 2 diabetic population 
Number (n) 
Age in yrs (SO) 
Female(%) 
Median duration of diabetes in yrs (IQR) 
Mean HbA 1 c % (SO) 
Diet only(%) 
Tablet treated (%) 
Insulin treated (%) 
Systolic blood pressure in mmHg (SO) 




















3.3. The 'stable' Type 2 diabetic population 
To avoid patients with poor control who were in the initial stages of having their 
therapy adjusted, I used a duration of diabetes of >3 years to define a group of 
patients who should be on optimized, possibly maximal, therapy. 1743 patients 
meet these criteria, of which 1467 (84%) had a current HbA1c reading. Of these, 
873 (58.7%) patients were in poor control, as defined by an HbA1c >=8%. 
Table 2 Characteristics of the stable Type 2 diabetic population (means (SO) unless 
otherwise stated). 
Age at diagnosis in years 




Sulphonylurea (SU) only 





Systolic blood pressure mmHg 





Previous myocardial infarction 
Stroke incidence in 1999 
Retinopathy 
Laser treatment in 1999 
Admission for hypoglycaemia in 1999 
GP care 
















































Interestingly, the characteristics of this group were similar to the total Type 2 
population except for their longer duration of diabetes as would be expected. 
There were fewer people on diet only and slightly more on insulin treatment. 
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Table 3 examines the effectiveness of the different treatment modalities in 
achieving good glycaemic control. The insulin treated group developed diabetes at 
an earlier age and had had their diabetes for longer than the other two groups. 
Glycaemic control had deteriorated across the groups despite intensifying 
treatment. Complication rates were similar for hypertension and macrovascular 
disease but with higher rates of retinopathy and photocoagulation in the insulin 
treated group. Weight as expressed by BMI was not significantly higher in the 
insulin group but they did have a higher rate of severe hypoglycaemia needing 
hospital admission. Secondary care was involved in a small proportion of the care 
of diet and tablet treated patients but was involved in almost two thirds of the 
insulin group. Again, no differences were seen in blood pressure, cholesterol, 
creatinine, gender, smoking status or BMI. 
Table 3 Stable Type 2 diabetes: characteristics of treatment groups of (means (SO) unless 
otherwise stated) 
Age at diagnosis in years 




Systolic blood pressure mmHg 





Previous myocardial infarction 
Stroke incidence in 1999 
Retinopathy 
Laser treatment in 1999 
Admission for hypoglycaemia in 1999 
GP care 




























































What were the differences between people whose diabetes was in good or in poor 
control? The poorly controlled group was characterized by an earlier age of onset 
and a longer duration of diabetes. As would be expected from the natural history of 
Type 2 diabetes as a progressive disease, very few poorly controlled patients were 
on diet alone and a higher proportion were on insulin. The proportion on tablet 
treatment was similar in both groups. There were no significant differences in 
blood pressure, serum cholesterol or serum creatinine between the two groups. 
The vast majority of patients (84-90%) received their care in general practice. 
However, more poorly controlled patients were seen in secondary care (36%), 
whether for total care or in a shared-care arrangement with general practice. 




Age in yrs (SO) 
Female(%) 
Median duration of diabetes in yrs (IQR) 
Mean HbAic% (SD) 
Diet only(%) 
Tablet treated (%) 
Insulin treated(%) 
GP care 









































As would be expected, most people on diet only were relatively well controlled; 
otherwise they would have been offered more intensified treatment. The 
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exceptions would be those with significant co-morbidity and limited life expectancy. 
Only half of the tablet treated group achieved good control leaving the same 
number in poor control, which should potentially have been offered insulin 
treatment. However, insulin treatment was even less successful at achieving good 
control with less than a third below the target level. 
Patients remaining in poor control on oral hypoglycaemic drugs (OHA) are of 
particular concern. Two questions required answering. Were these patients 
receiving maximal oral treatment and if so should they have received a trial of 
insulin therapy? Table 6 looks at this group in more detail. 
Table 6 Characteristics of stable Type 2 diabetic patients on oral treatment who remain in 
poor glycaemic control (means(SD) unless otherwise stated) 











9.2(1.14) 27.6(4.21) 7.5(4.0-11.0) 
9.1 (0.99) 31.2(5.21) 6.0(3.1-8.9) 
9.5(1.17) 29.4(5.28) 8.0(5.5-1 0.5) 
With 47% of patients on monotherapy, (36% on sulphonylurea monotherapy) there 
was a strong suggestion that oral treatment had not been maximized. 
Gastrointestinal side effects do occur in 20-30% of patients on metformin[139, 
140]. However, only 4-5% of patients cannot tolerate metformin therapy with a 
gradual titration of dose[139]. This would suggest that there was room for further 
optimization of oral therapy for a substantial number of patients. 
3.3.1. Glycaemic control and duration of diabetes. 
Figure 4 shows the duration of diabetes for the whole Type 2 diabetic population 
with a median duration (interquartile range, lOR) of 5.0(1.5-8.5) yrs. 
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Glycaemic control is known to deteriorate over time[128]. This is clearly shown, for 
the total Type 2 diabetic population (figure 5), when comparing mean glycaemic 
control (HbA 1 c) over time. 
duration of diabetes (yrs) 
Figure 4 Type 2 diabetic population: duration of diabetes (n=3000) 
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Figure 5 Total Type 2 diabetic population: glycaemic control over time expressed as mean 
HbA1c over quartiles of duration of diabetes 
Looking at this in detail (figure 6), there is a small initial improvement in control 
over the first year followed by a steady rise in HbA 1 cover time. 
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2.00 4.00 6.00 8.00 10.00 12.00 14.00 
1.00 3.00 5.00 7.00 9.00 11.00 13.00 15.00 
duration of diabetes (yrs) 
Figure 6 Total Type 2 diabetic population: mean change in glycaemic control (HbA1c) over a 
15yr period 
This was similar to the findings in the conventionally treated group of the UKPDS 
study[128]. However, the UKPDS patients had a significantly lower HbA1c at onset 
(HbA1c 7% v 7.8%) suggesting that patients were diagnosed at an earlier stage in 
their disease in the research study compared to routine care. 
3.4. Conc~usion 
When studying a 'stable' diabetic population who had had their diabetes for three 
or more years and therefore should have been on optimal treatment, 59% 
remained in poor glycaemic control (HbA 1 c >=8%). Of those, 50% of tablet treated 
and 71% of insulin treated patients were poorly controlled. In the tablet treated 
group 46% were on monotherapy suggesting that oral treatment may not have 
been maximized. 
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In most regards the poorly controlled group differed little from those patients who 
achieve good control. However, they were slightly younger (65.3yr v 68.6yr), had 
their diabetes for longer (9.0yr v 7.0yr) and a higher proportion were on insulin 
(36% v 11%). 
Regardless of level of glycaemic control the majority of patients remained under 
review by their general practitioners (good control 90%, 84% poor control). 
However, an increased proportion of poorly controlled patients were seen in 
secondary care (35% v 15%) under total hospital supervision or with some form of 
shared care. 
This situation presented a challenge to future improvements in care. There were 
issues around maximizing oral treatment and how intensive treatment should have 
been from the outset. Also the question of earlier use of insulin treatment needed 
to be addressed. There were major workload and resource implications if all 





4. Beliefs and attitudes of people with poorly 
controlled Type 2 diabetes 
4.1. Introduction 
Type 2 Diabetes is a chronic progressive disease causing significant morbidity 
and mortality. With the Western tendency to follow an increasingly sedentary 
lifestyle and the associated increase in obesity, diabetes is projected to double 
in prevalence by the year 201 0[134]. 
Patients are initially treated by dietary modification but most require the addition 
of oral diabetic drugs to maintain control. Up to ten percent of patients per 
annum fail to maintain glucose control despite oral diabetic drugs[28]. It is well 
recognized that prolonged hyperglycaemia increases the morbidity and mortality 
of people with diabetes[141, 142]. This has personal costs but also puts a 
significant strain on NHS resources with almost 5% of total NHS expenditure 
relating to diabetes care[143]. 
Most patients in poor glycaemic control on oral treatment will require insulin. 
However, many patients remain in poor control for prolonged periods of time, 
there often appearing to be collusion between patient and physician to avoid 
insulin treatment[144]. Why is this? Clinicians' concerns have centred on patient 
compliance as a major issue. Adopting the traditional biomedical model, 
clinicians have regarded non-compliance as a patient failure to follow advice 
with the sort of moral judgment that this entails. Attempts to improve compliance 
by improving patient education have been largely unsuccessful. However, 
physicians' perspectives have been shown to differ from those of patients. A 
study of thirty Type 2 diabetic patients and their physicians showed that the 
doctors overestimated the difficulties patients had in coping with both diet and 
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treatment[122]. Similar findings came out in the subsequent study on health 
care professionals' beliefs where clinicians overestimated the difficulties 
patients experienced converting to insulin therapy. To bridge this gap it is 
important to understand how patients view the experience of living with 
diabetes. This study sought to investigate the influence of patients' beliefs and 
attitudes on their management of their diabetes. 
4.2. Aims 
To explore the experiences of people with poorly controlled Type 2 diabetes 
seeking to identify and understand their beliefs and attitudes to their disease 
and insulin treatment in the context of family practice. 
4.3. Subjects and Methods 
4.3.1. Subjects 
After local research ethics committee approval I identified Type 2 diabetic 
patients in poor glycaemic control from a local district diabetes register 
representing a single Primary Care Group (PCG). I contacted general practices, 
one from each of the four main areas covered by the PCG. I invited them to 
participate in the study and supplied them with a list of patients in poor diabetic 
control in their practice from the district diabetes register. They were asked to 
identify suitable candidates from the list or from their own knowledge of 
patients. General practitioners made initial contact with their patients and after 
provisional agreement I contacted the patients by telephone outlining the study 
and supplying written information by post. I had no previous knowledge of 
patients. All patients contacted consented to participate. 
44 
4.3.2. Setting 
The study population was drawn from a single PCG area in the North of 
England. The four general practices were broadly representative of the different 
areas comprising the PCG area: three urban practices and one suburban 
practice. 
4.3.3. Focus group interviews 
This study was exploratory and a qualitative approach was felt to be 
appropriate. Focus groups have been widely used in health care to assess 
understandings of illness and illness behaviour[145]. They were chosen for their 
ability to examine not only what people think but also how they think and why 
they think that way[146], using their unique feature of participant interaction to 
allow refining and clarifying of individual's views. The focus groups were held in 
the teaching centre of the local district general hospital in a small quiet 
discussion room. I conducted four groups over a period of four months with a 
total of 27 participants. This was a purposive sample of people with poorly 
controlled Type 2 diabetes, stratified by age (under and over 65yrs of age) and 
by treatment (tablet treatment or insulin injections). 
4.3.4. Group process 
After refreshments were served I introduced myself as a local general 
practitioner with a particular interest in diabetes. The object of the discussion 
was stated as the need to understand how people felt about their diabetes and 
its treatment with the aim of improving diabetes care. I made clear that the 
discussion was confidential and that no one would be identifiable in the final 
report. The discussion was directed by a set of semi-structured open questions 
(appendix 1 and 2). Initial questions were designed to put people at ease and 
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establish group cohesion. These were followed by general questions leading in 
to more specific issues. Groups consisted of six to eight members and lasted 
75-90 minutes. Four groups were held at which point saturation was achieved 
with no new ideas coming forward. Audio recordings of the meetings were 
made for later transcription. 
4.3.5. Data analysis 
The audio recordings were transcribed in full and entered into the qualitative 
computer software programme QSR NUD.IST vivo (non-numerical unstructured 
data-indexing search and theory building) for analysis. Each group was initially 
analysed independently and then comparisons made across groups. Coding 
was performed using the editing organizing style described by Miller and 
Crabtree[147]. "Using the editing style, the analyst identifies new categories 
through direct interaction with and sifting and coding of the text." Codes were 
developed directly from the text by identifying relevant categories and themes in 
an iterative process between the text and the organizing process, bearing many 
similarities to grounded theory[148]. 
4.3.6. Validity and reliability 
Full transcripts of the focus groups were used for analysis with the use of 
computer software to encourage coding rigour. Stratified purposive sampling 
was used to maximize variation and to ensure representative groups were 
studied. It was felt on theoretical grounds that views might differ between the 
younger and older age groups and that participants already on insulin treatment 
might have a different perspective from those considering it. Two independent 
analyses of the text were made by the researcher (DAJ) and an experienced 
primary care researcher (APSH). 
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Reliability was also assessed by comparing statements within and across 
groups[149]. 
Confirming and disconfirming cases were sought (deviant case analysis)[150] 
where views contrary to the researchers' explanatory scheme were given fair 
account, examined, and why they might vary was discussed[151]. Respondent 
validation was used to feed back the findings to participants to confirm that they 
represented a reasonable account of their experience[152]. All participants were 
posted a summary of the results. They were asked to indicate their overall 
agreement with the summary on a five point Likert scale from strongly disagree 
to strongly agree. Other comments were encouraged and space left for these 
on the reply sheet. 
4.4. Results 
Four focus groups were held involving a total of 27 participants. The groups 
were stratified by age and treatment type each with six to eight members in 
each group. 
4.4.1. Demographics 
Participants were fairly evenly distributed across the groups. 
Table 7 Participant distribution by age, sex and treatment 
Age Treatment Sex 
<65yr >65yr Oral Insulin Male Female 
n= 14 13 14 13 15 12 
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Table 8 Participant demographics 
Age Treatment Age (yrs) Duration of HbA1c (%) BMI 
group mean (range) Diabetes 
(yrs) (yrs) 
n=27 n=27 n=24 n=24 
65 & Oral 69 13.6 9.5 29.2 
over 
(65-67) (8-19) (8.4-10) (28-
32) 
Insulin 70 14.3 10.4 25.6 
(65-75) (9-25) (8.7-12) (18-
31) 
Under Oral 59.5 5.9 9.5 32.7 
65 
(48-64) (5.4-1 0) (8.1-11.5) (26-
46) 
Insulin 55.5 11.5 9.6 33.6 
(45-64) (5.4-22) (8.3-11) (29-
36) 
Table 9 Demographics of the poorly controlled district diabetic population (HbA1c >8%) 
Age Treatment Age Duration of HbA1c BMI Sex 
group Mean Diabetes 
(yrs) (yrs) (yrs) (%) (%female) 
65 & Oral 73 10 9.3 28.1 52 
over 
Insulin 72 15.8 9.5 28.9 53 
Under Oral 57 7.5 9.5 30.2 35 
65 
Insulin 57 11 9.5 30.6 49 
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A number of concepts were identified relating to how participants perceived 
diabetes and how they evaluated information on management. 
4.4.2. Themes identified 
4.4.2.1. The nature of Type 2 diabetes 
Type 2 diabetes has previously been regarded as a mild disease by both the 
medical profession and public alike due in part to its insidious onset and mild or 
even no initial symptoms. However, it is now recognized that Type 2 diabetes 
carries a heavy toll in terms of morbidity and mortality especially from 
cardiovascular disease. Indeed it has been termed 'the silent killer'[153]. 
Participants still viewed diabetes as mild disease. 
P07G1: As an illness its nothing. . .. I can eat almost anything so to 
me it's not a disease it's an inconvenience. 
P1 OG2: I can't say it really bothered me being a diabetic. 
P14G3: If the doctor hadn't have told me I wouldn't have known any 
difference. I still don't feel as if I've got diabetes. It doesn't seem to 
affect me much really. 
However, a minority expressed an alternative view. 
P13G2: It is a serious problem. I think if you don't take your 
medication, like my sister who died a fortnight ago it starts affecting 
the rest of your body like your heart and kidneys and everything. 
know that because the doctor has explained it all to me. 
4.4.2.2. Diagnosis. and~causation 
Many participants had little initial knowledge or understanding of diabetes at 
diagnosis. 
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P16G3: I knew nothing about it at all. When I did get it I had all the 
symptoms and I hadn't a clue what the symptoms meant. Not at all. 
It wasn't until somebody told my wife it could be diabetes and we 
went to the doctors and found out that's what it was. But up until 
then I hadn't got a clue. 
The exceptions were those participants with experience of diabetes through 
friends or family. 
P21 G3: I had a couple of friends that had diabetes so I knew about it 
but mine was discovered on a routine visit to the vascular clinic. 
There was often considerable delay in initial diagnosis. 
P03G 1: I retired from work ill, never been diagnosed with diabetes 
and lost something like nearly 3 stone in a year and I was convinced 
I had cancer ... the doctors didn't pick it up until I was getting sick 
money and the DSS sent for me after 6 month to keep the sick 
money going, (I) walk in there, give a urine sample, sat in the waiting 
room and the nurse came out and said 'Oh I think I'd like you to go 
and see your own GP you've got sugar'. She never said diabetes, 
she said sugar. Well I walked out thinking 'sugar? That's diabetes, I 
haven't got cancer!' 
P01G1: What I found going to the doctors, in the end he said 'Oh its 
psychosomatic, its in your head'. And this went on and I just got to 
the extent that I just didn't want to go out of the house. . .. one day I 
went to the doctors and I hadn't been feeling well. This had been 
going on for some time, hadn't it, and I went over and I said to the 
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sister in the clinic, 'will you test me for sugar' and she said 'Yes ... I 
will' and it was diabetes. The doctors hadn't picked it up. 
The impact of being diagnosed with diabetes is considerable. Participants 
recalled their initial shock and denial to being told they had diabetes. 
P23G4: I didn't know anything about it at all and I was completely 
devastated. I was in denial for ages after they told me. I thought it 
was the worst thing that had happened in my life to be honest. 
P05G1: I knew nothing about it at all ... so I was completely numb. 
However, the majority rapidly came to terms with and accepted the diagnosis. 
P27G4: I don't look upon it as a nightmare. It's something that's 
happened and you have to get on with it. 
P15G3: I just felt cheated. I felt why should it happen to me, but 
once it's diagnosed you just get on with it. 
However, one participant expressed ongoing denial. 
P14G3: If the doctor hadn't have told me I wouldn't have known any 
difference. I still don't feel as if I've got diabetes. It doesn't seem to 
affect me much really. 
Participants attributed their diabetes to a variety of causes. Diabetes 'running in 
the family' was frequently cited although the concept of inheritance was not 
specifically mentioned. 
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P02G 1: My grandmother had diabetes and my mother and my 
younger brother who died last year unfortunately and I can't go back 
any further than that but it seems to be in the family you know and it 
unfortunately struck me. 
P13G2: really I wasn't surprised about being a diabetic because it 
runs in the family. My mother was a diabetic, my brother was a 
diabetic and he went blind through it. I lost my sister a fortnight ago 
and she was a diabetic but she used to cheat a Jot. 
Psychological and physical stress was mentioned across groups as a common 
cause of diabetes. 
P16G3: I think my heart attack brought on the diabetes. 
P05G 1: I had a stressful job for years and also I was suffering from a 
bleeding ulcer. And looking back I think that was the beginning of it 
because there is nobody in my family that ever had diabetes. 
P12G2: I put my wife's (diabetes) down to the shock of the operation 
and the stress it caused 
A variety of other causes were suggested included eating sweet foods, being 
overweight, excess alcohol and lifestyle. No mention was made of internal 
organ failure. 
P03G1: If you take mine ... I would say 90% due to just 2 things. I 
had about 12 or 14 cortisone injections for frozen shoulder and tennis 
elbow and ... there was tremendous stress at work 
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P01G1: Well, a friend gave me some rhubarb and I cooked this 
rhubarb and we were going to have it as a sweet and it was really 
sour so I put sugar on, more sugar, couldn't get any sweetness at all. 
And I took an awful lot of sugar in that one sweet and I think this was 
the start of the diabetes. 
P27G4: I put on quite a Jot of weight that's perhaps why I got it. 
One fatalistic view was expressed. 
P22G4: Maybe nobody knows and maybe its just one of those things 
that comes out in people. 
4.4.2.3. Relationship with clinicians 
A dichotomy of views towards physicians was expressed. Family doctors were 
seen as knowledgeable and caring, giving patients the opportunity to discuss 
concerns. Participants felt they had a good relationship with their doctor. They 
generally viewed the doctor as having a particular interest in diabetes. 
P06G1: Our doctor ... She is very good and gives plenty of advice. 
But she specialises in it you see. 
P04G1: Our doctor is very good. There are two doctors and she 
specialises in diabetes and she's really good. 
P02G1: I try to make out exactly what I want to know and we discuss 
it and whether it's over his time or not it doesn't really matter to him. 
That's how doctoring should be. 
POBG2: I'm lucky, I'm looked after by Dr B and I think I have a very 
good relationship with him. He is a great guy and I would think I 
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could ask anything and he tells me the ins and outs of everything. I 
wouldn't want to see anybody else really. 
In contrast, some saw their doctor as having little interest in or knowledge of 
diabetes. 
P07G1: The doctor doesn't know a thing about diabetes and if I talk 
to my doctor he says please talk to the nurse, I don't know anything 
about diabetes. 
P26G4: I find that they don't explain things. Even our own doctor, 
didn't explain the pros and cons or anything. I only found out by 
reading the pamphlets. 
P03G1: ... its very, very difficult to get the right information, even off 
your own doctor. . . . The doctors themselves, to me, the ones I've 
had, three different ones over the last 15 years, don't seem to know a 
Jot about the diet. 
One person mitigated this recognizing that family doctors inevitably have 
different interests and that not everyone can be 'a diabetes expert.' 
P05G1: Yes, well I suppose every doctor is good at something 
specialised. 
Practice Nurses were seen as 'specialists, giving helpful advice although 
perceived to be very busy by some. 
P07G1: The diabetic nurse, I'm on my third one, and each has been 
very very similar: dedicated, they know what they are doing and what 
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they are talking about and very full of advice. Excellent. That's my 
personal experience. Doctors nothing, nurses brilliant. 
Diabetic specialist nurses again were seen as knowledgeable but busy. 
P24G4: When I first went on insulin, she was the only diabetic nurse 
around here for 3000 people. But they do have more now. She's 
very approachable. 
The few comments made about dieticians were negative. 
P03G1: They send you to some young girl and she says you can 
have three slices of bread in the morning, you can do this and that ... 
and it doesn't work 
P23G4: They sent me to see the dietician and I felt all they were 
saying was that I was too fat. ... I feel that the dieticians are enemies 
tome. 
Their advice was not seen as useful but this has to be viewed in the context of 
dietary change being the most difficult area in which to make changes. 
4.4.2.4. Desire to life a normal life 
Participants felt they were able to live a normal life despite making some 
lifestyle changes. 
P17G3: Apart from taking pills I don't see any difference in my life 
whatsoever. . .. It doesn't run my life at all 
P22G4: When I was diagnosed and they were talking to me in the 
hospital they said that really it shouldn't affect your life and you 
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should be able to live a normal life. And I really feel that I do live a 
norma/life. 
P03G 1: . . . I slowly got round to accepting it . . . and like now I try to 
live, I play golf four times a week; I try to live a norma/life. 
Others saw the changes as more radical. 
P19G3: I think it's a case of changing your way of life. 
4.4.2.5. Compliance 
Participants did not see compliance as a major issue in contrast to clinician's 
views. They tended to gauge benefit by the presence or absence of symptoms. 
This is illustrated in a discussion on glycaemic control. 
P26G4: ... I feel its all very well for them to say you must be doing 
this and be in between these two markers, but when I've tried to get 
in between 4 and 8 I feel unwell. 
P23G4: I find that. 
P26G4: If I let it get a bit higher, I feel fine. I think my body is telling 
me what it needs. I tend to lie a bit and say Oh its fine because 
that's what they want to hear. They are not interested if you say I 
usually run about 12 they say that's not good. But if I increase the 
insulin and get the reading down, I feel unwell and I don't want to feel 
like that. 
P23G4: I'm exactly the same as you. If it gets below a certain Ievell 
feel unwell. I have to have it more or Jess on 10 or 12. 
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P26G4: I feel better on 12 but they say it's too high. I've got to work 
and don't want to get up in the morning and feel bad. 
P05G1: You know your own body. 
4.4.2.6. Diet 
Lifestyle changes are recognized as being difficult to successfully implement. 
Some people found major changes in diet to be necessary but for others simply 
omitting sweet items was felt to be enough. Adapting to these changes was 
easier for some than others. 
P19G3: ... (a) completely different diet to what I was brought up with. 
My grandmother used to have a pork butchers shop (and) my 
grandfather went fishing so that's how I was brought up meal wise. 
Now, I eat fish but olive oil and not lard. I use flora pro active, just a 
complete change in diet. 
P15G3: You get to a point sometimes when you think what the heck 
can I eat. You get bored with the same food ... 
POBG2: With a bit of organisation it's no problem really. 
P07G1: I have to watch my diet but not critically, it's not that limiting. 
I can eat almost anything ... 
An extreme view was that of consciously not eating the correct types of foods. 
P22G4: I feel great but I'm not living as they want me to live. I'm 
overweight, which is bad. I'm probably not eating the right food, 
which is bad, but I feel well. 
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4.4.2.7. Exercise 
Exercise was prescribed but suggestions were often felt to be unrealistic. 
Getting older and physical problems limited the range of possible activities, the 
most popular form of which was walking. 
P10G2: ... when I came to the clinic here for the first time she said 
'do an hours brisk walk every day.' But my brisk walking days are 
gone. I can walk, but not briskly, my hips and knees are getting worn. 
4.4.2.8. Drug treatment 
A progressive intensifying of treatment was recognized, progressing from diet 
alone through increasing numbers of tablets and eventually to insulin injections. 
POBG2: I find it goes in steps. It started off diet controlled and it's 
gone to small medication to medium medication, and now to as much 
medication you can look at before going onto insulin. 
Some felt regimented by the need to plan tablet taking and injections. 
P15G3: But you clock watch on account of your pills though. 
Others felt drug treatment interfered little with their daily routine. 
P26G4: I found them fine and I find it quite easy to regulate my 
diabetes. I've just changed onto a quick action insulin now because I 
just take it when I eat. I find that's brilliant. 
P19G3: Quite good really. The tablets have just about settled me out. 
Certainly it doesn't have a major effect on my life. I'm still working 
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and still active. The only change really to me is my diet and my 
family's diet. 
4.4.2.9. Converting to Insulin 
Those on oral treatment feared the introduction of insulin, particularly the idea of 
needles and injections. 
P21 G3: My doctor said I think its time you went on injections: I said 
'no way!' 
P07G1: My immediate reaction was 'No'. I'm not going to take any 
insulin. 'No! I'm 55, I've had a good life .. . therefore I've had enough. 
If it means that I have to stick a needle in me twice a day for the rest 
of my life and eat small sandwiches etc then I'm not going to let me 
or my family suffer to live with somebody like that. . . . but at first it 
was terrifying to think that you are going to have to register the whole 
of your life in-between injections. 
Several patients stated that they had actively resisted the change to insulin over 
a prolonged period of time. 
P15G3: No. My doctor tried to get me on (insulin) for about 18 
months and I fought him. I kept saying we'll try another couple of 
months doing this and that and I was trying different ways, watching 
my diet a bit more, being a bit more strict. 
The exceptions were the symptomatic patients who saw a potential benefit in 
switching to insulin. 
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P17G3: Whatever is good for me, that's it. I've got to go and see the 
doctor next week and it's going to be whether I go onto insulin or not . 
. . . if it's going to make me feel better that's all I'm interested in. 
P23G4: To be truthful I was glad in the end. The tablets and diet 
weren't controlling it and I was ill . ... The only other option was the 
insulin and I was glad and I did feel remarkably better when I went on 
it. 
However, there was usually a rapid acceptance of insulin once started and it 
was generally seen as beneficial. 
P06G 1: Well, I wasn't keen but once I found out it was doing me 
good you just accept it. 
P05G1: You accept it and get on with it .... If they gave me the option 
now I would opt for insulin instead of the tablets. 
Although insulin overall was seen as beneficial some could see no benefit in 
changing to insulin. 
P10G2: I don't think there would be any (benefit) as far as I'm 
concerned. 
P11 G2: Not for me either: more of a hindrance or a nuisance. 
Tablets are no problem, but to have to stop everything and go 
through the process of checking your blood and then having to take 
your insulin injection 4 times a day. 
Concerns were expressed regarding needles and injections. 
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P01G1: The first time I saw this was when I was working and going 
into a toilet and seeing one of the girls injecting herself with this great 
big glass thing and needle and I thought to myself 'Oh my God I don't 
think I could do that.' .. . how on earth do you stick a needle in 
yourself, it's horrible! 
P02G 1: My grandmother used to use needles like that and I used to 
cry and her legs were just one mass of bruises. 
Again these were mainly from the patients still on tablet treatments. 
P16G3: I was petrified because I cannot stand hypodermic syringes; 
I'm terrified of them. I could be an international sprinter if somebody 
produced a needle. I thought about the needle business and thought 
I can't be doing with this. I said if it's a needle, just leave it, I've had a 
fair innings. That's the affect needles have on me. I'd have sooner 
have kicked the bucket. Just leave me. 
Several participants expressed concern regarding the risk of hypoglycaemic 
episodes. 
P1 OG2: What worries me is going into one of these hypos, being the 
only driver 
POBG2: I suppose, living by myself, my other fear would be what 
would happen if I did go into a hypo? 
Many had no knowledge of hypoglycaemia prior to their first episode. 
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P07G1: Exactly. It's ok when you've had one, you know what it is. 
But when you haven't had one before and nobody has described 
exactly how it shows itself then its difficult. . .. I was getting hot and 
then the next thing I fell under the table and they carried me out and 
eventually got me to hospital. And that was my first hypo ... 
P02G1: Well, I've never had a hypo or anything like that. I get the 
shivers and shakes every now and then but as I've said I carry 
something with me or I suck a sweet or something and it goes off, 
then I have something to eat. 
Some saw Insulin as giving them increased control over their disease, while 
others saw the opposite. 
P15G3: But then again, if I went on the injections then the insulin is in 
charge of me, whereas I'm still in charge of my tablets. If I go on 
insulin then that's ruling me isn't it . ... I fought it for over a year just 
because I didn't want insulin being in charge of me. 
Personal experience and the experiences of friends were influential in forming 
participants' opinions on using insulin. 
P15G3: Even so, I know somebody now who has been a diabetic 
since she was 19 and she's on insulin and she's had readings of 30 
and 40 she said and she's been in hospital a couple of times 
because she's had lows of 1 point something. So I thought if she's 
been on it that long and still having problems, where does that leave 
me. 
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P13G2: I saw a chap in a restaurant a few months ago .... 1 just 
happened to look over and he just took this pen out and went through 
his trousers . .. . I've always thought it was more complicated than that . 
. . . I thought, well the doctor keeps threatening me with insulin and it 
always frightens me a little bit but since I've seen that bloke I've 
thought, well, its nothing that! 
P01G1: The first time I saw this was when I was working and going 
into a toilet and seeing one of the girls injecting herself with this great 
big glass thing and needle and I thought to myself 'Oh my God I don't 
think I could do that' 
4.4.2.10. Self monitoring 
Those on insulin saw monitoring their blood glucose as valuable in helping to 
reduce the risk of hypoglycaemia. 
P07G 1: . . . taking a blood test is the only way you know how to 
regulate your intake of insulin. Without those blood tests you have 
no control whatsoever. 
P15G3: Yes and I keep my recordings in a diary . .. . I've been testing 
4 times a day. Because if I have the grandchildren, I cannot put 
them at risk by me having a hypo ... 
Some however were disillusioned with testing, finding it painful and not fulfilling 
any purpose. There was negative reinforcement. Tablet treated patients tested 
and saw no change in the readings despite their best efforts. Insulin treated 
patients similarly made adjustments to their insulin dosage and again found no 
benefit. A few patients had given up testing all together. 
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P03G 1: I've stopped 
P07G1: You've stopped but you are still taking your insulin. So you 
don't care? .... 
P03G1: My hands got so sore that I gave it up. Well/ wasn't happy 
about this business about (blood sugars of) 3 to 15 and that and I 
went to the doctor . . . He said well for a fortnight can you do it 
morning, dinnertime, teatime, nighttime so I said ok then. So I went 
through this routine punching my fingers 4 times a day and at the end 
of the fortnight I go to the doctor and this was still floating from 3 to 
15 and 12 and he looks at it and he said I can't make head nor tail of 
that: just stay on the same insulin as that you are now. I couldn't pick 
my (golf) club up for a week after that! 
P21G3: I don't test my blood at all. 
4.4.2.11. Barriers 
Eating out posed problems for some participants. There was reluctance to dine 
out in restaurants some feeling embarrassment particularly with injecting in 
public. 
P01G1: We just stopped going out and having meals because of it. I 
felt embarrassed by it ... 
P05G1: You could do it at the table now because you can do it so 
quickly that the people surrounding doesn't even notice what you're 
doing I've gone to many restaurant where I've had to inject myself 
just took the thing, put it in and nobody even saw me doing it. 
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P07G1: This is very interesting to me because, like you, I'm restricted 
my dining out purely and simply on the fact of timing. If I have my 
injection before I leave the house, how long is it going to take the 
restaurant to give me the meal and so on. 
P03G 1: I mean, one chap that I sat next to, we were talking about 
injecting through your clothes and that's all he did. He just shoved it 
straight through his shirt and that's it. 
Some did not want to be singled out as 'diabetic' while others actively broadcast 
the fact, feeling that being open about the problem made it easier to deal with. 
P03G1: The people you associate with, if you tell them about your 
diabetes, I've found it's quite a joke. Some of them say 'Oh I could 
do with a bit of that'. I've never seen people take offence about it. 
You get sympathy 
P22G4: When I was diagnosed and they were talking to me in the 
hospital they said that really it shouldn't affect your life and you 
should be able to live a normal life. And I really feel that I do live a 
normal life. I have to tell people at work in case anything happens, 
but I'd rather not Jet anybody know to be honest. I can deal with it on 
my own, I don't like to talk about it and I just get on with it. 
Others saw no problem in dining out simply making minor adjustments to their 
menu, the commonest being to miss the sweet course. 
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P15G3: It doesn't bother me. I just watch what's on the menu. If I 
find something on my plate that I'm not meant to have I give it to my 
husband or leave it. 
One working participant felt there was discrimination in the workplace, mainly in 
relation to ignorance about diabetes. 
P23G4: I find that there is a little bit of prejudice, "Oh, she's diabetic!" 
Family and friends were seen as giving both positive and negative messages in 
regard to self-management. 
P27G4: I have a friend of nearly 40 years and every time I would go I 
used to like a little cake with a cherry in the middle she used to make 
and even when I go now she always asks if I want one and she 
knows full well that I can't. That makes me cross. However, my 
family is very good particularly my daughters and my little 
granddaughters aged 5 and 7 that know what Granny can or can't 
have. My husband is good. 
4.4.2.12. Potential complications from diabetes 
Loss of limb was a major concern expressed across the groups gleaned from 
personal experience or that of friends and acquaintances. Cataract, retinopathy 
and blindness were a worry to some. 
P03G 1: I think the biggest fear is when a lad who retired from work 
with me stubbed his big toe and 6 months later he died of gangrene 
and within 6 month he died and that frightened me to death and he 
just stubbed his toe 
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P07G1: I attended this hospital and the first time I attended, in the 
waiting room there were 3 young men around the mid 20's and each 
had had their big toe amputated and they were waiting to have their 
dressings changed. And that was my first experience in coming to 
the diabetic clinic in England and to see 3 young men with their big 
toes amputated and walking on crutches was absolutely terrifying ... 
P01G1: A girl that lived in village A, she had hard skin on her feet 
and it cracked and she got poisonous gangrene and she had to have 
both of her feet amputated. She didn't last very long once that was 
done. That rather frightened me when I saw that, consequently I'm 
looking at my feet with a scraper all the time getting rid of hard skin. 
But that was my first experience. . .. It's going to affect me feet and 
lose my feet and this sort of thing. That's my only worry because I've 
got very little and almost no feeling in my feet at all and they get 
tingly and they get hot yet my feet are like ice. 
P24G4: I had something to do with it. My mum got it after my dad 
died but that was just diet controlled and she never took any notice of 
the diet really because she was in her 70s but she didn't die of the 
diabetes, she died of a heart attack 
Although several participants had experienced heart disease and stroke the link 
between these and diabetes was recognized only by a few. 
P01G1: And 3 years ago I had a heart attack and that was the result 
of the diabetes and 6 month after I had a triple bypass and that's how 
it's gone up to now. 
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P13G2: It is a serious problem. I think if you don't take your 
medication, like my sister who died a fortnight ago, it starts affecting 
the rest of your body like your heart and kidneys and everything. I 
know that because the doctor has explained it all to me. 
4.4.2.13. Locus of control 
Decision-making was regarded as the doctor's responsibility. Participants 
showed anxiety in relation to taking responsibility themselves. 
P15G3: I always leave myself in the doctor's hands it's a simple as 
that. He knows more about it than I do so I hope that what he 
suggests is going to be the best thing for me. Alii can do is try it and 
if it doesn't work out - well ... 
P07G1: Would we like a choice? Personally, I wouldn't ... I would 
always be concerned about did I make the right choice ... I would like 
the medical profession, in my opinion, to do their job and tell me what 
I should do rather than give me a choice. 
4.4.2.14. Lay influences 
Participants' beliefs were strongly influenced by their own past experience and 
also the experiences of friends and family. These 'lay aetiological perspectives' 
were particularly evident in regard to attitudes at diagnosis and strongly 
governed how people thought about complications. Attitudes to insulin were 
also significantly influenced. 
P07G1: Can I give you my impressions before I was diagnosed? I 
only had very remote indications of somebody with diabetes. This 
was a colleague at work and my biggest impression was his 
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restricted diet. This is going back many years and at that time I was 
horrified to see him having for lunch vefY small sandwiches with vefY 
little filling and really critical amounts and he was restricted to that. If 
he felt like having a biscuit or something extra ... he had to refuse. 
And that to me was a terrible burden on any person's life to have to 
regiment his food ... 
P13G2: Really the thing that frightens me most about being a 
diabetic is going blind. With my brother going blind through it. 
P10G2: A's wife said to me, when I was telling her that I might have 
to go on it, she said you'd probably find it better once you got used to 
it. 
P15G3: Even so, I know somebody now who has been a diabetic 
since she was 19 and she's on insulin and she's had readings of 30 
and 40 she said and she's been in hospital a couple of times 
because she's had lows of 1 point something. So I thought if she's 
been on it that long and still having problems, where does that leave 
me. 
4.4.3. Respondent validation 
Participants were posted a summary of the research results and were invited to 
indicate their level of agreement with the findings on a five point Likert scale. 
Space was provided for additional comments on the reply slip. A reminder was 
issued after two weeks. 23 of the 27 participants responded (an 85% response 
rate). 21 of the 23 replies agreed or strongly agreed with the findings, with one 
respondent neither agreeing nor disagreeing and one strongly disagreeing with 
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the findings. The participant who disagreed with the results indicated that they 
felt diabetes had had a profound effect, viewing diabetes as 'affect(ing) your 
social life 100% and I found it hard to adjust to that.' 
The mean score for replies on the Likert scale was 4.2. 
Other comments received were equally positive: 
POBG2:1 think the summary has 'hit the nail on the head.' 
P15G3: Reading the report I felt as if I was back in the discussion 
4.5. Discussion 
4.5.1. Methodological issues 
A qualitative approach was used, as this was an exploratory study of an area 
that has received little research attention. The object was to provide insights 
into participants' perceptions and interpretations of Type 2 diabetes and its 
management from the viewpoint of the poorly controlled patient. No claim is 
made in regard to generalisability given the sampling method. Our aim was 
more to expose the variety and diversity of interpretation. 
Respondents were selected by their GP from their practice population of people 
with Type 2 diabetes in poor glycaemic control. All people agreeing to be 
approached regarding the study subsequently agreed to participate. Using a 
'gatekeeper' [154], such as the GP in this instance, can introduce several 
problems. Firstly, there may be bias introduced by the gatekeeper choosing the 
'most suitable patients,' e.g., the most eloquent or the most compliant patient. 
Secondly, an ethical issue, patients may be recruited without being given all the 
relevant information on which to give informed consent. This bias was limited to 
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the extent that General practitioners were asked to invite participants from a list 
of their failing diabetic patients from the diabetic register. Also, after their initial 
indication of willingness to participate, patients were given a full description of 
the study both orally over the telephone and a written explanatory leaflet by post 
before indicating their willingness to participate. 
Systematic methods were used to increase the reliability and validity of the 
study. Participating practices were chosen from the four main geographical 
areas of the PCG. Stratification of focus groups was used regarding age and 
treatment type as it was felt on theoretical grounds responses may vary across 
these groups. 
The researcher facilitating the groups being a GP introduces a potential for bias. 
Responses may have been different to a non-health professional. The GP 
researcher may in some circumstances be viewed as an 'expert' with an 
expectation of providing information, or may be seen as a 'judge' making moral 
judgments on participants and thus inhibiting comments[155]. However, a 
conscious effort was made to avoid these roles. The participants were not 
previously known to the researcher, and in such group discussion, there is a 
tendency for the group discussion to 'dilute' the effect of the researcher's 
persona as participants address each other during the discussion[154]. 
4.5.2. Main findings 
Type 2 Diabetes was generally perceived as a mild disease. This has 
implications for how participants manage their diabetes. The Health Belief 
Model[92, 93] of illness behaviour has been shown to apply across a variety of 
medical conditions[94]. This postulates that two of the key factors affecting the 
likelihood of a person following advice are the perceived severity of the 
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condition and the perceived vulnerability of the person to the disease. Viewing 
diabetes as a mild disease is therefore likely to reduce adherence to both 
lifestyle change and drug treatment. Why did participants see their diabetes as 
a mild disease? Most expressing this view equated lack of symptoms to 
'mildness' of their disease, as Murphy and Kinmonth put it: "no symptoms, no 
problem!" In their interview study of 46 people with Type 2 diabetes they found 
two variations in patients' perceptions of the seriousness of their diabetes: the 
extent to which patients primarily orientated themselves towards symptom 
control (a mild disease) or toward prevention of complications (a serious 
condition)[113]. 
The impact of being diagnosed with diabetes is considerable. Many people 
suffer symptoms of depression, anxiety and social withdrawal. Most work in this 
area has concentrated on children and adolescents suggesting that up to one 
third suffer significant psychological distress but that by the end of the first year 
virtually all recover[87]. In adults with Type 2 diabetes psychological distress is 
also observed but again sufferers tend to return to previous levels of functioning 
after adjustment[156]. The pattern of initial despondency followed by gradual 
acceptance and recovery was described in our groups. This should not be 
underestimated as the psychosocial impact of diabetes has been shown to be 
one of the best five predictors of mortality, ahead of many clinical indicators[71]. 
Participants perceived stress and the tendency for diabetes to run in the family 
as the commonest causes for their diabetes. There have been few studies 
looking at patients' views on the cause of their diabetes. Those that have, have 
investigated the views of minority groups[1 02, 103, 157, 158]. It is of interest to 
note the similarities in the ideas put forward. British Bangladeshis cited heredity 
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and stress to be commonly held causes of diabetes[157]. An ethnographic 
study of American Vietnamese people with Type 2 diabetes also highlighted 
stress as a major perceived cause[158]. In a study of Mexican-Americans, Hunt 
found heredity and diet frequently mentioned but qualified by an attempt to 
relate these to personal experience through provoking factors such as 
behaviours or events[1 02]. Stress has not been shown to directly influence the 
onset of Type 2 diabetes but animal studies have found stress interacts with 
obesity to produce glucose intolerance and hyperglycaemia[159]. 
Lifestyle issues are notoriously difficult to address. There were two themes to 
participants' views on dietary change. There were those who felt minimal 
change was necessary, simply avoiding sweet foods, and therefore viewed 
dietary change as having little impact. The second group saw the dietary 
change necessary as a total change to their normal practice and hence as a 
great imposition. Co-morbidity with increasing age was seen as a barrier to 
exercise with clinicians often setting unrealistic targets. 
Conversion to insulin was seen as a last resort, was dreaded and all too often 
actively delayed as long as possible by participants. Barriers put forward were 
the fear of needles and injections, the inconvenience, particularly socially, the 
fear that insulin would be somehow more controlling than oral treatment and the 
risk of hypoglycaemia. Despite these barriers most participants saw insulin as 
beneficial mainly as a means of improving well-being. This concurs with the 
earlier work of Hunt et al. in an interview study of low-income Mexican-
American Type 2 patients[160]. 
Concerns regarding complications stemmed from personal or lay influence. 
Seeing relatives or friends with amputations or visual impairment influenced 
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participants' anxieties towards complications more than health professionals' 
advice. The lack of appreciation of cardiovascular disease as a major diabetic 
complication (despite several members having personal experience of heart 
disease and stroke) is of concern. 
Participants had at least one healthcare professional that they could relate to 
who was valued as a reliable source of advice. For some it was their GP, for 
others it was the practice or diabetic specialist nurse. However, participation in 
decision-making in the consultation was acceptable only to a minority. More 
involvement in the decision-making process has been shown to improve 
outcomes[161, 162]. Participants' attitudes may reflect the older age groups 
involved. Future generations may be more consumer-orientated and less willing 
to uncritically accept their doctors' advice. It is of interest that Peyrot found 
devolving control to health care professionals (an external locus of control) had 
a negative effect on diabetes control, whereas control lying with significant 
others such as relatives had a more positive effect[1 08]. 
How does the patient make decisions on self-care? The traditional bio-medical 
model sees the doctor I patient encounter as central, with the doctor as the 
'expert' who 'knows best' and the patient as the passive, obedient recipient of 
that advice. In this context compliance is the norm and non-compliance is seen 
as deviant behaviour, the fault of the patient. However, default is in the eye of 
the beholder. Compliance was not a major issue for participants. To the patient 
the consultation is but one small part of the decision-making process. Other 
sources of medical advice are likely to be sought. Advice and treatment is 
received against the background of previous experience and belief. Lay 
informants contributed significantly to participants' beliefs about diabetes with 
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health professionals infrequently cited. This concurs with Greenhalgh's findings 
in Bangladeshi diabetic patients[157]. As Greenhalgh pointed out there may be 
more similarities than we at first surmise between diabetic groups across 
cultural or other divides. There is a danger that investigators may be so focused 
on finding something new or different that they fail to recognize the similarities, 
a concept Silverman terms 'tourism'[163]. Professional advice is likely to be 
discussed with family or friends before a 'cost-benefit' decision is made on 
whether to accept, wholly or in part, that advice. Patients use this 'reasoned 
decision-making' to make the best decision that they can[79]. As Stimson 
reflected "we therefore have to take account of the patient as a decision making 
individual living in a culture from which he is receiving information about health 
and illness[75]." Patients' beliefs are constantly being remodelled in an active 
process with the receipt of new information from both lay and professional 
networks. 
There was a strong desire to live as normal a life as possible. An earlier study of 
fairly well controlled Mexican American diabetic patients noted patients' concern 
with the experiential and social aspects of living with diabetes contrasting this 
with health care professionals' preoccupation with glucose control and 
instruction on self-care behaviours[164]. Participants made sense of diabetes 
by fitting it into their daily routine, in the most part resisting the tendency for 
diabetes to control their lives while avoiding physical symptoms. In this study 
participants often made decisions based on symptom control. Some participants 
feeling unwell when their blood sugars were well controlled graphically 
illustrated this. They made a conscious decision to run higher blood sugars to 
avoid this malaise. Hunt found similar influences in an interview study of 51 
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Mexican American informants with type2 diabetes[76]. Murphy and Kinmonth 
found patients were either orientated to avoidance of short term symptoms such 
as malaise, tiredness or frequency of micturition, or to avoiding complications 
such as gangrene or blindness[113]: the former representing a short-term 
symptomatic approach, the latter a longer term preventive approach. 
4.5.3. Implications for practice 
It is clear that any population of people with diabetes will contain a diverse 
range of personal interpretations of the disease. Any strategy for care will need 
to explore, respect and build on these perceptions. 
Empowering patients, giving patients the means to make informed decisions 
about their own care, has received more attention of late[165]. Where patients 
have been encouraged to participate in their care through asking their own 
questions outcomes can be improved[162]. 
We can no longer assume that poor outcomes are due to ignorance or lack of 
motivation[76]. We need to explore not only what people are doing, but also 
why they behave in the way they do. 
This study of people with poorly controlled Type 2 diabetes suggests that their 
beliefs differ little from those of the general diabetic population maintained on 
diet only or oral therapy[113]. The beliefs of patients on oral drugs or insulin 
treatment were similar, out with the higher levels of anxiety that the oral drug 
groups had towards starting insulin. These beliefs also concur with many of the 
core beliefs seen in minority groups explored in previous studies. 
The gap between patient and health professional perspectives has been 
documented[122]. An appreciation of the patient's beliefs and the underlying 
76 
lay aetiological perspectives is required if we are to successfully influence 
diabetes self-management. Interventions can then be better tailored to patients' 
needs. It is of concern that participants in this study based their decisions on the 
presence or absence of symptoms; lack of symptoms equating to good control. 
Consequently they viewed diabetes as a mild disease because they had few if 
any immediate symptoms. Beliefs are dynamic and open to influence by both 
professional and lay influences. Establishing patient beliefs should enable 
clinicians to provide context relevant information that is acceptable to patients 
and more likely to encourage behavioural change and help reduce the conflict 
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care provoder beliefs and attotudes. 
5.1. Introduction 
In the United Kingdom, Type 2 diabetes affects 1.8 million people with an 
estimated 1 million currently undiagnosed[3]., comprising 2-4% of the 
population and up to 10% of those over 65 years of age. It causes significant 
mortality and morbidity, particularly from coronary heart disease, stroke, renal 
failure, blindness and lower limb amputations. It has major economic 
consequences with doubling of secondary care costs and for those of working 
age, significant loss of earnings. Many of these patients are elderly and the 
majority is cared for in primary care. Glycaemic control is often poor and there 
appears to be reluctance on the part of both patient and their doctors to tackle 
the problem when maximal oral treatment is failing[144]. The recent UKPDS 
study has shown that good glycaemic control can reduce morbidity from 
microvascular complications by 25%[128], and that tight blood pressure control 
can further reduce morbidity as well as reducing diabetes associated deaths by 
32%[166]. Changing elderly and often frail patients to insulin therapy is not 
always seen as desirable because of concerns about the patient's ability to 
cope with the regime[167]. However, many patients feel better on insulin and 
the elderly generally do cope well with insulin[168, 169]. 
An assumption that doctors base their management strictly on medical science 
has been made, particularly with the current emphasis on evidence-based 
medicine [115, 116]. Ley, reviewing work on compliance of pharmacists, 
doctors and nurses found a high level of non-compliance: lack of knowledge, 
errors of interpretation and deliberate disregard due to beliefs or social 
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pressures being cited as some of the reasons for discrepancy. Doctors' beliefs 
have been shown to have a significant effect on outcomes. Kinmonth, in a 
questionnaire study of 34 general practice trainers, found that they had a more 
pessimistic outlook on diabetes than that found in an earlier study of hospital 
doctors[119]. They perceived that the disease carried greater risks and were 
less confident that tight blood glucose control would reduce those risks. Doctors 
have also been shown to vary in their beliefs. Weinberger compared 12 
physicians who were 'more successful' with 12 physicians who were 'less 
successful' in achieving good glycaemic control in their diabetic patients[121]. 
Knowledge did not discriminate between the two groups but their beliefs about 
diabetes did. The successful group believed more strongly that strict blood 
glucose control would reduce the risks of complications. 
Significant discrepancies have also been shown between doctor and patient 
goals for treatment. D'Eramo-Melkus, surveying 54 patients and their 
physicians, found discrepancies of 54% in overall treatment goals with a 57% 
and 43% discrepancy in the specific goals of weight loss and blood glucose 
levels respectively[123]. In a study of 47 Type 2 diabetic patients, nurses' 
attempts to exert considerable control during consultations were shown to be 
counterproductive and contribute to poorer outcomes[127]. 
Current guidelines clearly state that when good glycaemic control is not 
achieved on maximal oral treatment then insulin should be considered [170]. 
However, in practice, patients are seen who have continued in very poor control 
for long periods of time. It often appears there is collusion between doctor and 
patient to avoid insulin therapy[144, 171]. What difficulties and uncertainties do 
doctors have in treating the failing Type 2 diabetic patient particularly regarding 
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insulin treatment? It is this dilemma that the present study seeks to address. 
Understanding the attitudes and beliefs of primary care clinicians involved in 
diabetes care is important if implementation of current guidelines is to be 
improved. 
5.2. Aims 
This study sets out to describe the beliefs and attitudes of primary care 
clinicians (general practitioners and practice nurses) towards the care of people 
with Type 2 diabetes in poor glycaemic control on maximal oral treatment. 
5.3. Method 
5.3.1. Setting 
The study was undertaken in North East England, an area with above average 
unemployment (6.7% v 3.9% for Great Britain). There were high rates of 
ischaemic heart disease and cancer, high levels of deprivation and higher than 
average general practice list sizes. The subjects were general practitioners and 
practice nurses working in primary care in Durham and Tees Health Authority 
areas. Durham has a population of 630,000 and Tees HA a population of 
555,835. GP provision is around 49 per 100,000 population for both areas, in 
the lowest tertile of the country (46 to 64 per 100,000 population)[172]. 
5.3.2. Subjects 
Ethical approval was obtained from the local research ethics committee. A list 
of general practices and general practitioners (GP) was obtained from the 
Health Authority, a list of GP trainers on the local Vocational Training Scheme 
and a list of Practice Nurses from a local Primary Care Group area. Practices 
were telephoned asking to speak to an available partner. The study was briefly 
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outlined and if that doctor could not participate they were asked to nominate 
one of their partners who was subsequently similarly contacted. No specific 
attempt was made to enrol doctors with a special interest in diabetes and only 
one doctor per practice was recruited as a purposive sample. Doctors agreeing 
to participate were then sent written information on the study. Similarly, GP 
trainers were contacted by telephone and invited to participate. Practice Nurses 
from all practices within the local PCG area and meeting regularly as part a 
Practice Nurse Support Group were invited, one from each general practice. 
5.3.3. Focus group interviews 
A qualitative explorative approach was felt to be most appropriate given the 
paucity of studies exploring primary care clinicians' views on diabetes care. 
Focus groups were used for their ability to allow participants to pursue their 
own concepts and priorities while allowing exploration of how points of view are 
constructed and expressed. They are particularly suited to the study of attitudes 
and experiences around specific topics[154]. The focus groups were held in an 
informal quiet meeting room with a relaxed atmosphere, in practice premises or 
in a university department. 
5.3.4. Group Process 
Refreshments were provided prior to the discussions. I introduced myself as a 
local GP conducting research into the management of Type 2 diabetes. 
However, I previously knew a number, but not all, of participants. The 
discussion was directed by a set of semi-structured open questions (appendix 
9). The definition of what constituted a failing diabetic patient was intentionally 
not specified at the outset so as to obtain participants' own definitions and 
interpretations. Initial questions were designed to put people at ease and 
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establish group cohesion. These were followed by general questions leading in 
to more specific issues. With consent the groups were recorded for later 
transcription. Confidentiality was stressed with no individual identifiable in the 
final report. 
5.3.5. Data analysis 
The process used was similar to that used in Chapter 4. Participants were 
encouraged to freely discuss their views and opinions on Type 2 diabetes 
within the broad areas covered. The audio recordings were transcribed in full 
and entered into the qualitative computer software programme QSR NUD.IST 
vivo for analysis. Each group was initially analysed independently and then 
comparisons made across groups. Analysis began after the first focus group 
was held to allow emergent themes and concepts to be incorporated and 
explored in subsequent focus groups. An iterative approach to coding following 
the 'editing organizing style' described by Miller and Crabtree[147] was used. 
Codes were developed directly from the text by identifying relevant categories 
and themes in an iterative process between the text and the organizing 
process, bearing many similarities to grounded theory[148]. The transcripts 
were coded independently by the researcher (DAJ) and an experienced primary 
care researcher (APSH). 
5.3.6. Validity and reliability 
The approach followed reflected that used in Chapter 4. Full transcripts of the 
focus groups were used for the analysis. The qualitative computer software 
programme QSR NUD.IST vivo was used to assist with consistency and 
reproducibility of coding and cross-referencing. Purposive sampling was used 
to maximize variation and ensure representative groups were studied. It was 
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felt on theoretical grounds that views might differ between general practitioners 
and practice nurses because of their different backgrounds. GP trainers might 
be expected to be more up-to-date with recent developments in diabetes being 
concerned with teaching chronic disease care including diabetes management 
to their trainees. Focus groups were therefore drawn from all three groups of 
clinicians. Two independent analyses were performed on the same data to 
improve reliability. Reliability was also assessed by comparing statements 
within and across groups[149]. 
Confirming and disconfirming views were sought (deviant case analysis)[148] 
where views contrary to the researchers' explanatory scheme are given fair 
account, examined and why they might vary was discussed[151]. Respondent 
validation was used to feed back the findings to participants to confirm that they 
represented a reasonable account of their experience[152]. 
5.4. Results 
Four focus groups were held involving 23 clinicians. Two focus groups with GP 
participants (groups 1 and 2) were held and separate focus groups held for 
practice nurses (group 3) and GP trainers (group 4). A total of fifteen general 
practitioners and eight practice nurses participated. There were between four 
and eight participants in each group. Original quotations were coded by type of 
clinician (D/N = doctor or nurse), gender (M/F), identification number, focus 
group number (e.g. FG3), and transcript paragraph number. 
Table 10 GP demographics 
Number Years MRCGP held Training GP Trainer 
(female) qualified Practice 
15 (4) 12-41yr 12 7 4 
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Table 11 PN demographics 
Number (male) Years Qualified Years in post as Diabetic 
PN qualification* 
8 (0) 6-28 2-14 7 




Table 12- Summary of Results (*W =weak, M =moderate, S =strong support) 
Opposed 
Theme Construct Collective views* 
support* 
Organization Place of Diabetic care should be delivered in s Nil 
of care diabetic care primary care. 
Changing roles Team approach, routine care s Nil 
devolved to nurses with a changing 
Resources GP role. 
Need for increased resources to 
deliver chan_g_es. 
Attitudes to Attitude to Enthusiasm for active management. s Nil 
care diabetes Uncertainty of definition. s Nil 
What is a A need to avoid apportioning blame. 
failing diabetic? Patients need to be empowered to M w 
Whose fault is take more control of their diabetes. s Nil 
it? A major life event could influence 
Empowerment diabetic control. M Nil 
Conversion 
experience 
Non- Clinician Difficulty judging compliance, with s w 
compliance attitude wide estimates of the scale of the 
problem. s Nil 
Patient attitude Misunderstanding, ignorance or 
intentional decision? 
Use of Benefit of Insulin viewed positively by s Nil 
insulin insulin therapy clinicians. 
Delay in s Nil 
instituting Patients seen as very reluctant to 
insulin convert to insulin. M w 
Doctors delay decision to start s Nil 
Initiating insulin insulin. 
A role for the DSN in primary care. 
Social Family Effect on diet M w 
factors Lay networks' sometimes spurious M w 
advice. 
Ethnic Cultural norms Difficulty understanding and dealing M Nil 
minority with cultural differences in lifestyle. 
groups Communication Language difficulties hamper M Nil 
effective communication 
Interpreters Use of family members as M Nil 
interpreters can introduce family 
tensions to the consultation. 
Doctor The above difficulties can lead to M Nil 
frustration significant doctor frustration to the 
detriment of patient care. 
Treatment Target setting Targets need to be achievable to act s Nil 
goals as an incentive. 
Polypharmacy The need for multiple drug therapy M w 
was seen as a major difficulty. 
The elderly How aggressive should care be. s Nil 
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5.4.1. Themes identified 
5.4.1.1. Organizational issues 
5.4.1.1.1. The place of care 
There was a strong feeling across the groups that Primary Care was the best 
place for routine diabetic care. It was seen as able to provide better care in 
regard to continuity, consistency, commitment and accessibility. Total care by 
the primary care team was seen as preferable for the majority of patients; with 
a minority requiring secondary care for more complex problems and very few 
requiring shared care. 
'I think that the general tenure of the articles one reads is that if 
primary care can do it well it is probably a lot better than the routine 
hospital clinics that I used to go to as a student and as a houseman 
where it was a bit of a chore. 'DM01/FG1163 
'I believe we do provide a better service than the hospital and the 
patients have told us so ... ' 'DM01/FG1163 
'We probably have fewer, now than ever, being referred to the 
hospital. I can probably count on one hand those patients who now 
have formal shared diabetic care with the hospital ... ' DM02/FG1/66 
'I think that care in general practice is probably much more 
consistent. In hospital outpatients we get the next SHO who does a 
six month job ... I don't think they are really particularly involved in 
what is going on, whereas in a General Practitioner setting I think 
you have more continuity of care with both practice nurses and 
doctors who are there usually for years and years. The set up is 
friendlier and more accessible to patients. 'DF03/FG1/69 
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'I think that in the absence of serious complications I see no reason 
why it (diabetes) shouldn't be dealt with almost entirely in general 
practice. 'DM07/FG2173 
5.4.1.1.2. Changing roles 
An issue arose as to who should be responsible for the delivery of diabetic care 
in the practice situation. Increasingly, General practitioners were devolving 
routine care to the Practice Nurses. 
'Our diabetes care is mainly given by one of our Practice Nurses and 
one of the other partners. We always do a joint clinic, although most 
of the care is done by the Practice Nurse. 'DF20/FG4/38 
'The care is largely devolved to the Practice Nurse. 'DM22/FG4154 
'In our practice, ... more and more routine monitoring is being done 
by the practice nurse'DM01/FG1/22 
With the practice nurse looking after routine care, some doctors saw their role 
changing to look after the more complex issues. The question of intermediate 
care was raised in relation to doctors with a particular interest in diabetes 
holding PCG wide specialist clinics to both improve quality of care in primary 
care and to allow secondary care to concentrate on patients with complex 
problems. 
'You've got to be an enthusiast ... the enthusiast probably gets 
superb results, you know, he's intensely interested. 'DM08/FG21263 
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'Things that I think we do now ... ought to be ... passed on to nurses 
so that the role of the General Practitioner, I believe, has to be 
changed. 'DM07/FG2173 
I think with primary care pilots, different ways of providing care, 
you may actually get a community diabetic clinic rather than a 
practice diabetic clinic. 'DMOBIFG2191 
5.4.1.1.3. Resources 
There was recognition that to actively manage Type 2 diabetes to current and 
future guidelines requires an increased input from all members of the diabetes 
team. The increasing numbers of patients diagnosed with diabetes was also 
seen as putting a strain on already stretched resources. It was felt that 
increased resources would be required in primary care to cope with this 
demand. This need was particularly highlighted in relation to the initiation of 
insulin therapy. 
'I don't think we have the resources to commence people on insulin. 
We don't have the free time' NF12/FG3/340 
:As we get more and more diabetics in our practice the nurse kind of 
groans every time you find another diabetic, they're just so busy at 
the moment, 'DF20/FG411 00 
'It's the time resource which is a problem, not necessarily the 
management of that individual's diabetes. 'DM22/FG41188 
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'I don't think we have enough specialist diabetic nurses. You get the 
impression that there's a feeling of helplessness 
almost. 'DM07/FG2/205 
Community resources for chiropody and dietetics were seen as inadequate with 
many participants' practices having insufficient support often with long waiting 
times for assessment. 
'I think our problem is the resources you get - not enough dieticians' 
DM23/FG4/1 005 
'You take months and months to try and persuade someone to 
actually become a little bit more active and introduce the idea of 
actually doing something like LEAP (exercise on prescription 
scheme), and they go down to the fitness centre and they've got 
weeks and weeks to wait.' NF13/FG3/821 
'We have audited it . . . there are not enough chiropody 
appointments'. NF12/FG3/136 
5.4.1.2. Attitudes to care 
5.4.1.2.1. Enthusiasm 
Doctors and nurses were enthusiastic about diabetes care, feeling they could 
deliver a first class service in primary care if adequately resourced. 
'I think we are pedalling pretty fast on this. We've got lots of 
encouragement from the hospital consultant and the diabetic liaison 
nurse and the PCT (Primary Care Trust) is also encouraging us. We 
are, I think most of us, we are in the health promotion bit for diabetes 
which is not a financial incentive. 'DM01/FG11357 
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'You've just got to keep on trying really haven't you, with the failing 
diabetic. 'DF03/FG 11590 
However, it was recognized that not all doctors subscribed to this view and that 
some may accept lower standards. 
'There, you know, are the partners who are quite happy at people 
running along with glycated haemoglobins of 9% or whatever and 
blood pressure of 170/95'DM23/FG41750 
Doctors saw nurses as enthusiastic and knowledgeable about diabetic 
management. 
'We are delegating a lot to the nurse, we've got a very enthusiastic 
nurse. 'DF04/FG1178 
'One of our Nurses has developed a really strong interest in diabetes 
and takes a great interest in it. 'DM23/FG4177 
5.4.1.3. Defining the failing diabetic 
There was some confusion as to what constituted a failing diabetic patient. 
Some saw it as a patient problem with issues around compliance and 
education. To others it was associated with disease progression out with the 
patients' control. 
'A failing diabetic is often just failing because they don't realise it's 
important to be looked after. 'DF06/FG2197 
'There is def,in~tely another failing type who jus( reckons that the task 
is insurmountable and doesn't bother to try, 'DM10/FG2199 
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Some gave a more formal, biochemical definition of failure. 
'Anything (HbA 1 c) between 7 and 8 is borderline and anything over 8 
being poor control ... 'DM10/FG2/105 
'If glycosylated haemoglobin is over 7 and they're on full dosage of 
sulphonylurea and metformin' DM23/FG4/256 
The ethical dilemma of the patient poorly controlled on oral treatment who, after 
full counselling, decides not to go onto insulin was raised. Is this a failing 
diabetic? 
'The fully counselled patient who doesn't want to go on insulin but 
has an unacceptable glycosylated haemoglobin, where do they fit 
into this, are they a failure?'DM21/FG4/263 
Other patients were seen as being overwhelmed by what was being required of 
them. 
'But they think, 'I can't do it at all, I'll just give in and not 
bother. 'DF/06/FG21101 
5.4.1.4. Blame 
Blame was mentioned in several contexts both in relation to the patient and the 
health care professionals. 
'You always blame compliance and other problems on the patient or 
put the blame on you (yourself for) not doing it properly. You never 
quite know how the land lies.' DM10/FG21237 
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5.4.1.5. Empowerment 
It was felt that patients needed to be empowered to take responsibility for their 
own diabetes and that compliance issues were to some extent negated by 
patients informed decisions not to comply. 
'The better motivated ones are really into it and they take great pride 
in showing you their book and their values and it reinforces, I think, 
they've got control. 'DM01/FG11346 
'I sometimes can see an improvement in compliance when they 
switch to insulin which underlines the fact that they contribute to the 
management of their illness. And they decide they've got to 
contribute a bit more to the management of their 
illness. 'DM05/FG21241 
'The patient's got to feel they are doing something, that they're 
managing it. 'DF06/FG21322 
'I think we've given a lot of diabetics control of their diabetes. In the 
past, it used to be the doctors and nurses that looked after 
them. 'NF15/FG31227 
'We're the gate keepers; we're giving them permission to take it 
on. 'NF12/FG3!656 
5.4.1.6. A conversion experience 
Some saw the need for a major event, such as a myocardial infarction or 
chronic leg ulcer, to effect good compliance: a conversion experience. Others 
thought shock-aversion therapy with explicit pictures of unpleasant 
complications was needed. 
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5.4.1. 7. Non-compliance 
5.4.1.7.1. Clinicians' attitudes 
Clinicians found it difficult to assess levels of compliance and understand the 
size of the problem. 
'It's difficult to know how much they are complying and whether their 
sugars are being controlled. 'DM10/FG21237 
'I think they comply reasonably well with tablets but I don't think they 
comply at all with diet. 'DM21/FG4/946 
Polypharmacy was recognized as having a significant adverse effect on 
compliance. 
We know compliance is worse the more things people have to take 
and the more complicated their regimes are. 'DF20/FG41400 
Views varied widely on the size of the problem. 
'Was there a figure ... just a few weeks ago ... was it that 213 of Type 
2 diabetics don't redeem their prescriptions?' DM19/FG4/380 
'I don't find compliance a great problem ... on the whole I would say 
compliance is pretty good in terms of medication .. 'NF15/FG3/577 
5.4.1.7.2. Patient attitudes 
Some difficulties in this area were felt to be related to a lack of basic education 
about diabetes and its treatment. 
'I don't think it's always deliberate, is it?'NF12/FG3/584 
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' ... People that possibly have come in with the idea that they've got 
diabetes and if they take this course of tablets they will get rid of it, 
and then they stop taking it purely because it hasn't been explained 
to them sufficiently in the first place, they haven't grasped the fact 
that that's it, they've got it for life.' NF15/FG31576 
'The ones that actually genuinely say, "oh, I stopped taking those 
blood pressure tablets because I thought it was all right now" They're 
the genuine - they're not the problem... you can educate them.' 
NF12/FG3/597 
Misunderstanding of provided information was also seen as influencing 
compliance. 
'Misunderstandings cause the problem. Polypharmacy with 
hypertension is causing us an awful lot of problems, because there 
isn't the time to explain properly to them, half the time they don't 
remember - they need it writing down . . . that they're having 
something added in and not changed ... so there's a lot to do with the 
education in the first place when it's been prescribed, and I think 
you've got to keep reiterating that because they just forget, don't 
they?'NF18/FG31579 
A group of patients were seen to be keen to comply with advice. However, the 
difficulty of maintaining this effort, even for this motivated group, in the long-
term was recognized. 
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'Some people are like that ... / mean, once you've told them 
something, that's it. They toe the line. Not like the rest of us that 
cheat. 'NF18/FG31320 
'Some people's compliance is to be very keen at first but when it 
becomes a chronic illness, they seem to lose interest'DM05/FG21253 
'Yes, there are no obvious consequences of not controlling it well to 
start with, are there? They don't realise. 'DF06/FG21251 
'I mean it's a complete pain to have diabetes. . .. you always have to 
be thinking about yourself, the way that other people don't. When are 
you going to eat? When are you going to have your 
injections?'DMOBIFG2/287 
Some patients were felt to be consciously disregarding advice, but their right to 
choose was recognised. 
'I think one of the real difficult things with medications is if you know 
from your computer screen that they haven't ordered a prescription 
for the past five months and their control is really, really poor, and 
you're asking them about what medication they are taking and they 
are hand on heart saying, yes, they're taking it and they're describing 
it to you. There's nothing you can do .. .'NF13/FG31609 
'You can always tell when you get a death and there's 3 carrier bags 
full of stuff comes back in... So, maybe our failing diabetics aren't 
(taking their medication). But that's their choice isn't it?' 
NF12/FG31598 
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'If you say, "it's a long time since you've had a prescription"- "oh, I 
had a backlog". And you think, where did you get the backlog from. 
It's very, very difficult, but, again, it's their choice. 'NF13/FG3161 0 
5.4.1.8. Insulin 
5.4.1.8.1. Insulin was viewed positively 
Insulin therapy was seen as beneficial for the Type 2 diabetic patient in poor 
glycaemic control. 
'I'm sure it's a good thing and I'm sure some of our people on oral 
hypoglycaemics that should be on it aren't on it ... it's a good thing to 
change them earlier rather than leave it ... having had another year 
or so with high blood sugar levels which really aren't doing them 
much good. 'DM01/FG11171 
'You can't beat insulin. It's the gold standard'DM02/FG11288 
5.4.1.8.2. Delay in initiating insulin 
There was reluctance to initiate insulin treatment. In the past this had been 
linked to a lack of belief in the efficacy of insulin in this context. Here it was 
more related to a lack of familiarity with the practicalities of initiating insulin 
treatment. 
'It's just that step in my own personal repertoire of things that I would 
rather put off. I think I subconsciously put it off more than I 
should. 'DM01/FG11171 
'I'm the same as you in stalling suggesting changes to insulin. I think 
because of the advice we used to get re insulin 
resistance. 'DM02/FG11180 
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'I wouldn't actually take this decision myself ... partly, because it's a 
long time since I have done it'DM08/FG21133 
Patients were seen as very reluctant to start insulin. Health care professionals 
perceived patients as highly resistant to starting insulin, seeing it as 
representing failure and associating it with complications. The concept of 
collusion between doctor and patient in avoiding insulin was also raised. 
'They've often been on oral hypoglycaemics for years and years and 
they nearly all know other diabetics who have been on insulin and 
have had major complications, and they see that as the beginning of 
a slippery slope. That's their resistance to insulin. They see that as 
being their point of failure almost. I think that some patients can be 
very persuasive to us to let you say you don't want me on insulin. 
The patients don't want to go on it. So there is a joint tendency that 
they don't go on it. 'DM02/FG11204 
'I think probably they think it's the end, that's it, there's nothing else 
they can have after that. 'NF12/FG31304 
5.4.1.8.3. Patients' fears 
Clinicians saw patients as having two major fears regarding insulin, namely, a 
fear of needles and injections and a fear of hypoglycaemia. 
' Surely, one of the biggest barriers is this fear of going onto needles 
for the rest of your life. 'DM23/FG4/431 
'It's a major step up in the perception of the patient. Now we've got 
to have injections'DM08/FG2/184 
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'I think the effect of getting older is that they hate the idea of 
hypoglycaemia as well. They get vel)l frightened of that. 'DF/041149 
'Fear of hypoglycaemia is another factor, we've got several patients I 
can think of who deliberately run their sugar high because they're 
terrified about having a hypo... it's just difficult to influence 
them. 'P05G4 
However, opposite views were expressed. 
' ... Patients find the idea of going on to insulin less problematic than 
they used to do. Whether that's because we prepare them... or 
whether there's more immediate information available ... but it 
doesn't seem to be too much of a problem. 'DM19/FG41532 
5.4.1.8.4. Support to initiate insulin 
There was a perceived need for more support to facilitate the introduction of 
insulin. The role of the Diabetic Specialist Nurse in this context was highlighted. 
'I certainly don't have the experience ... putting patients on insulin, 
what dose and when'DF04/FG11499 
'I think I need my hand held a little bit on that one. That's basically 
my attitude. 'DM01/FG1/177 
'It's (initiating insulin) where the diabetic liaison nurse is so 
invaluable. It make that step much easier to take. 'DM01/FG11171 
'It's the process of getting them onto the insulin . . . that's where we 
need the support ... I certainly don't have the experience as you 
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rightly said, putting patients on insulin, what dose and when, we 
need a diabetic liaison nurse and she is going to be 
swamped'DF04/FG 11499 
'If there is a problem with the diabetes we can usually sort it out 
between ourselves. That is, the General practitioners, the practice 
nurses and the diabetic liaison nurse. 'DM02/FG1/66 
'(Diabetic Liaison) Nurses are helpful . . . they have the confidence 
where I don't in starting insulin'DM06/FG21138 
'We find her (the Diabetic Liaison Nurse) far more useful than the 
medical team at the Hospital, 'DM23/FG4183 
5.4.1.9. Social influences 
Family and friends were felt to exert significant influence over diabetic patients 
behaviour. This was generally seen in a negative light, particularly towards 
eating habits . 
... The husband doesn't want to eat what she eats. So she has to 
cook different meals. DF03/FG11224 
'You know it's people who mean well say, "Go on have one, you 
know one doesn't matter". I'm sure that they are easily persuaded. I 
think it's a lot to do with people around you.' DM05/FG21122 
Oh, it's very relevant, especially if you are a man and don't do any of 
the cooking. You just get what the wife gives you. DF06/FG21311 
Yes, I think so. I mean, more adversely than good, I think, if quite 
often they will come back with a tale saying "oh, so and so told me I 
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shouldn't be having this" and they're actually sticking to a really good 
diet, but there's these myths that are still going about and they'll get 
the wrong information from family and friends. NF15/FG31450 
5.4.1.1 0. Ethnic minority groups 
Ethnic minority groups were perceived as presenting particular problems. 
Culture was seen a major influence with regard to body image and eating 
habits. The strong extended family exerted a particularly important influence. 
'I think there might be a cultural thing that some people in the Indian 
subcontinent who regard being thin as being poor and being well 
built and fat as like successful ... they seem to not worry about being 
overweight and this has terrible consequences for them. They don't 
like the idea of having to slim right down again to be 
fit. 'DM021FG11116 
'It's just a totally different ball game isn't it, you just don't know what 
their underlying cultural beliefs about - about insulin therapy or giving 
injections'DM23/FG4/927 
'I found race as well - a lot of the Indian people don't want to know 
about Insulin, they'll do absolutely anything rather than go on to 
insulin. It's supposed to be something to do with their culture isn't it, 
it's seen as a failure or something. 'NF13/FG3/462 
'We see patients twice a year and the family and friends are there all 
the time, you know, I mean, we are supposed to be more powerful 
figures, but I mean, it's quite difficult to overcome very different 
beliefs within the family. 'DF20/FG4/919 
101 
5.4.1.1 0.1. Communication 
Language difficulties were highlighted across the focus groups. Relationships 
with authoritarian figures, such as doctors, were felt to be more paternalistic 
and unquestioning than the more open, discursive relationship currently 
espoused in the UK. 
'I mean, but also the ethnic groups often have different ways of 
communicating with doctors and nurses, aren't they, because there's 
a much more traditional, you just tell people what to do, there's not 
so much a tradition of negotiation. 'DF20/FG41937 
'I suspect like Caucasians they choose what advice they take, and 
what not, and it all somehow gets mixed up in the interpretation of 
the translation ... 'DM22/FG41958 
5.4.1.1 0.2. Interpreters 
The older Asian patient often had a poor grasp of English requiring an 
interpreter in the consultation. It was common for a younger member of the 
family to accompany a parent or grandparent to act as an interpreter. This was 
seen as a potential cause of difficulty and misunderstanding between doctor 
and patient and as a potential source of friction within the family. 
'I find that the Asian groups, they're bringing an interpreter along ... 
usually a daughter or a son .. . I think there's a lot of aggravation 
within families. 'NF18/FG3/550 
'(The) other big problem group is the Asian community. Family and 
friends there are very big influences . . . it's always triangular 
consultations, it's a nightmare. 'DM21/FG41895 
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5.4.1.1 0.3. Frustration 
Clinicians felt their lack of insight into the cultural aspects of the lives of ethnic 
minority patients hampered their ability to deliver good diabetes care and 
caused a degree of professional frustration. Perceived cultural beliefs were felt 
to be contradictory to current medical practice particularly in regard to body 
image. 
'My other impression is that some of our foreign patients, Indians, 
Eastern Europeans, have an attitude problem. I'm sure it's not just 
communication because they can speak English, but they seem not 
to make an effort with diet, exercise and sticking to things. They 
seem to do badly as well. 'DM01/FG11104 
'But, I mean, communication, they don't even speak the language, 
you've got a hell of a problem before you start,'DM21/FG41896 
'The ones who are really difficult are the ... young 'Westemverts' 
who have all been brought up in this country with a local accent, 
they're just totally suspicious of doctors, you know, Caucasian, you 
find. 'DM23/FG41950 
5.4.1.11. Treatment 
5.4.1.11.1. Achievable goals 
The need to set achievable goals for treatment and the need for advice to be 
based on good evidence was emphasized, giving the example of the changing 
dietary advice over recent years. 
'If you are going to try to alter people's lifestyles ... there's got to be 
good evidence that it's justifiable. 'DMOBIFG21529 
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'Twenty or thirty years ago there was not a lot of evidence, but we 
put people on low carbohydrate and high fat diets, God! We probably 
did more harm than good!'DM08/FG21520 
5.4.1.11.2. Polypharmacy 
The need for tighter control of not only glycaemia but also blood pressure and 
lipids was recognized. However, the inevitable polypharmacy that this leads to 
was highlighted as a concern both to patients and to clinicians themselves. 
'Well, the frightening thing that's happened since the UKPDS is 
someone will come in to the clinic and the haemoglobin A 1 is 7. 8 
and their blood pressure is 1601100 and the cholesterol is 6. 2, and 
you think, well, how do I introduce the subject to 15 new 
tablets. 'DM17/FG41n54 
'I find (it) difficult telling people "You were okay but now I've got new 
guidelines and you need to have more medication.' DF03/FG1/431 
'Polypharmacy with hypertension is causing us an awful lot of 
problems, because there isn't the time to explain (it) properly to 
them'NF18/FG3/579 
There was recognition that this was not a universal view and that there were 
colleagues who might accept lower standards. 
'There's also the doctor equation, isn't there? ... all the partners who 
are quite happy with people's blood pressure of 170/95 - there's that 
in the equation as weii'DM23/FG41n50 
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5.4.1.11.3. Insulin and the elderly 
The question of insulin therapy for the elderly engendered a range of opinions. 
Some felt treatment should be fairly aggressive regardless of age. 
'There is no reason, age or not, why you should not be in better 
control. 'DMOB/FG21128 
' ... you're not going to want to think you've been written off because 
you're 70 are you?'NF18/FG3/328 
'I always say that as long as they are under eighty they are not old 
as far as I am concerned. 'DF03/FG1/163 
' ... the elderly ... They will often benefit from going on to Insulin. You 
might not actually improve their glycaemic control very much, but 
you will improve their symptoms, so it's worthwhile ... 'NF18/FG31425 
Others advised caution feeling that the elderly patient's ability to cope with 
more complicated regimes was often limited. There was concern over the 
higher risks of side effects and their potential for greater harm in the elderly. 
'There are certain exceptions but the vast amount of people who are 
elderly they're not going to manage this ... 'DF04/FG11265 
'Older people cope with change much less well ... can get much 
more confused ... you do get hypos and potential side effects which 
can be very worrying.. . it raises the whole temperature of the 
situation. I think that you've got to be very certain the person 
understands he's going to be able to cope with it emotionally and 
intellectually ... 'DMOBIFG 21199 
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A realistic estimation of the potential benefit to the elderly person of intensifying 
their treatment was felt to be necessary. Balanced against this was the need to 
assess the individual's capabilities, co-morbidities and social circumstances in 
drawing up a management plan. 
'You know the old lady ... her eyesight's very poor and she is dead 
set against insulin therapy. One wonders whether she will cope with 
injections ... 'DM07 IFG21124 
'I'm not going to hit an 80 year-old with complications (with 
insulin). 'NF12/FG3/300 
'I think it depends on the person and their ability to enjoy life ... 
You've got to be realistic, haven't you?'NF10/FG3/334 
I think you've got to look at the individual, and it's up to them, some 
people wouldn't want to go on the insulin, but it's a decision for the 
patient ... 'NF18/FG3/425 
5.4.2. Participant validation 
The full results and discussion sections of the study were posted to participants 
inviting their comments and their overall level of agreement on a five point 
Likert scale. A reminder letter was sent after two weeks. 21 of the 23 
participants replied, representing an 87% response rate. Two participants were 
not contactable having moved abroad. All 21 replies indicated agreement or 
strong agreement with the results. The mean Likert score was 4.24. Comments 
reinforced the strong support for prima_ry care diabetes management but with 
concerns about the resource issues and the need for a primary care role for the 
specialist diabetic nurse. The difficulties of managing diabetes in ethnic 
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minorities were emphasized regarding communication and culturally relevant 
dietary advice. 
5.5. Discussion 
5.5.1. Methodological issues 
There has been a relative paucity of information relating to clinicians' attitudes 
and beliefs in the area of Type 2 diabetes, particularly towards those patients 
who are in poor glycaemic control. Earlier questionnaire studies have looked at 
the beliefs of secondary care physicians about diabetes in general or Type 1 
diabetes in particular[120, 121]. Views of General Practitioner trainers have 
been retrospectively compared to those of hospital physicians in a further 
questionnaire study[119]. This study specifically sought the beliefs of primary 
care clinicians towards Type 2 diabetes. As this was an exploratory study with 
the aim of exposing the variety and diversity of clinicians' views a qualitative 
approach was felt to be appropriate. Focus groups have not been used 
specifically in this area but have several potential advantages. Clinicians, used 
to small group discussion in their service work, would be at ease in this 
situation. Focus groups with their interactive approach allow participants to 
develop and refine their opinions. The influence of the researcher as a GP was 
also minimized as discussed below. 
Given the methodological approach, no claim to generalisability was made in 
this study, but systematic methods of data collection and analysis were used to 
increase validity and reliability. 
The researcher, as a fellow GP known to a number of the participants, 
introduces a potential for bias. Chew-Graham and colleagues investigated this 
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in the context of semi-structured interviews with primary care physicians [155]. 
Where the interviewer was recognized as a clinician interviews were broader in 
scope, providing richer and more personal accounts. The general practitioner 
was at times identified as an 'expert' and as such a judge of clinical decision-
making. However, they were also seen by some to be judging the morality of 
decisions made by clinicians in their work. In the present study these potential 
biases were reduced by the choice of a focus group approach, which diluted 
the effect of the researcher's persona as participants tend to address each 
other during the discussions[154]. Moments were recognized within the groups 
when there were attempts to impose certain roles on the researcher, 
particularly that of the 'expert'. These were consciously resisted with questions 
being reflected back to the group. 
5.5.2. Main findings 
All groups felt general practice was the preferred place for care for the majority 
of people with Type 2 diabetes. They felt total care was practical for the 
uncomplicated patient with relatively few patients requiring shared care. This 
contrasts with many models of care suggested that have shared care between 
primary and secondary care as a major component. However, recent national 
policy with financial incentives to practices providing organized diabetes care 
has been influential[173]. Primary care was seen as offering several 
advantages. General practitioners and practice nurses were seen as 
enthusiastic and capable of providing high quality care and indeed this has 
been previously demonstrated[174]. The unique long-term relationships 
possible in general practice between patient, doctor and nurse were seen to be 
of particular value given the complexities of diabetes management. The need to 
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keep up to date with the rapid advances being made in diabetic care was seen 
as essential and there was a realization that not every general practitioner in a 
practice could be expected to be able to do this and there was a need for a 
degree of specialization. 
However, resources were flagged up as a major obstacle to care. Doctors 
found diabetes care to be time consuming with inadequate time available for 
the increasing number of patients being diagnosed. With increasingly organized 
care in general practice, the detection rate for diabetes has increased 
significantly[175]. The annual consultation rate for diabetic patients in general 
practice is around double that of the average patient[175]. Insulin therapy 
creates its own resource implications. Some participants experienced long 
waiting times to access secondary care for initiation of insulin therapy. 
Community resources for chiropody and dietetics were seen to be unable to 
provide an adequate service for all patients. Increasing input from diabetic 
specialist nurses (DSNs), nurses, doctors and dieticians was seen as 
inevitable. The knock on effect on district nursing time was highlighted with the 
need for education for the housebound and for once or twice daily visits to give 
insulin injections to a substantial number of infirmed patients living alone. 
Doctors were felt to be willing to devolve the majority of routine diabetic care to 
practice nurses who were seen as knowledgeable and enthusiastic. A 
developing role for the DSN as part of the primary care team was seen, 
contrasting with their more traditional hospital based secondary care role. Both 
doctors and nurses referred directly to the DSN where access was available. 
The DSN was seen as a valued resource, particularly at the time of initiating 
insulin therapy. With the widening role of the PN the general practitioner's role 
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was seen to be changing. The possibility of developing an intermediate role, 
with a small group of interested doctors running community specialist clinics 
was mooted. Indeed, this is now being seen in several other areas such as 
minor surgery and dermatology at the Primary Care Group level. 
Insulin was seen as an effective treatment, which contrasts with earlier studies 
[119]. The publication of the landmark UKPDS trial is likely to have influenced 
this [128]. There was, however, a perceived reluctance to initiate insulin. In the 
past this was associated with concerns over efficacy but in this study it was 
related more to a perceived skills deficit, with lack of experience and training in 
insulin initiation. The DSN was seen as a potential means of overcoming this 
hiatus. 
The suitability of insulin therapy for the elderly Type 2 diabetic patient 
generated a range of opinions. Many felt age, per se, should not be a barrier 
and that insulin offered advantages even in many over 80-year olds. This is in 
line with current evidence[176]. Others highlighted instances where insulin had 
been started inappropriately in frail patients with multiple pathology and a short 
life expectancy. All groups stressed the need to make a global assessment of 
the individual patient taking into account social circumstances, the patient's 
views and the potential benefits of treatment. 
The need for patients to 'own' and take responsibility for their diabetes was felt 
to be important. Empowering patients to feel in control of their condition was 
seen as an important task for health care professionals. Realistic and 
achievable targets were seen as important if patients are to feel in control of 
their diabetes. 
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Ideas on how to define the failing diabetic patient varied considerably. Some 
saw this in strict glycaemic terms based on glycosylated haemoglobin readings, 
while others equated failure with lack of compliance or lack of understanding. 
There has been a similar lack of clarity and variety of definition in the 
literature[28, 36, 177]. Caution in translating trial results to individual patients 
was mentioned. It was felt these were not always representative. 
Views varied regarding compliance with treatment. There was agreement that 
compliance was better for drug treatment than for diet or exercise. Some felt 
compliance with drug treatment was high, while others recalled studies 
suggesting up to two thirds of patients fail to take their medication regularly. 
Compliance was felt to be related to lack of information or education for some 
patients. Polypharmacy with multiple drugs for diabetes, hypertension and 
hyperlipidaemia was raised as a cause for concern, particularly regarding 
compliance issues. Compliance was a source of much frustration for doctors, 
difficult to assess, and a potential source of conflict with patients. 
Participants saw diabetes as an important and serious disease. However, 
patients were perceived as viewing diabetes as a mild disease and that 
education was failing. It was felt patients gave diabetes a low priority and that 
this affected compliance. This equates with the 'no symptoms, no problem' 
patients described by Murphy[113]. Participants saw patients as being very 
reluctant to start insulin, fearing needles and the risk of hypoglycaemic 
episodes. They felt some patients saw insulin as representing failure, 'the end 
of the road', associating it with the inevitability of complications. Earlier 
literature does suggests that clinicians tend to be more pessimistic than 
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patients and overestimate the barriers patients have in complying with 
treatment[119, 122]. 
It was felt patient education needed to be improved to recognise the 
seriousness and progressive nature of diabetes. Some saw this happening 
through direct education; others felt shock tactics were necessary presenting 
patients with the dire consequences of severe diabetic complications. The 
'conversion' experience of a major event such as a myocardial infarction or leg 
ulcer was seen as a boost to compliance, albeit late in the day. The need to be 
aware of the patient's own agenda was stressed. 
Ethnic minorities were seen as a high-risk group that posed unique problems. 
Communication was seen as a major frustration and the use of interpreters, 
usually younger family members, was seen as an added problem where family 
agendas might colour interpretation. Interestingly, ethnic minority patients 
themselves, appear to have similar frustrations with the use of family members 
as interpreters[157]. Culture was perceived as hindering good diabetic control. 
There was a feeling that Asian culture viewed obesity as equating to wealth and 
this acted against weight reduction and dietary control. Bangladeshi people with 
diabetes have been shown to equate large body size with 'more health' while 
recognizing that 'too much health' is undesirable[157]. There appeared to be a 
general lack of understanding of ethnic minorities across the groups. By 
displaying, what on the surface, appear to be understandable frustrations 
doctors seem to have closed their minds to active and effective intervention in 
one of the neediest group of diabetic patients. There is some evidence from the 
transcripts that general practitioners disengage themselves from the active 
management of ethnic minority patients. Patients of ethnic Asian origin are 
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seen as a 'closed group' with whom 'normal' dialogue and clinical intervention 
is problematical and barriers are difficult to overcome. Ethnic minority 
populations are small in the practice populations of the participants and this 
may help to explain some of the misconceptions. 
Differences might have been anticipated between the views of general 
practitioners without a particular interest in diabetic care and nurses specifically 
involved in diabetic clinics. General practitioner trainers might be more aware of 
issues surrounding diabetes care because of their teaching role. However, the 
themes discussed were expressed across the groups. 
5.6. Conclusions 
Overall, there appears to have been a change in how Type 2 diabetes is 
viewed in primary care. It was previously seen as a mild disease where tight 
glycaemic control was not necessary. Here, it is viewed as a serious disease in 
need of energetic treatment. Reluctance to initiate insulin is still apparent but 
the reasons have changed. In the past doubts existed about the efficacy of 
insulin for the Type 2 patient. Here insulin was seen as efficacious but there 
was resistance due to a skills deficit, a lack of confidence and experience in 
initiating insulin. There was evidence of Balint's concept of collusion between 
patient and doctor to avoid insulin which both regarded as problematic[178]. 
Compliance with the diabetes regime unearthed elements of uncertainty, guilt 
and blame. The size of the problem on the whole was underestimated and 
there was much discussion on whose problem it was and what should be done 
about it. Was it the doctor's or nurse's fault for not providing adequate 
education, or was the patient to blame for wilfully not following advice? Patient 
autonomy was highlighted and how this impinges on compliance discussed. Is 
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a patient who consciously makes an informed decision not to follow advice, 
non-compliant? The merits of a shorter happy life versus a longer but restricted 
life were discussed. 
5. 7. Implications for practice 
This study suggests general practitioners were very positive about primary care 
management of Type 2 diabetes. They felt that high quality care could be 
provided for the majority of patients within primary care. Practice nurses were 
seen to have the skills and enthusiasm to take on much of the routine care of 
diabetic patients. However, the increasing diabetes workload was recognized 
which, together with the current inadequate and patchy provision of support 
services as regards dietetic and chiropody input, gave concern for the future. A 
large increase in resources was felt to be necessary. This is reinforced by the 
recent publication of the requirements of the National Service Framework for 
diabetes, which supports the increasing role of primary care in providing a 
better diabetes service[179]. 
With more patients requiring insulin at an earlier stage, secondary care will be 
unable to cope with the major increase in workload generated. Primary care will 
need to take on much of this work. There appears to be a willingness and 
enthusiasm to embrace the challenge but we identified a skills deficit with 
general practitioners reluctant and somewhat fearful of initiating insulin 
treatment themselves. This has educational implications. The development of a 
community role for the DSN was seen as necessary as a direct support for 
primary care clinicians, possibly linked to a community diabetes clinic run by 
general practitioners with a special interest in diabetes. Indeed, the need for a 
degree of specialization in diabetes was seen as an increasingly necessary 
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measure in dealing with the complexities of modern diabetes care. Increasingly 
one or two doctors within a group practice are likely to take on this role. 
With the recognition that compliance with treatment is increasingly poor given 
the current complex treatment regimes and resultant polypharmacy, it was 
recognized that we needed to be adopting a more patient-orientated approach. 
Patients' perspectives and beliefs need to be identified, and used to empower 
them to take greater control of their own illness. The challenge is to translate 




6. The management of tlhe failing diabetic patient: 
can consensus be reached? 
6.1. Introduction 
A dilemma exists with regard to the management of people with Type 2 
diabetes who are poorly controlled on maximal oral drug treatment. The 
landmark United Kingdom Prospective Diabetes Study (UKPDS) has shown 
that tight blood glucose control can reduce microvascular diabetic 
complications by up to 25% but fell short of showing a statistical reduction in 
cardiovascular disease morbidity or mortality[128]. However, several studies 
have suggested a link between high blood glucose levels and increased 
mortality[141, 180, 181]. The benefits to the patient of switching to insulin 
injections have been debated[167, 182]. There is an acknowledged reticence 
on the part of both patient and clinician to take this step resulting in patients 
remaining in poor glycaemic control for prolonged periods[144]. Views of 
patients and clinicians have been explored earlier in this thesis but how do 
these perceptions translate into everyday diabetes management? This study 
examines how these decisions are made in general practice and hospital 
diabetic clinics. 
6.2. Aims 
To ascertain the views of general practitioners (GPs), practice nurses (PNs), 
diabetologists, and patients in a group setting and to explore if a cogent 
management plan for people with Type 2 diabetes in poor glycaemic control on 
maximal oral therapy could be achieved. 
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6.3. Method 
A meeting was arranged on the local university campus attended by patients, 
nurses and physicians and chaired by APSH. The structure was that of an 
informal round table discussion but the aim was to attempt to drive the 
participants towards a possible consensus plan. 
6.4. Process 
The results of the previous studies were presented, giving an outline of 
clinicians' and patients' beliefs. The discussion was then opened with clinical 
vignettes to stimulate debate. The meeting was audio recorded. A secretary 
was present to make notes to facilitate later transcription of the recording. The 
transcripts were analysed independently by both researchers. In addition, DAJ 
(the author) conducted one to one interviews with general practitioners and 
hospital consultants to widen the debate. The findings were fed back to 
participants and comments invited to provide participant validation. 
6.5. Results 
The consensus group was composed of three people with Type 2 diabetes, 
three general practitioners, two practice nurses, two diabetologists, a diabetic 
specialist nurse, and a public health physician. In addition, two general 
practitioners and two hospital physicians were interviewed separately. 
6.5.1. Common themes 
6.5.1.1. Lifestyle is difficult to influence 
All groups of clinicians recognized their impotence at changing patients' 
lifestyle. 
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"I feel that talking to people; you can only ask so much of them 
dietary wise, if you make the control so rigid they are just not going 
to adhere to it." N01-143 
"The simple things are to lose weight on a diet, which is not simple, 
stick to a diet, which is not simple, and to stop smoking, which is 
impossible! So a// the time as doctors, we're telling patients not to do 
this and that and to do something they don't really want to do." C02-
93 
6.5.1.2. Whose fault is it? 
Clinicians felt that patients could easily blame themselves for their 'failing' 
diabetes; that they were not trying hard enough with diet and exercise. It was 
also felt to be all too easy for clinicians to blame patients, that they were not 
complying with advice, and that this needed to be countered. 
"Many patients do feel they're to blame don't they." N03-55 
"I think you've got to be very careful that you don't start to blame the 
patient otherwise you are just going to alienate them. . .. I think it's 
making sure that the patient doesn't feel that they are letting you 
down. You have responsibilities to each other." N02-199 
"Diabetes is a progressive illness and a deterioration in your indices 
and your measurements doesn't mean you are less of a person or a 




Patients were not keen to switch over to insulin therapy but were accepting of 
this if their doctors advised it. They saw this very much as the doctor's decision 
by which they would abide. Patient participants' comments included: 
"I think in the last analysis, I think the doctor is the one who decides 
when the time is ready. I would go along with that but I say I 
wouldn't be too happy but I would go along with it.2 P01-367 
"Well he's always given me that decision; I've never ever questioned 
it." P03-212 
All groups of clinicians felt that some form of joint decision-making should take 
place. They felt they were responsible for providing and interpreting relevant 
information and empowering the patient to make a choice. 
"I think we should approach this as a partnership not as a sort of 
teacher/pupil relationship where the doctor says you've got to do 
this, but to empower the patient by explaining the nature of it ... It has 
to be a partnership where the patient, the person with diabetes 
should I say, understands as much about diabetes as they need to 
know, as they want to know and then the decision is theirs." C02-93 
Clinicians raised the issue of compliance with treatment. This was interpreted 
both as a patient fault and as part of the decision-making process with patients 
making the final decision. 
"That's the point we have missed, very strict compliance. . . She (the 
DSN) went to the person's house and kept on visiting and eventually 
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found out it was a compliance problem above anything else." GP01-
163 
"There's another aspect of compliance and that is the information we 
have about compliance of patients from a study in Tayside called the 
DARTS study ... only a proportion of the patients are actually taking 
home enough tablets to give themselves . . . what we are seeing are 
patients voting with their feet, to coin a phrase, or not voting with 
their feet, in not going to the pharmacy to collect the treatment. So 
they must feel well enough without it." C01-165, 173 
6.5.1.4. What is the value of insulin? 
Current evidence was felt to have perhaps overemphasized the value of insulin 
treatment for the patient. What were the real benefits and risks to the patient? 
"I have to tell you that I'm unimpressed by the evidence that very 
good control of Type 2 diabetes is necessarily what everyone would 
automatically choose for themselves." C01-1 05 
"But I ask myself what would I do? Would I personally feel that I 
would rush to go on insulin at the earliest opportunity and intensively 
treat myself and I say probably not." C01-109 
"Insulin is guaranteed to bring it down to normal if you take enough 
and if you take precautions not to have a hypo, but you are stuck 
with injections and you are probably stuck with weight gain and there 
isn't a quick fix on this. It's a very complex problem, which is why I 
like to share it with a patient." C02-115 
121 
"You've got to be convinced that you're actually going to make his 
life better by suggesting that he does tighten up on the control ... I 
think this is what we've got to go for, to try and give him some idea of 
what his options really are and what its going to mean for him and 
offer him the choice." C01-203 
6.5.1.5. Uncertainty on when to introduce insulin. 
General practitioners and patients both felt that they put off making the decision 
to start insulin. 
"I'd rather stop on tablets because I'm feeling alright but one day I 
might have to go on insulin." P02-58 
"As long as things stay as they are I'd like to stay off insulin as long 
as I can." P01-68 
"Very often we would agree that perhaps we would not make the 
referral yet, but we'll watch things over the next 4-6 months." GP02-
132 
However, general practitioners and nurses believed they were now referring 
patients for insulin earlier than they would have done previously. 
"I think consultant A will attest to the fact that he gets loads more 
referrals now than before. I think if months ago you'd asked me the 
question I'd have teased them along, whereas I don't now." GP02-
240 
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"I feel it (referrals) perhaps has gone up because the nurses' 
knowledge has increased and so you discuss it more with the 
doctor." N01-153 
Consultants also expressed uncertainty when considering starting insulin in the 
asymptomatic patient. 
"We all struggle though . . . its not just the nurses and primary care 
physicians that are struggling because that patient comes to hospital 
so I go through the same rigmarole." C01-157 
6.5.1.6. Motivation 
Patients' motivation was seen as paramount in relation to successfully 
switching to insulin treatment. It was recognized that many patients did not 
possess the will to change and uncertainty on how best to manage these 
patients was voiced. Consultants felt this area was best explored initially in 
primary care before referral. 
"Don't you think the whole thing boils down to motivation on behalf of 
the patient?" GP03-175 
"The crunch comes is if you've got a patient who is asymptomatic 
and not too concerned really. I think the motivation issue is the key 
issue. Unless you feel you are referring them to be motivated you 
see, which is a pretty dubious concept, when you come to a diabetes 
clinic ... You've then got to be convinced that the patient feels that 
there is an advantage for them and that decision has to be gone 
through to some extent with the patient in primary care because 
otherwise you simply have a cut off point, of HBA 1 C or blood sugar, 
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and lots of people get sent to the hospital clinic who really didn't 
want to go." C01-275,279 
6.5.1.7. Lack of resources 
Lack of adequate resources was seen as a barrier to good patient care in this 
area, both in the primary and secondary care arenas. 
"I can't initiate it (insulin therapy) in primary basically because of my 
own lack of skill and the lack of skill in my team I have around me." 
GP02-124 
"But there isn't time in the universe between now and the crack of 
doom to explain this in detail." C02-115 
6.6. Consensus management plan 
The group discussed the options available for treating poor glycaemic control in 
the Type 2 diabetic patient on maximal oral treatment. The potential barriers to 
effective treatment were explored. Initiating insulin treatment was seen to be 
useful but not necessarily in every instance. There was complete agreement on 
its use for the symptomatic patient and when very high levels of blood glucose 
were present. When patients were asymptomatic, with moderately elevated 
blood glucose levels, consensus was less clear. Here patient views and 
motivation were seen to play an important part. Several tentative options were 
explored and a final plan was agreed. 
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Figure 7 Consensus management plan 
Drawing on participants views, a flow-chart for the consensus management of 
the patient with poorly controlled Type 2 diabetes was arrived at: 
Yes 
I msuLm I ·~~~~--
Poorly controlled Type 2 
diabetic patient on 





Are blood sugars or 
HbA 1 c very high? 









Diabetic care may appear to be an exact science but this group showed it to be 
quite a difficult concept to engage with. 
6. 7 .1. Who does what and where? 
The management plan threw up as many questions as answers. Although there 
was agreement that the symptomatic patient would benefit from insulin, much 
confusion and uncertainty remained in relation to the management of the 
asymptomatic patient (the majority of patients). General practitioners had 
difficultly deciding when to refer, and surprisingly, given their authoritative role 
in diabetic management, hospital physicians equally had many reservations. 
Decisions could not be made solely on grounds of high blood glucose levels. 
Initiation of insulin treatment was seen as a secondary care activity. General 
practitioners did not feel they had the skills or resources to take on this work. 
However, hospital physicians felt the limited available resources were already 
stretched and they had difficulty in managing the current secondary care 
workload, particularly in regard to informing and involving the patient in the 
decision process. If earlier intervention is instituted, the number of patients 
referred to secondary care is likely to overwhelm available resources. 
A strong argument could be made for some form of intermediate care involving 
general practitioners with a special interest in diabetes to run community clinics 
together with diabetic specialist nurses. Whichever route is chosen resources 
would have to be made available to support the initiative. 
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6. 7 .2. Risk assessment 
An important question raised regarded the presentation of information on risk to 
the patient. This has ramifications across many other areas of medical practice 
where risks have to be quantified, expressed and evaluated. There appear to 
be discrepancies between patient and physician assessment of risk. Physicians 
have tended to overestimate the diabetic patient's reluctance to accept 
insulin[119, 122]. Devereaux et al found similar discrepancies when looking at 
the acceptability of antithrombotic therapy for stroke prevention in atrial 
fibrillation[183]. Patients were willing to accept a lower risk reduction than 
physicians, to accept treatment, and also to accept a higher risk of side effects 
from treatment. How do we convey the concept of risk to the patient? 
6. 7 .3. Shared decision-making 
How should decisions on medical management be made? The concept of a 
partnership between patient and doctor is widely accepted and indeed has 
been adopted as national policy[184]. The exact form of this partnership is 
debated. Byrne and Long found the traditional paternalistic model in which 'the 
doctor knows best' was most commonly used[185]. The opposite of this 
traditional model is the 'informed choice' model. Here, the patient is presented 
with the relevant information and the decision-making process is vested entirely 
with the patient. This may lead to marked patient anxiety or even feelings of 
abandonment[186]. A middle ground is represented by 'shared decision-
making' in which both parties actively participate in the decision-making 
process[187]. However, it is not a skill that is adequately taught in medical 
training. It requires the availability of reliable information and a readiness of 
patients to accept an active role in the process. Type 2 diabetes does have 
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many areas where this approach is applicable. However, the information needs 
to be made available and easily accessible particularly at the primary care 
level. 
Patients in this group deferred to medical advice. It could be argued that this 
was due to these patients adopting the accepted medical role in the presence 
of doctors. However, similar views were expressed in patient focus groups held 
earlier. Consultants were surprisingly liberal in their advice, not presenting the 
traditional, more didactic opinion. Not every patient is happy to take on this 
active participation in decision-making and patient wishes need to be assessed 
and respected at the outset, otherwise needless anxiety and anguish may be 
engendered. So, in practice how feasible is shared decision-making? Elwyn et 
al have enumerated the difficulties with this approach[188], most importantly 
the extra time required, the lack of easily available risk information, and the lack 
of the necessary doctor skills. They concluded that new ways of communicating 
risk and improved communication skills were needed. 
6.8. Conclusion 
The management of people with poorly controlled Type 2 diabetes who are on 
maximal oral treatment is not straightforward and some uncertainty is evident. 
Shared decision-making between patient and clinician was seen as desirable. 
However, empowering the patient to share decision-making required readily 
accessible, reliable information, a change in health care provider consulting 
behaviour and a significant increase in resources to accomplish. The roles of 
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community and secondary care need to be reassessed to make best use of 




7.1nsulin treatment for Type 2 diabetes: what is 
the impact on quaiDty of Ufe? 
7 .1. Introduction 
Type 2 diabetes is a progressive disease characterized by deterioration in 
glycaemic control over time for the majority of patients despite intensification of 
treatment[31]. The United Kingdom Prospective Diabetes Study demonstrated 
that tight blood glucose control in newly diagnosed Type 2 diabetes reduced 
microvascular complications by up to 25 percent although not statistically 
reducing cardiovascular morbidity or mortality[128]. However, a positive 
relationship between higher blood sugars and increased mortality has been 
demonstrated in several studies[181, 189]. Strict glucose control is therefore 
generally recommended[1 0]. However, interpretation biases have been 
highlighted suggesting an overoptimistic interpretation of the evidence[190]. 
When maximum oral treatment fails to control blood glucose, insulin by injection 
is usually necessary. 
Discrepancies have been demonstrated between patient and clinician views on 
the priorities of diabetes care[1 01, 122, 123, 191, 192]. Clinicians are often 
concerned more with blood glucose control and inducing patients to improve 
their self-care procedures (diet, exercise, and drug treatment) whereas patients 
are more concerned with how they feel and their ability to maintain a normal 
life[164]. These quality of life (Qol) issues are particularly relevant to the 
introduction of insulin treatment with the need for injections and stricter blood 
glucose self-monitoring. Several studies have looked at Qol with the 
introduction of insulin. Some have shown improved Qol with better glucose 
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control[193, 194] while others have not[195-197]. Most studies have used 
generic instruments such as SF-36[198] but it has been argued that whilst such 
instruments allow comparisons across diseases they may be less suitable for 
measurements within a disease type[199]. Validated disease-specific measures 
of Qol are now available for diabetes[200]. This study used the Audit of 
Diabetes Dependant Qol (ADDQoL - described below) where patients rate 
only personally applicable life domains, indicating importance and the impact of 
diabetes[199]. It is likely therefore to give a more accurate reflection of the 
impact of diabetes specifically[201]. The Diabetes Treatment Satisfaction 
questionnaire [202] (DTSQ - also described below) was used to assess patient 
satisfaction with treatment, before and after the introduction of insulin therapy. 
7.2. Aims 
To compare the quality of life and glycaemic control of Type 2 diabetic patients 
in poor glycaemic control on maximal oral therapy, who elect to start insulin 
treatment with those who decide to continue oral treatment. 
7 .3. Study design 
A prospective, parallel cohort study of people with Type 2 diabetes in poor 
glycaemic control referred for consideration of insulin treatment, comparing 
patients transferring to insulin with those who decide to continue on oral 
therapy. 
7.4. Method 
Ethical approval was obtained from the local medical ethics committee. 
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7.4.1. Subjects 
Type 2 diabetic patients with failure of oral hypoglycaemic treatment referred 
routinely by their general practitioners to the hospital diabetic service for 
consideration of insulin therapy. Failure was defined as a glycosylated 
haemoglobin (HbA 1 c) of >8% over a period of at least twelve months, despite 
maximal doses of a sulphonylurea and/or metformin. 
7.4.2. Setting 
Two district general hospitals in the North-East of England were chosen as not 
currently undertaking diabetes research that would compromise the proposed 
study and were accessible to the researcher: the Memorial Hospital Darlington, 
County Durham and Bishop Auckland Hospital, Bishop Auckland, County 
Durham. They serve a population of 99,900 and 87,400 from Darlington 
Primary Care Trust (PCT) and Durham Dales PCT respectively (2001 National 
census figures). The age distribution of the population is similar to the national 
average, 98% white ethnic origin, 48% male, and unemployment slightly higher 
than the national average at 4%. The prevalence of known diabetes is around 
3.2%, which again is close to the national average[3]. The diabetes service was 
provided at each site by an endocrinologist I general physician running 
outpatient clinics supported by two diabetes specialist nurses (DSN). 
7.4.3. Process 
Patients being considered for insulin therapy were referred directly to the 
diabetic clinic by their general practitioner and seen by the DSN. Initial 
consultations reviewed dietary advice, self care activities and oral treatment 
and these were maximized where possible. Insulin therapy was fully discussed 
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and a joint decision with the patient made as to whether or not to start insulin 
therapy, and which regime was used. The standard regime was to use a single 
daily injection of basal insulin analogue. A twice-daily injection of mixed insulin 
or, on occasions, a basal bolus regime was considered, depending on patient 
requirements and lifestyle. Insulin therapy was initiated and closely supervised 
by the DSN. She remained in touch with the patient until optimum control was 
achieved and then the patient was returned to the care of their general 
practitioner. 
At the initial consultation, the study was explained to the patient by the DSN 
and time was provided to answer any queries. This was backed up by a written 
study information leaflet (Appendix 12). Informed consent was obtained and 
routine baseline demographic, clinical and laboratory data collected (Appendix 
15). Patients were then asked to complete the study questionnaires. 
Patients changing to insulin usually maintained one or more of their oral drugs. 
Metformin was continued for its ability to minimize the dose of insulin required 
and limit weight gain normally associated with the introduction of insulin. 
Sulphonylureas were continued if the patient was intolerant of metformin to 
again limit the insulin dose required. Continuing oral drugs facilitated the use of 
a simple basal insulin regime where this was felt appropriate. Patients deciding 
not to start insulin continued on maximal oral treatment. 
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Table 13 Study baseline data recorded for each participant 
Demographic data 
Study ID number 
Surname 
First name 
















Systolic blood pressure 








Peripheral Vascular Disease 





Fasting plasma glucose 






All patients, regardless of treatment option, were followed up after three and six 
months. Questionnaires, clinical and laboratory data were repeated at each 
visit. 
Figure 8 Study process flow-chart 




Lifestyle and treatment advice 
I 
Treatment decision 
(oral or insulin therapy) 
Oral Insulin 
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3m assessment 3m assessment 
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7 .4.4. Instruments 
The importance of distinguishing between health status and quality of life is 
important when looking at a disease specific intervention such as change in 
type of treatment, particularly change from oral drugs to insulin therapy, with 
the need for frequent blood glucose monitoring and daily injections. Generic 
measures, though shown to be valid and reliable are influenced by significant 
morbidity, whether related to diabetes or not[201], and are less sensitive to 
smaller changes in relation to disease specific change[203]. Therefore they 
may miss important Qol changes when assessing the effect of change of 
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treatment. A patient may make sweeping lifestyle changes that they feel will 
improve their health, yet may impose restrictions on, for instance, their social 
life that may significantly reduce their overall quality of life. 
Health status questionnaires measure how patients feel about their physical 
and mental health. People who feel their health is poor may also feel that their 
quality of life is also poor, but not necessarily so. It is possible that good health 
is maintained at the expense of Qol, with increased limitations particularly 
socially, and with increased anxiety about their health. Equally, patients may 
recognize their poor health yet still achieve a good Qol. The need for a specific 
measure of Qol is evident. One that is disease specific, by filtering out 
variables such as other co-morbidity, gives a more sensitive instrument to 
detect effects such as treatment change on Qol in chronic diseases such as 
diabetes. Change in Qol is important to detect, particularly if negative, and may 
affect areas such as compliance. 
7 .4.5. The Audit of Diabetes- Dependant Quality of Life 
(ADDQol) 
The ADDQoL questionnaire[199] was chosen as being a diabetes specific 
instrument with the novel facility to take in to account the importance of the 
various domains to the individual patient (including the ability to exclude areas 
not relevant to that individual). It measures general quality of life, the overall 
impact of diabetes on quality of life, and quality of life across 18 specific 
domains. Each domain is scored on a seven-point scale from -3 to +3. The 
domain is then rated for importance to the individual patient, from very 
important (3) to not at all important (0). Weighted scores are then calculated by 
multiplying the domain score by the importance score. The overall ADDQoL 
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score is calculated as the sum of the weighted ratings of applicable domains 
divided by the number of applicable domains. Scores may therefore range from 
-9 (maximum negative impact of diabetes) to +9 (maximum positive impact of 
diabetes). 
Table 14 Summary of the 18 domain specific ADDQol items and response options. 
"If I did not have diabetes ................... ..would (be) ..... 
. . . my working life and work-related very much better - very much worse 
opportunities* 
... family life* very much better- very much worse 
... my friendships and social life very much better- very much worse 
... my sex life* very much better - very much worse 
... my physical appearance very much better - very much worse 
... the things that I can do physically very much increased - very much 
decreased 
... my holidays or leisure activities very much better- very much worse 
... ease of travelling (local or long very much better - very much worse 
distance) 
... my confidence in my ability to do very much increased - very much 
things decreased 
... my motivation to achieve things very much increased - very much 
decreased 
... the way society at large reacts to me very much better- very much worse 
... my worries about the future very much decreased - very much 
increased 
... my finances very much better - very much worse 
... my need to depend on others for things very much decreased - very much 
I would like to do for myself increased 
... my living conditions very much better - very much worse 
... my freedom to eat as I wish very much increased - very much 
decreased 
... my enjoyment of food very much increased - very much 
decreased 
... my freedom to drink as I wish (e.g. very much increased- very much 
sweetened hot or cold drinks, fruit juice, decreased 
alcohol) 
*these items include a 'non-applicable' 
response option 
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7.4.6. The Diabetes Treatment Satisfaction Questionnaire 
(DTSQ) 
Initial treatment satisfaction was measured using the DTSQ (status) 
questionnaire. Treatment satisfaction scores tend to be high generally and 
there was concern that a 'ceiling effect' may occur, confounding response to 
treatment change. The DTSQ (change) version was developed to prevent this. 
The DTSQ consists of six questions covering satisfaction with current 
treatment, treatment convenience, treatment flexibility, understanding of 
diabetes, recommending treatment to other diabetic patients, and satisfaction to 
continue present treatment. Each question is scored on a seven-point scale 
from 0-6 for the DTSQ status instrument, and from -3 to +3 for the DTSQ 
change instrument. Total score for each instrument is the sum of the individual 
scores (range 0-36 and -18 to +18 respectively). Two separate questions 
address perceived hyperglycaemia and perceived hypoglycaemia. 
The DSN recorded the baseline data on to a proforma by hand. The proforma 
and questionnaires were then passed to the researcher (DAJ) and the data 
entered onto an SPSS spreadsheet for analysis. 
7 .5. Study Outcomes 
A change to diabetes treatment involving daily injections and more frequent 
self-blood sampling is seen by many patients as a major hurdle to overcome. 
Variable results from previous work purporting to measure quality of life have 
given variable results. Many, in fact, were measuring health status as 
mentioned earlier. The study outcomes were based on changes in measures of 
quality of life and satisfaction with treatment. It was felt that a sensitive disease 
specific measure was required to investigate the effect that changing to insulin 
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therapy had on patients. The ADDQoL questionnaire was chosen to fulfil that 
role. How happy patients were with their treatment was also felt to have 
implications for longer-term compliance with treatment. The DTSQ was chosen 
as a well-validated instrument to measure this. Overall glycaemic control was 
measured to judge the effectiveness of the treatment change. Previous work 
suggests that this is not directly related to Qol. 
7.5.1. Summary of study outcome measures. 
a) The change in quality of life scores, as measured by the ADDQoL 
diabetes specific questionnaire. 
b) The change in the DTSQ scores. 
c) The change in glycated haemoglobin (HbA 1 c). 
7.6. Sample size 
The study was designed to detect a one percent change in HbA 1 c with 90% 
power at the 5 percent significance level. This required a study population of 60 
patients, 30 in each group. We envisaged a recruitment of 3-4 patients per 
month from each site to achieve the desired study population over a period of 
up to 1 0 months. 
7 .6.1. Analysis 
Data were entered into the SPSS 11 statistical software programme using a 
double entry technique. Data before and at the end of the study were compared 




The sample was calculated to need a recruitment period of ten months. 
However, it became clear that this would not be achieved andr the study period 
was initially extended by a further three months. Recruitment remained low and 
the period was again extended by three months. At the end of this period (15 
months from the start) a decision was made to close recruitment. The analysis 
is based on the numbers achieved at this stage. Reasons for recruitment 
difficulties are discussed below. 
Choice of participant sites for the study was initially limited by involvement of 
several local hospital diabetic units in an ongoing research trial that would have 
compromised this study. Initially two recruitment sites were used but 
recruitment from one site (BAGH) was very poor despite regular 
encouragement. Only two patients were recruited from this site. This may have 
been related to a number of local practices beginning to initiate insulin 
themselves and the DSN adopting more of an outreach approach to support 
them in the community. A decision was made to continue with recruitment from 
a single site (DMH) and extend the recruitment period. However, recruitment 
remained slow with a significant drop out rate despite reminders being sent. 
46 patients were enrolled into the study instead of the anticipated 60 patients, 
but only 20 patients completed the three-month assessment and 23 patients 
completed the six-month assessment. Only 14 patients completed both 
assessments. Of those patients completing assessments, 34 commenced 
insulin therapy and 12 remained on oral therapy alone. Because of these 
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limited numbers the study does not achieve the 90% power expected. The 
results obtained for the insulin group are, however, presented as a pilot study to 
inform future work. 
The demographics and co-morbidity shown in tables 15 and 16 approximate to 
those found in the general Type 2 diabetic population who are in poor 
glycaemic control as illustrated by the North Tees figures discussed earlier in 
Chapter 3. 
Just over half the patients were male, the majority living with their spouse, with 
only a small minority of smokers. 
Table 15 Demographic details of insulin treated patients 
Number Percent 
Female 15 44% 
Married 27 82% 
Living alone 3 9% 
Current smoker 2 6% 
The high incidence of hypertension and ischaemic heart disease found mirrors 
that of the general diabetic population. The low study incidence of 
microvascular complications, particularly retinopathy suggests under-reporting. 
There was also a low reported incidence of other morbidity unrelated to 
diabetes. 
142 
Table 16 Co-morbidity of insulin treated patients 
N Percent 
Hypertension 25 74% 
Myocardial infarction 4 12% 
Angina 10 29% 
Heart failure 7 21% 
Peripheral vascular disease 3 9% 
Stroke 1 3% 
Locomotor problems 1 3% 
Pulmonary pathology 1 3% 
Psychosocial problems 3 9% 
Retinopathy 4 12% 
Nephropathy 1 3% 
Neuropathy 4 12% 
Medication at entry to the study again followed standard practice with three 
quarters of patients taking metformin or sulphonylureas, in combination if 
tolerated (Table 17). 
Table 17. Medication at entry to study 
Number Percent 
Metformin 24 71% 
Sulphonylurea 25 78% 
Glitazone 13 41% 
Acarbose 1 3% 
The study population was aged around 60yrs, having had their diabetes for 
almost 9yrs, and in poor glycaemic control with an HbA 1 c of over 9%. They 
were not overweight (BMI =24), differing from the average Type 2 diabetic 
population. Full baseline data are shown in Table 18. Blood pressure and lipids 
were well controlled. 
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Table 18 Baseline data at entry to study 
N Mean Std Deviation 
Age (yrs) 34 60.6 12.47 
Duration diabetes (yrs) 34 8.8 6.48 
BMI 34 24.7 5.06 
Systolic BP (mmHg) 34 138.9 19.07 
Diastolic BP (mmHg) 34 79.8 8.09 
HbA1c (%) 34 10.0 1.40 
Total cholesterol 
34 4.7 0.83 
(mmol/1) 
Hdl cholesterol (mmol/1) 31 1.3 0.39 
Ldl cholesterol (mmol/1) 30 2.4 0.75 
Trigycerides (mmol/1) 34 2.5 1.18 
7.7.2. Main outcome measures 
Glycaemic control (HbA 1 c) improved significantly at three months by just over 
one percent and this was maintained at six months (Table 19). However, 
weight, increased by a mean 1 kg and 5.6kg at three months and six months 
respectively (not statistically significant). 
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Table 19 Outcome scores for questionnaires, glycaemic control and weight for insulin 
patients 
n Initial score Final score t df Sig 
QA(sd)0-3m 20 0.25(0.967) 0.30(1.380) -.170 19 0.867 
QA(sd)0-6m 24 0.71 (1.160) 0.88(1.296) -.811 23 0.426 
QB(sd)0-3m 20 -1.60(1.046) -1.65( 1.046) 0.203 19 0.841 
QB(sd)0-6m 24 -1.67(0. 917) -1.33(1.01) -1.282 23 0.213 
ADDQOL(sd) 0-3m 20 -2.12(1.578) -2.76(2.097) 1.675 19 0.110 
ADDQOL(sd) 0-6m 23 -2.00(1. 721) -2.54(2.269) 1.511 22 0.145 
DTSQstatus( sd) 32 27.1(7.08) 
DTSQchange(sd) 3m 21 10.3(7.40) 6.395 20 0.000 
DTSQchange(sd) 6m 25 11.5(6.00) 9.599 24 0.000 
HbAlc%(sd) 0-3m 20 9.9(1.27) 8.9(0.84) 4.014 19 0.001 
HbAlc%(sd) 0-6m 24 9.9(1.46) 8.6(1.60) 3.201 23 0.004 
Weight kg(sd) 0-3m 18 83.3(16.49) 84.3( 18.01) -.823 17 0.422 
Weight kg(sd) 0-6m 25 80.5(14.15) 86.9(22.54) -1.394 24 0.176 
There were two single item Qol questions. Present Qol on entry to the study 
(QA) was assessed as slightly better than the mid line ('neither good nor bad') 
and did not change significantly during the study. Qol if the person had not had 
diabetes (QB) was assessed as -1.6, being between 'a little better' and 'much 
better', again showing no significant change over the study period. 
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The initial ADDQoL scores showed a positively skewed distribution towards a 
small negative effect of diabetes on Qol. No participants scored a positive 
score. 
-7.00 -6.00 -5.00 -4.00 -3.00 -2.00 -1 .00 0.00 
-6.50 -5.50 -4.50 -3.50 -2.50 -1.50 -.50 
ADDQOL 
Std. Dev = 1.69 
rvlean = -2 .12 
N = 32.00 
Figure 9 ADDQol scores at Om, with normal distribution curve 
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At 3 months the ADDQoL scores remained positively skewed, but less so than 







-9.0 -8.0 -7.0 -6.0 -5.0 -4.0 -3.0 -2.0 -1.0 0.0 
ADDQOL3M 
Std. D:lv = 2.05 
IVIean = -2 .7 
N = 21 .00 
Figure 10 ADDQol scores at 3m, with normal distribution curve 
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The 6-month ADDQoL scores remained very similar to those obtained at 3 
months. 
-9.0 -8.0 -7.0 -6.0 -5.0 -4.0 -3.0 -2.0 -1 .0 0.0 
ADDQOL6M 
Std. Dev = 2.20 
1\Aean = -2.5 
N = 25.00 
Figure 11 ADDQoL scores at 6m, with normal distribution curve 
The main ADDQoL and DTSQ scores were positively skewed from the 
expected normal distribution. Therefore data were transformed using reflection 
and square root to produce a more normal distribution prior to use of the t-test 
for analysis. 
The ADDQoL quality of life measure is scored on a scale of -9 (maximum 
negative impact of diabetes) to +9 (maximum positive impact of diabetes). 
Initial scores showed a very small negative impact that increased slightly but 
not significantly during the study. 
Treatment satisfaction measured by the DTSQs (status) is scored from 0-36. 
Satisfaction with treatment scores at enrolment was high at a mean (sd) of 
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27.1 (7.08). The DTDQc (change) was used to assess change in satisfaction at 
3 and 6 months. This showed a 10 and 12 point change respectively, both 
figures being significant at the p>O.OOO level, indicating an increase in 
satisfaction with treatment after starting insulin therapy. 
Perceived frequency of hyperglycaemia and hypoglycaemia are measured 
separately in the DTSQ. Initial perception of frequency of hyperglycaemia was 
high at over 5 (maximum of 6), while the perceived frequency of hypoglycaemia 
was very low at 0.57 (maximum of 6). The values changed insignificantly over 
the study period. 
7 .8. Discussion 
The poor recruitment and high drop out rate limit the conclusions from the 
study. The study was 'blighted' by fast moving changes to the management of 
diabetes within the primary car environment after the study was launched. 
7.8.1. Problems with recruitment centres 
The study period was a time of change in the NHS and with hindsight an over-
optimistic expectation of the hospital staff was made. The implementation of the 
Diabetes National Service Framework (NSF)[22] highlighted the need for 
improved glycaemic control and the introduction of the new General Medical 
Services contract[204] for general practice had the effect of concentrating a 
greater proportion of diabetes care in the community. Relying on only two sites 
for recruitment (with only one site effective) was a mistake, but the obvious 
option at the start of the study. The very poor recruitment from one of the sites 
is likely to have been influenced by an increasing trend to insulin initiation within 
general practice noted in that area; cognizance of this may have altered the 
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choice of recruitment sites. Unfortunately, these factors were beyond our 
control once the study commenced. 
7 .8.2. Recruitment 
Recruitment from the main site (DMH) averaged three patients per month. This 
was at the lower estimate for recruitment allowed for in the study plan. However 
this was only half that needed and the study had to be closed for practical 
reasons before the estimated 20 months that would have been needed to enrol 
the desired 60 patients. Stretching the fieldwork to 20 months would have 
meant doubling the study duration from the originally planned ten months; in 
the end we were able to continue recruitment for 15 months. These problems 
were also symptomatic of dropping levels of patient participation in research 
studies. Questionnaire returns have dropped from the 70% level previously 
expected, often to levels as low as 30% in some studies. 
7 .8.3. Drop-out rate 
The drop out rate was higher than expected and would have required a 
significant increase in patients recruited to obtain the required number of 
participants to fulfil the power requirement of the study. The return rate of 
questionnaires was poor. Initially it was proposed that participants would 
complete questionnaires in the waiting room prior to their appointment with the 
DSN. However, clinic time was an issue and participants were given the 
questionnaires to complete at home. Subsequently many were forgotten when 
patients returned for their next appointment or, the appointment was missed 
altogether. Reminders were posted to those who did not return the 
questionnaires and where possible, telephone contact was made to encourage 
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return of all questionnaires. 53% failed to complete the three-month 
questionnaire and 33% the six-month questionnaire. The picture was further 
complicated by the fact that only 31% completed both questionnaires, thereby 
preventing comparison of results at three and six months. With hindsight it may 
have been better to have simplified the study design and to have made only 
one post-treatment assessment at 6 months. 
Few of our patients opted to stay on oral therapy. This probably reflected 
selection at the primary care level by general practitioners and practice nurses 
prior to referral: essentially these were patients being channelled for conversion 
to insulin. 
The improvement in glycated haemoglobin of 1% concurs with earlier work[31], 
as does the associated weight gain of up to 5.6kg (although not statistically 
significant in this study). 
Quality of life was perceived as slightly negative at the initial stage, with a small 
non-significant deterioration over the study period. Earlier work has given 
conflicting results but often did not use disease specific instruments[193, 194, 
196, 197, 199]. Satisfaction with treatment was generally high on oral treatment 
yet improved significantly on insulin therapy. 
A direct association between glycaemic control (HbA 1 c) and Qol has not been 
confirmed[195, 197]. However, the presence of symptoms of hyperglycaemia 
can predict the strength of association between glycaemic control and 
Qol[197]. It would possibly have been useful to have used a diabetes symptom 
checklist in our study to assess this potential influence. The perceived level of 
hyperglycaemia as measured in the DTSQ was high but did not change during 
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the treatment period. The modest fall in HbA1c of 1% in our study would go 
some way to explain the low level of perceived hypoglycaemia reported. 
Patients changing to insulin therapy tend to be in poorer glycaemic control and 
have a lower BMI than patients continuing on oral therapy[197]. Our study 
population supported this regarding BMI, and similarly showed a significant 
reduction in HbA1c on insulin, at the expense of weight gain. 
It is increasingly realized that diabetic complications are related to total 
glycaemic exposure rather than current glycaemic levels[205]. Even small 
improvements in glycaemic control can bring significant benefits in health and 
health costs. Health status may improve but concern remains about the effect 
of more intensive treatment on the effects on patients' Qol. Research into 
tighter targets for glycaemic control needs to assess diabetes specific Qol to 
fully assess the impact of such treatment. 
7.9. Conclusion 
The study was limited by low recruitment. This was a significant learning point. 
It was largely out of our control as these changes occurred after the study was 
launched. Nonetheless, with hindsight, it may have been better to have 
conducted the study within the primary care setting directly. In the current 
climate the trend in diabetes care has shifted significantly towards primary care 
including the initiation of insulin. 
Within the constraints of the reduced subject numbers the following points were 
ascertained: 
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a. In routine hospital care, the initiation of insulin resulted in a small 
but significant improvement in glycaemic control of one 
percentage point in glycosylated haemoglobin but at the expense 
of weight gain. 
b. The introduction of insulin treatment was not associated with a 
change in perceived quality of life after three or six months of 
treatment. 
c. Patient satisfaction with treatment was high on oral treatment 
despite poor glycaemic control but improved significantly after the 





This research was conducted to gain a better understanding of the plight 
of the diabetic patient in poor glycaemic control despite maximal 
tolerated oral therapy. The aim was to ascertain the size of the problem, 
to understand both patient and health carers' views about diabetes and 
in particular their views around the thorny issue of starting insulin 
treatment, to look for a consensus on management, and to address 
issues of the effect on quality of life when patients are changing to 
insulin therapy. 
The overwhelming evidence from the literature stresses that lifestyle 
advice and treatment advances alone cannot achieve the best outcomes 
for patients. An understanding of patient and health care professionals' 
beliefs and motivations is required if we are to achieve our aim of helping 
the person with diabetes to live a long and healthy life free of diabetic 
complications. The particular situation of the Type 2 diabetic patient in 
poor glycaemic control on maximal oral therapy has been little explored 
in the primary care setting. This research aimed to obtain further 
information about this group of patients, exploring their beliefs and those 
of their carers and to examine specific quality of life issues around 
insulin initiation. 
This thesis follows a sequence: an evaluation of the extent of diabetes 
and the failing diabetic problem in the locality, followed by qualitative 
work to gain the views and perspectives of people with diabetes and 
their clinicians. This was followed by the creation of a consensus-based 
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management plan with both patients and clinicians consulted. A 
pragmatic clinical study on the quality of life issues for diabetic patients 
who were in poor glycaemic control and might need conversion to insulin 
was then conducted. 
8.1. Data 
The analysis of the existing North Tees database indicated that almost 
60% of people with Type 2 diabetes were in poor glycaemic control and 
that 60% of these were not on insulin therapy. It suggested a lack of 
maximisation of treatment. Of those poorly controlled patients on oral 
treatment 46% were on only one drug, rather than a full range of two or 
three drugs. The majority of patients in this category were still cared for 
by their general practitioners (84%). However, more of those with poorer 
control had secondary care input compared with those in good control 
(35% v 15%). It highlighted the need for more intensive treatment with 
probable greater use of insulin. This would be associated with major 
workload and resource implications. 
The research based on the North Tees register can be criticised for 
having been based on a retrospective database, with information only 
available a year after recording. However, this is the inherent nature of 
any disease database. An independent worker trained in data extraction 
collected the data directly from primary care records, and this greatly 
increased the quality and reliability of the data. The coverage was 
extensive and the findings were representative of the diabetic population 
as a whole. The database was created prior to the NICE guidelines[204] 
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having been released and before the publication of the National Service 
Framework for diabetes[22]. The duration of the research in this thesis 
necessarily draws upon data from that period, and perhaps usefully, 
paints a picture of the diabetic population before the interventions in the 
various general practice contracts and their requirements. As the thesis 
progressed many of the arguments and problems over poor diabetic 
control have altered or even evaporated - the current mode of data 
collection, audit and reimbursement based on clinical outcomes has cut 
through the paradigms which otherwise came in the way of ensuring 
good control. Nonetheless, the basic issue about decision making in 
poorly controlled diabetic patients is a salient one. 
Chapter 4 was a qualitative study of patients' attitudes and beliefs. The 
main finding was that diabetes was essentially regarded as a mild illness 
and the most important outcomes for patients were to be symptom free, 
and to feel and to be treated as normal individuals. 
This may appear obvious on first reading. However, not many clinicians 
and carers were aware of patients' own priorities. In a field where 
biochemical and clinical outcomes are regarded as paramount it is 
obvious to see how there would be a conflict, or at the very least, a 
cross-purpose between the wishes of the patient and those of their 
doctors. 'Well-being' as an outcome is more familiar to patients than to 
doctors: a genuine partnership needs to be based on a mutual 
understanding and appreciation of goals. There are indications now that 
diabetes management programmes are more aggressive and bear 
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heavily upon the patient to conform to clinicians' views and regimens. 
Paradoxically, the role of the patient and patients' wishes may be more 
marginalized than before in light of the new general practice contract 
with payments for achieving quality targets. Again, these developments 
superseded many of the basic premises of this thesis. However, such 
premises are worthy of revisiting lest we forget what our patients really 
want. 
With hindsight, from the methodological viewpoint, it might have been 
more productive to have used in-depth interviews rather than focus 
groups, or a combination of the two for this study. This may have 
provided additional information with improved triangulation. However, the 
focus groups, done with due rigour, did allow the essential constructs to 
emerge. Again, although more research has been published since our 
study was performed, ours was one of the first to explore patients' views 
in this way in primary care. 
Chapter 5, in contrast with chapter 4, considered the care providers' 
viewpoint. In particular, the general practitioners and practice nurses 
invariably felt that patients underestimated the nature and seriousness of 
diabetes, seeing it as a mild disease. The clinicians viewed insulin 
treatment positively but felt patients actively resisted such treatment. 
Concerns were expressed around the areas of patient compliance with 
the multiple drug therapy required to treat diabetes and the difficulties of 
treating patients from ethnic minorities. Again, the methodology could 
have used interviews rather than focus groups. However, the findings 
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were valid as groups of participants in several focus groups gave their 
views and there was good correlation between the groups. The 
participants were purposively sampled but this alone does not reduce 
the validity of the findings. A possible problem was that the researcher 
led the focus groups. This could be seen as a possible source of bias, as 
being seen as an 'expert' may have influenced views expressed with the 
possibility of judgement passed on clinical decision-making. However, 
the use of focus groups dilutes the effect of the researchers persona as 
participants address each other during discussions[154]. 
Following research with diabetic patients and with clinicians, the next 
phase was to ascertain if consensus could be reached about the 
management of people with poorly controlled Type 2 diabetes. Local 
stakeholders in the care of people with poorly controlled diabetes were 
invited to a group discussion, including patient representatives. 
Emerging themes included difficulty in making lifestyle changes and 
concern that patients blamed themselves for 'failing'. This bordered on 
having moral implications, in that it was felt patients often felt they were 
letting family or carers down, with expressions of guilt for not conforming 
to diabetic regimes. Doubt was expressed about the universal adoption 
of insulin treatment for these patients, particularly regarding the point at 
which insulin should be introduced. The place of patient empowerment 
and shared decision-making was emphasised but patient 
representatives still very much saw the decision-making process lying 
with the doctor. The study could be criticised for having been based on a 
convenience sample of some of those involved in diabetes care and not 
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representative of the wider national perspective. However, the findings 
did reflect the views of the local diabetic community on how it perceived 
current services and how improvements in those services could be made 
to achieve better care. Indeed, similar teams provide most care across 
the country. 
Approaches to consensus management require a 'buy-in' from both 
those who are likely to require care and those delivering care. This 
particular project was unique in the North East of England -there were 
no recorded prior instances of clinicians and patients both working 
together to reach consensus on management. The dynamics of this 
group were fascinating - the patients, normally used to a carer-user 
relationship, were invited to a meeting where all had apparently equal 
status. The evolving dynamic of the group enabled the patients to be 
more frank about what they saw as their priorities. In turn, the clinicians 
were open in terms of what they saw as pragmatic management 
decisions rather than tightly bio-medically bound solutions. 
Chapter 7 considered the quality of life and glycaemic control in patients 
who elected to commence insulin, compared to those who did not. This 
study was "blighted" by a number of significant problems. Foremost was 
the advent of the new General Medical Services contract (nGMS) Quality 
and outcomes Framework (QoF) for diabetes[204] and a turnaround in 
the way poorly controlled diabetes care was managed. The nGMS 
contract was introduced in 2004. The QoF was a predetermined set of 
criteria for management of chronic medical conditions designed to 
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improve quality of care and using, for the first time, outcomes to 
determine practice remuneration. In diabetes this involved targets for 
glycaemic control as well as for blood pressure and lipid levels. This 
had the effect of reducing the number of patients entering the study and 
the duration of data collection had to be extended twice. In addition, one 
centre, which had agreed to participate in the study, in the end, supplied 
only two patients. The reasons for this were not exactly clear but were 
likely to be related to changes in clinical workload with a shift in work 
away from secondary care towards primary care. In effect the study 
required salvage at mid-point. This was done by extending the duration 
of data collection. 
The study explored quality of life issues around insulin initiation for Type 
2 diabetic patients. The main outcomes were that glycaemic control was 
improved modestly but at the expense of weight gain. Satisfaction with 
treatment, high initially, improved further on changing to insulin. Quality 
of life scores, which were slightly negative at the beginning of the study, 
showed a further small negative swing, although this was not statistically 
significant on the measures used. 
8.2. Changes in diabetic management over the 
last 10 years. 
This thesis was conceived at a time of significant political initiatives 
aimed at improving health care within the NHS. In 1998 the UK 
government launched a ten-year strategy for quality improvement 
throughout the NHS[206]. The concept of clinical governance was 
introduced as part of this strategy, placing attention equally on 
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accountability for existing care and improving future care. This was 
followed by national guidelines for chronic disease management, the 
national service frameworks (NSF). The NSF for diabetes was published 
in 2001 setting minimum standards for diabetes care for the health 
services in England[207], with further advice on implementation of the 
framework being issued in 2002[208]. The landmark UKPDS study[128, 
166], published in 1998, confirmed the benefit of more aggressive 
treatment of both glycaemia and hypertension. This was implemented in 
primary care subsequently. Over this period, the National Institute for 
Clinical Excellence (NICE) issued technical guidance on various aspects 
of the care of Type 2 diabetes, notably on glycaemic control, patient 
education models, hypertension, and lipid management. Most recently, 
financial incentives for improved chronic disease management, with a 
strong emphasis on diabetes, were introduced as part of a new contract 
for general practice starting in April 2004.[209]. The effect of these 
initiatives has been to increase awareness of diabetes standards of care 
and bring about improvements in care through education, audit and 
incentives, particularly in primary care. Patient empowerment and 
education have been encouraged and efforts made to standardise 
educational input. 
Inevitably, the environment in which the thesis was conducted changed 
immeasurably as the work proceeded. However, the conclusions remain 
valid if to some extent overcome by developments. 
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An example of the shift in diabetic management has been the 
redefinition of poor glycaemic control. This is now seen as a prevalent 
HbA1c of >?mmol/1 (or even >6.5mmol/l in some instances) and 
practices are under pressure to actively manage and attain such levels. 
This is in part linked to remuneration issues and has rewritten the 
management plans for diabetes, as well as for many other measurable 
indices for other chronic conditions. 
8.3. Conclusions 
This thesis highlights the importance of understanding and applying 
patient views and perceptions and being able to reconcile these with 
those of clinicians about the management of diabetes. Within the 
constraints of the methods used, and not withstanding the new initiatives 
in diabetes management, the following conclusions were drawn: 
Patients greatly value a sense of wellbeing even at the expense of future 
problems. Normality and the need to be seen to be living a normal life 
was a high priority. 
Clinicians are well cognisant of the limitations of their management. Not 
withstanding the relatively tough outcomes proposed as a consequence 
of the UKPDS study and NICE guidelines, they are in fact, willing to be 
reassuringly flexible in their approach. 
A consensus-based approach involving patients and clinicians in a 
condition such as diabetes is challenging. The divide between the 'users' 
and the 'carers' is a wide one in terms of information, knowledge, and 
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aspirations. Clinicians were not clear-cut in their attitudes towards insulin 
initiation. 
The use of insulin in a cohort of failing diabetic patients did not produce 
an overwhelmingly positive outcome and the modest gain in glycaemic 
control was at the expense of weight gain. 
Inevitably, the 'new' changes in diabetic management have superseded 
some of the ideas and precepts of this thesis but this research reinforces 
the central role of the patient in any care-management system. 
8.4. Areas for future research 
These include the need to ascertain diabetic patients' views of the 
current, more tightly targeted regimes, whether these are potentially at 
conflict with their desire for 'normality' in living, and what problems are 
associated with tighter management regimes. Overall compliance and 
outcomes are still likely to be influenced by patient factors. Also, the 
current system of data recording and outcome measures (such as 
glycaemic control and HbA 1 levels) offer a wealth of opportunities for 
research in terms of clinical outcomes. As the prevalence of diabetes 
rises and patients become more active participants in their management 
this is a rich seam of potential research on patient directed management 
issues. Technical factors are likely to be less important than human 
factors in diabetic patients remaining healthier for longer. 
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Appendix 1 - Patient Beliefs Invitation 
19 October, 2000 
Dear Fore name 
Meeting: How do people feel about their diabetes? 
Venue: North Tees Hospital Education Centre 
Date: 12 December 2000, 2pm. 
I am a local GP with a special interest in diabetes. I am looking at how we can 
improve diabetes care in General Practice in our area. Your GP practice is helping me 
with this. 
We need to know how people feel about their diabetes. Can you help? 
To get peoples' views we are holding a number of meetings. I would like to invite you 
to one of these. The meeting will be held in the Education Centre at the North Tees 
General Hospital, directions are enclosed. Reasonable travelling expenses (up to £25) 
can be paid. 
The meeting will last about an hour. The group will consist of up to 8 people. The 
discussion will be confidential and only the researcher will hold any information. 
I hope you will be able to help us with this important work. Enclosed are two 
information leaflets giving details about the study together with a consent form. 
Please complete the reply sheet and return it the envelope enclosed to let me know if 
you can help. 
Please bring the completed consent form with you to the meeting. 
Attending the meeting is entirely voluntary and refusing will in no way affect your 
normal care. 
Thank you for your help, 
Yours sincerely 
Dr David Jeavons. 
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Appendix 2 - Patient Beliefs Leaflet 
Taking part in. Research 
Information for patients about the study 
Late onset (Type 2) diabetes: 
a study of patients' views 
An invitation to take part in this study 
You are being invited to take part in a research project. Here is some information to 
help you decide whether or not to take part. Please take time to read the following 
information carefully and discuss it with friends, relatives and your GP if you wish. 
Ask us if there is anything you do not understand or if you would like more 
information. Take time to decide whether or not you wish to take part. Thank you for 
reading this. 
What is the purpose of the study? 
Diabetes is a very common problem. It affects many people in later life. Managing 
diabetes usually needs changes to diet, exercise and often tablets or insulin. This study 
looks at how people feel about their diabetes and its treatment. We hope to use this 
information to help improve local diabetes care for the future. 
Why have I been chosen? 
You have been chosen randomly from the North Tees Diabetic Register. This is a list 
of all people with diabetes treated in General Practice or hospital in the area. You are 
one of about 40 people chosen to attend one of these small group meetings. 
Who is organising the study? 
This study is funded by the NHS and run by Dr David Jeavons and Professor Pali 
Hungin. Both are General Practitioners in the local area. The study will take four 
weeks to complete. 
What will happen to me if I take part? 
You will be invited to a meeting with up to 7 other people who like you have diabetes. 
Reasonable travelling expenses will be paid if required. The meeting will last about 
one hour. Tea and coffee will be served beforehand The meeting will be very informal 
allowing people to talk about the experiences and views mentioned. The meeting will 
be organised by Dr Jeavons and recorded so that the points made are not overlooked. 
What are the potential risks and benefits from taking part in this study? 
The main benefit from this study is the opportunity to discuss how you feel about 
diabetes and hear other peoples' views. There are no specific risks. 
Is my doctor being paid for including me in the study? 
No, there is no payment to your doctor. 
What if something goes wrong? 
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If you are harmed by taking part in this study, there are no special compensation 
arrangements. If you are harmed due to someone's negligence, then you may have 
grounds for legal action. Regardless of this, if you have any cause to complain about 
any aspect of the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms are available to 
you. 
Confidentiality -who will know I am taking part in the study? 
Your General Practitioner has been asked only if it would be suitable to invite you to 
this meeting. Some people may be too frail or ill with other problems to attend. Dr 
Jeavons will keep all information from the meeting strictly confidential. 
Local Research Ethics Committee (LREC) approval? 
The North Tees LREC has reviewed and approved this study. 
What will happen to the results of this study? 
The results of this study may be published in one of the well-known medical journals. 
We would expect the article to be published 9 to 12 months after the end of the study. 
If you would like a summary of the study if and when it is published please ask. Of 
course, you will not be identified in the article. 
Contact for further information 
Please feel free to contact Dr David Jeavons at the Centre for Health Studies, 
University ofDurham, 32 Old Elvet, DH1 3HN. Tel. 0191-374-1840. lfyourequire 
independent advice about any aspect of the study please discuss it with your own 
doctor. 
What to do now 
Thank you for taking the time to read this leaflet. If you can help please return the 
enclosed postcard adding your telephone number if possible, in case we need to let 
you know of any last minute changes. 
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Appendix 3 - Patient Beliefs Consent Form 
Study number: 34/99-2000 
CONSENT FORM 
Title of project: Late onset (Type 2) diabetes: 
a study of patients' views 
Name of researcher: Dr David Jeavons 
Please initial box 
1. 
2. I understand that my participation is voluntary and that I 
am free to withdraw at any time without my medical care D 
or legal rights being affected .......................................... .. 
3. I agree to take part in the above study ................................ ·D 
Name of patient 







Appendix 4 - Patient focus group questions for 
oha groiUip 
Introduction 
No right or wrong answers 
Seeking different views and opinions 
Meeting is confidential 
One person speaking at a time, for the recording 
Opening question 
Tell us your name, where you live and what your favorite 
hobby is. 
Introduction 
looking back, what were your impressions of diabetes before 
you developed it? 
What did you know about it? 
Belief model 
With what you know now, how serious a problem do you feel 
diabetes is? 
Diabetes can cause complications; how likely do you feel you 
are to develop any of these? 
What do you see as the benefits of looking after your diabetes 
well? 
Feel better 
A void complications 
What are the problems or difficulties with controlling your 
diabetes well? 
Initial reaction 
How did you feel when you were told you had diabetes? 
How did you adapt? 
Shock, denial, emotion? 
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Lay be~iefs 




Lack of exercise 
Medication 
How effective do you feel diabetic medicines are? 
Do you have any worries about taking about taking 
medication long term? 
Barriers 
How difficult was it to make changes? 





What effect do family and friends have on you managing your 
diabetes? 
Good or bad? 
Doctor I patient relationship 
When you go to see the doctor or nurse about your diabetes, 
how useful do you find the visits? 
Can you ask questions easily? 
Do they listen to your concerns? 
Do you have enough time? 
Are goals realistic?How could these be improved? 
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Would you rather the doctor make decisions for you or would 
you rather be given choices? 
Significant others 
When you have been given advice do you talk it over with 
anyone afterwards before deciding to follow the advice? 
What effect do family and friends have on you managing your 
diabetes? 
Good or bad? 
Insulin 
How would you feel about insulin treatment if it was 
suggested for you? 
Shock, rejection, failure 
More serious phase of illness , complications 
How do think your doctor feel about insulin? 
What do you see as the benefits of insulin treatment? 
What worries you about insulin treatment? 
Needles 
Hypos 
How in control do you feel about managing your diabetes? 
Do you experiment with diet or treatment to find out what suits you best? 
Do you control your diabetes or does it control you? 
How easy is it for you to live a normal life? 
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Appendix 5 - Patient focus group questions for 
insulin group 
Introduction 
No right or wrong answers 
Seeking different views and opinions 
Meeting is confidential 
One person speaking at a time, for the recording 
Opening question 
Tell us your name, where you live and what your favorite hobby is. 
In traduction 
Looking back, what were your impressions of diabetes before you 
developed it? 
What did you know about it? 
Belief model 
With what you know now, how serious a problem do you feel diabetes 
is? 
Diabetes can cause complications; how likely do you feel you are to 
develop any of these? 
What do you see as the benefits of looking after your diabetes well? 
Feel better 
A void complications 
What are the problems or difficulties with controlling your diabetes well? 
Initial reaction 
How did you feel when you were told you had diabetes? 
How did you adapt? 
Shock, denial, emotion? 
Lay beliefs 




Lack of exercise 
Medication 
How effective do you feel diabetic medicines are? 
Do you have any worries about taking about taking medication long 
term? 
Barriers 
How difficult was it to make changes? 





What effect do family and friends have on you managing your diabetes? 
Good or bad? 
Doctor I patient relationship 
When you go to see the doctor or nurse about your diabetes, how useful 
do you find the visits? 
Can you ask questions easily? 
Do they listen to your concerns? 
Do you have enough time? 
Are goals realistic? 
How could these be improved? 
Would you rather the doctor make decisions for you or would you rather 
be given choices? 
Significant others 
When you have been given advice do you talk it over with anyone 
afterwards before deciding to follow the advice? 
What effect do family and friends have on you managing your diabetes? 
Good or bad? 
Insulin 
How would you feel about insulin treatment if it was suggested for you? 
Shock, rejection, failure 
More serious phase of illness , complications 
How do think your doctor feel about insulin? 
What do you see as the benefits of insulin treatment? 
What worries you about insulin treatment? 
Needles 
Hypos 
How in control do you feel about managing your diabetes? 
Do you experiment with diet or treatment to find out what suits you best? 
Do you control your diabetes or does it control you? 
How easy is it for you to live a normal life? 
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Appendix 6 - Patient Beliefs Va~ndation 1 
NETHERLA W SURGERY 
Dr. David A. Jeavons 
Dr. Susan M. Waterworth 
Dr. Andrew F. Michie 
Dr. Andrea B. Jones 
353141 
350938 
Mr Campbell Q. Lees 
Practice Manager 
Date 
Name and address 
Dear 
28 Stanhope Road 
Darlington 




Re: Late onset (Type 2) diabetes: a study of Patients' views. 
Teaching Centre, North Tees Hospital, Hardwick, Stockton on Tees 
Thank you again for attending one of the discussion groups for this study. 
We have now been able to look at the results of the meetings. I enclose a 
summary of the main ideas and feelings expressed in the groups. It would be 
very helpful to have your comments on this as to whether or not you agree 
with them. There is space at the end of the summary sheet for your 
comments. If you have any other comments not covered by the summary 
please feel free to add these as well. A self-addressed envelope is enclosed 
for your reply. A prompt reply would be very helpful if at all possible. 
Thank you again for your help with this important work. 
Yours Sincerely 
Dr David A Jeavons. 
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Appendix 7 Patient Beliefs Validation 2 
NlETHERLA W SURGERY 
Dr. David A. Jeavons 
Dr. Susan M. Waterworth 
Dr. Andrew F. Michie 
Dr. Andrea B. Jones 
353141 
350938 
Mr Campbell Q. Lees 
Practice Manager 
Date 
Name and address 
Dear 
28 Stanhope Road 
Darlington 




Re: Late onset (Type 2) diabetes: a study of Patients' views. 
Teaching Centre, North Tees Hospital, Hardwick, Stockton on Tees 
Thank you again for attending one of the discussion groups for this study. 
Before Christmas I wrote asking for your comments on the results of the group 
meetings that we held last year. I have had some replies but I realise life is 
always hectic over the Christmas period. If you have not replied already I 
would be grateful if you could look at the enclosed summary of the main ideas 
and feelings expressed in the groups. It would be very helpful to have your 
comments on this as to whether or not you agree with them. There is space at 
the end of the summary sheet for your comments. If you have any other 
comments not covered by the summary please feel free to add these as well. 
It would be helpful if you could sign the reply slip, but it is fine if you prefer not 
to. A self-addressed envelope is enclosed for your reply. A prompt reply would 
be very helpful if at all possible. 
Thank you again for your help with this important work. 
Yours Sincerely 
Dr David A Jeavons. 
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Appendix 8 - Late onset (Type 2) diabetes: a 
study of Patients' views: a summary of resu~ts 
A number of concepts were identified relating to how people saw their 
diabetes and how they managed it. 
Impact of the diagnosis of diabetes 
• Little was known about diabetes before diagnosis 
• Diabetes was seen as a mild disease 
• The initial reaction was of shock and denial 
Why did I develop diabetes? 
• 'it runs in the family' was frequently mentioned 
• 'Stress'- both psychological (especially work stress) and physical 
(illnesses) was often mentioned 
• Other causes - overweight, too much sugar 
Role of professionals 
• Doctors were generally seen as helpful, especially if they were seen to 
have an 'interest in diabetes.' 
• Nurses were seen as 'specialists' in diabetes. 
Managing diabetes 
• Diet changes: 
o Some participants felt that only minor changes to diet were 
necessary 
o Others felt major changes to their diet were necessary. 
• Exercise: 
o Often unrealistic targets were set for exercise 
o Many found physical problems stopped them exercising 
o The commonest form of exercise was walking. 
• Insulin: 
o There was strong initial resistance to starting insulin 
o There were worries about needles, injections and low sugar 
'hypoglycaemic' attacks 
o Once started insulin treatment was rapidly accepted 
o Insulin treatment was seen as beneficial 
• Self-monitoring 
o Seen as necessary to avoid symptoms and maintain good 
control 
o Sometimes seen as more trouble than it's worth 
Complications 
• Loss of limb (amputation) and subsequent death worried many 
• Eye problems were a concern for some 
• Heart disease was not seen as a particular complication of diabetes 
How people coped with diabetes 
• Participants made sense of diabetes by fitting it into their daily routine 
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• They drew on personal experience and the experiences of friends and 
family when making decisions 
• Professionals (doctors and nurses) advice was less often mentioned 
when making decisions about diabetes 
• Doctors' advice was discussed with family or friends and then weighed 
up (benefits against disadvantages) before deciding whether to follow 
the advice 
• There was a strong desire: 
o to live as normal a life as possible 
o to avoid physical symptoms 
Conclusions 
Diabetes was regarded as a mild disease. However, participants were 
attempting to control their diabetes but with a strong desire to live a normal life 
and avoid physical symptoms. Family and friends contributed significantly to 
participants' beliefs about diabetes with health professionals infrequently 
quoted. 
An appreciation of patients perspectives is required if we are to successfully 
improve diabetes self-management. 
Your comments 
Please tick the statement that you most agree with: 
o I very strongly agree with the summary 
o I strongly agree with the summary 
o I neither agree nor disagree with the summary 
o I disagree agree with the summary 
o I strongly disagree with the summary 
Please add any other comments below (continue overleaf if necessary): 
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Appendix 9- HCP Focus Group Questions 
Questionnaire 
Basic demographics: year of qualification, mrcgp, trainer, training practice. 
Opening 
Can I start by asking everyone in tum to introduce themselves? Tell us where you 
practice and what you most enjoy doing when you are not working? 
Introductory 
Type 2 diabetes is a common problem taking up increasing amounts of our time in 
general practice. 
1. How is diabetic care delivered in your practice? 
Transition 
2. What do you see as our role in diabetes care? How much of 
diabetic care should we be involved in? 
All too many patients are poorly controlled. 
3. How would you define the Failing Diabetic? 
Level of control? 
Key 
4. How do you feel yourself when you are faced with one of 
these people with poorly controlled! Type 2 diabetes? 
How confident are you? 
How optimistic do you feel managing the failing diabetic patient? 
5. How do you manage the failing patient? 
What goals do you set? 
6. How do you feel about insulin therapy for Type 2 diabetes? 
What do you see as the benefits and disadvantages, the pros and cons, of 
insulin? 
How-docyou feel patients-view thecprospect of insulin therapy? 
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7. Many of these patients are older. Does this affect your 
management? 
8. We here a lot about patient compliance these days. How 
much of a problem do you find this? 
What do you find affects compliance? 
9. What do you see as the barriers to good diabetic care? 
From the patient's point of view? 
Prompt list effect of family 
Summary 
Ending 
Friends (significant other) 
hcp 
10. Do you feel there are any important areas that we have not touched on? 
Vignettes 
Mrs Brown 
Age 65yr. Obese BMI 34. HbA 1 c 11%, hypertension, previous MI 
On max gliclazide and metformin, weight increasing 
Husband out of work and financial difficulties 
Mr White 
62yr old, overweight BMI 28, hypertensive. HbA 1 c 10% 
On max gliclazide and intolerant of metformin, weight steady 
After dinner speaker attending frequent functions 
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Appendix 10- HCP validation 1 
NETHERLAWSURGERY 
Dr. David A. Jeavons 
Dr. Susan M. Waterworth 
Dr. Andrew F. Michie 
Dr. Andrea B. Jones 




Mr Campbell Q. Lees Practice Manager 
21 February 2002 
Name and address 
Dear Firstname 
Re: The Failing Diabetic Patient in Primary Care 
28 Stanhope Road 
Darlington 




Thank you once again for participating in one of the focus group discussions 
discussing primary care clinicians views on management of the failing Type 2 
diabetic patient. 
We have now analysed the results, a summary of which I enclose. I would very much 
appreciate your feedback on the accuracy of the summary and any further comments 
you feel would be helpful. 
Please feel free to annotate the summary and I or add comments on the sheet provided 
and return them in the sae provided. I have included a simple scale on which to 
indicate your overall level of agreement with the summary. All replies will be strictly 
confidential and not identified in any future report. 
I appreciate that this is a further demand on your already busy schedule and as a small 
token I enclose an Oddbins voucher with which I hope you will enjoy a bottle of wine 
with me! 
Once more thank you for your help with this study, which we hope to publish in the 
not too distant future. 
Yours Sincerely 
Dr David A Jeavons. 
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Appendix 11 ~ HCP Validatio01 2 
NlE'fHlERLA W SURGERY 
Dr. David A. Jeavons 
Dr. Susan M. Waterworth 
Dr. Andrew F. Michie 
Dr. Andrea B. Jones 




Mr Campbell Q. Lees 
Practice Manager 
15 Apr. 2002 
N arne and address 
Dear Firstname 
Re: The Failing Diabetic Patient in Primary Care 
28 Stanhope Road 
Darlington 




I would very much appreciate your views on the accuracy of the enclosed summary. I 
hope you received my earlier mailing including the Oddbins voucher! I have taken the 
liberty of enclosing a further copy of the summary and sae for your reply. 
Thank you once again for participating in one of the focus group discussions 
discussing primary care clinicians views on management of the failing Type 2 
diabetic patient. We have now analysed the results. I would very much appreciate 
your feedback on the accuracy ofthe summary and any further comments you feel 
would be helpful. 
Please feel free to annotate the summary and I or add comments on the sheet provided 
and return them in the sae provided. I have included a simple scale on which to 
indicate your overall level of agreement with the summary. All replies will be strictly 
confidential and not identified in any future report. 
I appreciate that this is a further demand on your already busy schedule but your help 
is greatly appreciated. Once more thank you for your help with this study, which we 
hope to publish in the not too distant future. 
¥ours Sincerely 
Dr David A Jeavons. 
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Appendix 12 ~ Patient information ~eaflet 
Taking part in Research 
Information for patients about the study 
Poorly controUed Type 2 diabetes: 
Choice of treatment and qiUiaUty of life. 
An invitation to take part in this study 
You are being invited to take part in a research study. Before you decide it is 
important for you t understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with friends, relatives and your GP if you wish. Ask us ifthere is anything you do not 
understand or if you would like more information. Take time to decide whether or not 
you wish to take part. 
What is the purpose of the study? 
Diabetes affects many people in later life. Often tablets do not control diabetes 
sufficiently well. Insulin is then considered. A decision has to be made to change to 
insulin or continue on tablets. How do people decide? How does it affect peoples' 
lives? Do they feel better for starting insulin? What changes occur to the control of 
their diabetes? We hope to answer these questions. The study will last six months. 
The information will be used to improve local services. 
Why have I been chosen? 
All people with diabetes referred by their GP to the diabetes clinic who may need 
insulin treatment are being asked to help. About sixty people will be asked to take 
part. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take part you will 
be given this information sheet to keep and asked to sign a consent form. It you decide 
to take part you are still free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive. 
What will happen to me if I take part? 
You will be asked to complete two questionnaires when you attend the hospital 
diabetic clinic. This should take ten to fifteen minutes. The questions ask about the 
effects diabetes has on your quality of life and how satisfied you are with your 
treatment. You will be asked to repeat these again after three and six months. Your 
normal care in the diabetic clinic_ will not be altered by taking parting the study. 
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What are the potential risks and benefits from taking part in 
this study? 
There are no specific risks from taking part in this study. Information obtained from 
the study will be used to help improve the local service. 
What if something goes wrong? 
If you are harmed by taking part in this study, there are no special compensation 
arrangements. If you are harmed due to someone's negligence, then you may have 
grounds for legal action. Regardless of this, if you have any cause to complain about 
any aspect of the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms are available to 
you. 
Confidentiality -who will know I am taking part in the study? 
All information that is collected about you during the course of the research will be 
kept strictly confidential. Any information that leaves the hospital will have your 
name and address removed so that you cannot be recognised from it. Your own GP 
will be informed that you are taking part in the study. 
What will happen to the results of this study? 
The results of this study may be published in one of the well-known medical journals. 
You will not be identified in any report or publication. We would expect the article to 
be published 9 to 12 months after the end of the study. If you would like a summary 
ofthe study if and when it is published please ask. The study is run by Dr David 
Jeavons (a local GP), and Dr Barnes and Dr McCulloch (diabetic specialists), with the 
help of Professor Hungin (an experienced GP researcher). 
Who is organising and funding the research? 
The study is sponsored through an NHS Research and Development grant. The 
research is overseen by the Centre for Integrated Health Care Research, Durham 
University. The doctors involved are not paid for including patients in the study.The 
North Tees LREC has reviewed and approved this study. 
Contact for further information 
Please feel free to contact Dr David Jeavons at Netherlaw Surgery, 28 Stanhope Road, 
Darlington, tel. 01325-380640, with any queries. 
If you require independent advice about any aspect ofthe study please discuss it with 
your own doctor. 
Thank you for taking the time to read this leaflet. If you can help please read and sign 
the attached consent form. You will be given a copy of the information sheet and a 
signed consent form to keep. 
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Appendix 13- lnsuiin Qol Consent form 
Centre Number: 
Study Number: 
Patient Identification Number for this trial: 
CONSENT FORM 
Poorly controlled Type 2 diabetes: choice of treatment and quality of life. 
Name of Researcher: Dr. D. A. Jeavons 
Please initial boxes 
1. I confirm that I have read and understand the information sheet dated 
10/08/2003 (version 1.1) for the above and have had an opportunity to ask 
questions. D 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected. D 
3. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from regulatory authorities where it is relevant to my 
taking part in research. I give permission for these individuals to have access 
to my records. D 
4. I agree to take part in the above study. 
D 
Name of Patient Signature Date 
Researcher Signature Date 
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Appendix 14- Insulin Qol Data form 



































































Dr DA Jeavons 
widowed d ivorced/seperated 

















fasting plasma glucose 






Appendox 15 -lnsuon Qol Review Data 












hip (ems) ___ _ 
sbp 
----
dbp ___ _ 
Changing to insulin yes no 
if so continuing: 
metformin yes no 








Study no. D ......... . 
Date com leted I 
--~----------~ 
--------------~ 
Appendix 16- ADQol questionnaire 
ADDQol 
This questionnaire asks about your quality of life and the effects of your diabetes on your quality of 
life. Your quality of life is how good or bad you feel your life to be. 
Please shade the circle which best indicates your response on each scale. 
There are no right or wrong answers; we just want to know how you feel about your life now. 


















For the next statement please consider the effects of your diabetes, its management and any 
complications you may have. 
II) If I did not have diabetes;--my quality of life would be: 
















For each statement, please consider the effects of your diabetes, its management and any 
complications you may have on the aspect of life described by the statement. 
In each of the following boxes: 
a) shade a circle to show how diabetes affects this aspect of your life; 
b) shade a circle to show how important this aspect of your life is to your quality of life. 
Some statements have a "not applicable" option. Please shade this "not applicable" circle if that 
aspect of life does not apply to you. 
AOOQoL ©Prof Clare Bradley: 24.2.94. Standard UK English (rev. 3.11.98) Page 1 of 6 
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1a) If I did not have diabetes, my working life and work-related opportunities 
would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 0 
better better better worse worse worse 
not 
1b) This aspect of my life is: applicable 
0 0 0 0 
very important somewhat not at all 
important important important 
2a) If I did not have diabetes, my family life would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 0 
better better better worse worse worse 
not 
2b) This aspect of my life is: applicable 
0 0 0 0 
very important somewhat not at all 
important important important 
3a) If I did not have diabetes, my friendships and social life would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
better better better worse worse worse 
3b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
4a) If I did not have diabetes, my sex life would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 0 
better better better worse worse worse 
not 
4b) This aspect of my life is: applicable 
0 0 0 0 
very important somewhat not at all 
important important important 
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Sa) If I did not have diabetes, my physical appearance would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
better better better worse worse worse 
5b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
6a) If I did not have diabetes, the things I could do physically would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
increased increased increased decreased decreased decreased 
6b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
7a) If I did not have diabetes, my holidays or leisure activities would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
better better better worse worse worse 
7b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
Sa) If I did not have diabetes, ease of travelling (local or long distance) would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
better better better worse worse worse 
8b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
ADDQol ©Prof Clare Bradley: 24.2.94. Standard UK English (rev. 3.11.98) Page 3 of 6 
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9a) If I did not have diabetes, my confidence in my ability to do things would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
increased increased increased decreased decreased decreased 
9b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
10a) If I did not have diabetes, my motivation to achieve things would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
increased increased increased decreased decreased decreased 
10b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
11 a) If I did not have diabetes, the way society at large reacts to me would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
better better better worse worse worse 
11b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
12a) If I did not have diabetes, my worries about the future would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
decreased decreased decreased increased increased increased 
12b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
Page 4 of 6 
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13a) If I did not have diabetes, my finances would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
better better better worse worse worse 
13b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
14a) If I did not have diabetes, my need to depend on others for things I would 
like to do for myself would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
decreased decreased decreased increased increased increased 
14b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
15a) If I did not have diabetes, my living conditions would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
better better better worse worse worse 
15b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
16a) If I did not have diabetes, my freedom to eat as I wish would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
increased increased increased decreased decreased decreased 
16b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
ADDQoL ©Prof Clare Bradley: 24.2.94. Standard UK English (rev. 3.11.98) Page 5 of 6 
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17a) If I did not have diabetes, my enjoyment of food would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
increased increased increased decreased decreased decreased 
17b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
18a) If I did not have diabetes, my freedom to drink as I wish (e.g. sweetened hot 
and cold drinks, fruit juice, alcohol) would be: 
0 0 0 0 0 0 0 
very much much a little the same a little much very much 
increased increased increased decreased decreased decreased 
18b) This aspect of my life is: 
0 0 0 0 
very important somewhat not at all 
important important important 
If there are any other ways in which diabetes, its management and any complications affect 
your quality of life, please say what they are below: 
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Appendix 17- DTSQ (change) 
The Diabetes Treatment Satisfaction Questionnaire (change): DTSQc 
For the past few months you have been taking part in a diabetes treatment study. At the start of 
the study you may have had a change of treatment. Today we would like to know how your 
experience of your current treatment (including medication and diet) has changed from your 
experience of treatment before the study began. Please answer each question by circling a 
number on each of the scales to indicate the extent to which you have experienced changes. If 
you have experienced no change, please circle '0'. 
1. How satisfied are you with your current treatment? 
much more 
satisfied now 
3 2 0 -1 -2 -3 much less 
satisfied now 
2. How often have you felt that your blood sugars have been unacceptably high recently? 
much more of 
the time now 
3 2 0 -1 -2 -3 much less of the 
time now 
3. How often have you felt that your blood sugars have been unacceptably low recently? 
much more of 
the time now 
3 2 0 -1 -2 -3 
4. How convenient have you been finding your treatment to be recently? 
much more 
convenient now 
3 2 0 -1 -2 -3 
5. How flexible have you been finding your treatmentto be recently? 
much more 
flexible now 
3 2 0 -1 -2 -3 
6. How satisfied are you with your understanding of your diabetes? 
much more 
satisfied now 
3 2 0, -1 -2 -3 








7. How likely would you be to recommend your present treatment to someone else with your 
kind of diabetes? 
much more likely 3 
to recommend the 
treatment now 
2 0 -1 -2 -3 much less likely 
to recommend the 
treatment now 
8. How satisfied would you be to continue with your present form of treatment? 
much mo~e 
satisfied now 
3 2 0 -1 -2 -3 much less 
satisfied now 
Please make sure that you have circled one number on each of the scales. 
DTSQc ©Prof Clam Bradley 11.9.96 Standard UK English (rev. 4.3.98; generic intra. mv. 28.2.02) 
Health Psychology Research, Dept of Psychology, Royal Holloway, University of London, Egham, Surrey, TW20 OEX, UK. 
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Appendix- 18 DTSQ (status) 
The Diabetes Treatment Satisfaction Questionnaire: DTSQs 
The following questions are concerned with the treatment for your diabetes (including 
insulin, tablets and/or diet) and your experience over the past few weeks. Please answer 
each question by circling a number on each of the scales. 
1. How satisfied are you with your current treatment? 
very satisfied 6 5 4 3 2 0 very dissatisfied 
2. How often have you felt that your blood sugars have been unacceptably high recently? 
most of the time 6 5 4 3 2 0 none of the time 
3. How often have you felt that your blood sugars have been unacceptably low recently? 
most of the time 6 5 4 3 2 0 none of the time 
4. How convenient have you been finding your treatment to be recently? 
very convenient 6 5 4 3 2 0 very inconvenient 
5. How flexible have you been finding your treatment to be recently? 
very flexible 6 5 4 3 2 0 very inflexible 
6. How satisfied are you with your understanding of your diabetes? 
very satisfied 6 5 4 3 2 0 very dissatisfied 
7. Would you recommend this form of treatment to someone else with your kind of diabetes? 
Yes, I would 6 5 4 
definitely recommend 
the treatment 
3 2 0 No, I would definitely 
not recommend 
the treatment 
8. How satisfied would you be to continue with your present form of treatment? 
very satisfied 6 5 4 3 2 0 very dissatisfied 
Please make sure that you have circled one number on each of the scales. 
DTSQs ©Prof Clare Bradley 9/93 Standard UK English (rev. 7/94) 
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